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The human immunodeficiency virus (HIV) is the most powerful risk factor predisposing patients to active 
tuberculosis (TB) infection, the number one HIV-related cause of death. In South Africa (SA), 62% of TB 
patients are HIV+. The pathogenesis of both of these diseases is predominantly orchestrated by a pathogen 
driven cluster differentiation (CD) 4+ T-cell response, the nature of which is largely uncharacterised in co-
infection. This knowledge gap is especially notable in TB pleurisy, the most common form of 
extrapulmonary HIV-related TB.  
 
T-helper (Th) 17 and T-regulatory (Treg) lymphocytes are CD4+ T-cell subsets with opposing functions. 
Th17 cells are characterised by the production of pro-inflammatory interleukin (IL)-17A/F, IL-21 and IL-22, 
critical in mucosal immunity. Tregs and the lineage specific transcription factor forkhead box p3 (Foxp3) 
suppress effector lymphocyte function preventing immunopathology. Monocytes play a pivotal role in CD4+ 
T-cell polarisation by contributing to the cytokine microenvironment. Pathogen-driven alterations in 
Th17/Treg stability and function, as well as monocyte cytokine production, have been indicated in both TB 
and HIV mono-infections but have not been assessed in co-infection.  
 
We investigated Treg stability and Th17 proportion, functional characteristics and the associated cytokine 
milieu in TB/HIV pleurisy in vitro and ex vivo. We also determined the effect of a TB+HIV+ 
microenvironment on monocyte (THP-1) cytokine production and downstream Th17/Treg polarisation in 
vitro using a supernatant transfer model. Th17, Treg proportion was measured by flow cytometry. Micro 
(miR) and messenger (m) ribonucleic acid (RNA) expression was assessed by quantitative polymerase chain 
reaction. Protein levels were determined by western blotting and flow cytometry. The cytokine 
microenvironment was quantified using enzyme-linked immunosorbent assay and Bio-Plex. 
 
TB+HIV+ pleural effusion mononuclear cells (PEMCs) showed increased Foxp3 transcript expression 
(p=0.0022) but decreased protein levels (p=0.0008). MiR-155 is a direct target of Foxp3 and positively 
regulates Treg stability by repressing translation of suppressor of cytokine signalling 1 (SOCS1), conferring 
Treg IL-2 competitive fitness. TB+HIV+ pleurisy demonstrated reduced miR-155 levels (p=0.0022) and 
increased SOCS1 expression (p<0.0001). This was associated with a lower proportion of Tregs ex vivo 
(p=0.0084) and confirmed in vitro (p=0.0467). Furthermore, diminished levels of Treg characteristic 
cytokine IL-35 were observed in co-infected pleural effusion fluid (PEF) (p=0.0258), suggesting a Treg 
functional deficit. This indicates that the TB/HIV microenvironment decreases the stability and functional 
capacity of Tregs due to altered miR-155/SOCS1 dynamics. 
 
TB+HIV+ PEMCs showed a reduced frequency of Th17 cells ex vivo (p=0.0054) and in vitro (p=0.0001). 
This was not associated with alterations in polarising cytokines IL-6, IL-21 and IL-23 or signature cytokines 
IL-17A and F in PEF. Notably; however, there was upregulation of Th17 signaling molecules; IL-6 
xxvi 
 
(p=0.0022), IL-6 receptor (p=0.0247), signal transducer and activator of transcription (STAT) 3 (p=0.0022) 
mRNA, and IL-1β mRNA (p=0.0022) and protein (p=0.0008). In this study the TB/HIV microenvironment 
reduced Th17 proportion by mechanisms independent of Th17 polarising cytokines and signaling molecules 
and without alteration in the levels of IL-17A/F. 
 
TB/HIV co-infection significantly increased monocyte production of IL-1β (p=0.0217), a Th17 generating 
cytokine. Following supernatant transfer, the TB+HIV+ treated monocyte milieu stimulated significant 
polarisation of healthy CD4+ conventional T-cells into Th17 lymphocytes and Tregs (p<0.0001). However, a 
significantly greater proportion of Th17 cells (p=0.0001) was observed associated with elevated IL-17A 
intracellular protein expression (p<0.0001) and 2.278 and 8.191 fold increases in the production of IL-17A 
and IL-21 respectively. This indicates that the TB/HIV microenvironment modifies monocyte T-cell 





















Tuberculosis ranks as the second leading killer globally from a single infectious agent, the first being HIV. 
South Africa has the second highest rate of new TB cases [1] and the greatest number of people living with 
human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) globally [2]. 
Consequently, 62% of TB patients are HIV positive [3, 4]. Both HIV and TB result in immune dysfunction 
and synergise to accelerate individual disease pathology [5]. The immunological consequences of 
simultaneous co-exposure to TB and HIV are largely uncharacterised. 
 
Mycobacterium tuberculosis (MTB) is the causative pathogen of TB, with an estimated 7.3-14.0% annual 
risk of infection in SA [6]. Tuberculosis is classified as a granulomatous inflammatory condition where 
effector cells accumulate at the site of mycobacterial infection to form a characteristic tubercle. This 
physically contains the infection suppressing bacterial replication and preventing dissemination resulting in 
subclinical disease. However, the granuloma also shields the bacteria from the immune system providing a 
niche of bacterial survival. Latency is considered the hallmark of protective immunity, classically attributed 
to the co-ordinated activity of the host CD4+ T-cell responses and successful in approximately 90% of 
infected individuals [7]. 
 
Primary active disease or reactivation is generally considered a failure of CD4+ T-cell immunity. However, 
rather than the absence of immune activity to explain the re-emergence of a pathogen, active TB infection 
displays areas of intense immune infiltrate [8, 9]. A contrasting school of thought ascribes active disease 
progression to MTB mediated dysregulation of the protective CD4+ T-cell response into a pathological 
productive infection. This results in necrotic liquidation of granulomas and facilitates the extracellular 
dissemination of bacilli which are expelled out of the lungs on coughing [8]. 
 
Typically, HIV causes gradual immunosuppression culminating in AIDS at a CD4+ T-cell count below 
200cells/μl. The virus primarily targets and replicates within C-C motif receptor (CCR) 5+/C-X-C motif 
receptor (CXCR) 4+CD4+ T-cells. Infection is characterised by progressive depletion of CD4+ T-cells and 
chronic immune activation resulting in exhaustion and failure of the immune system and onset of 
opportunistic infections, predominantly TB, and AIDS-related malignancies [10]. Both the innate and 
adaptive immune branches contribute to anti-HIV defence but are insufficient to eradicate the pathogen or 
maintain long term control of viral replication. Evidence indicates that T-cell responses are significant 
determinants in elite control of HIV replication, the mechanisms of which are poorly understood [11]. 
 
CD4+ T-lymphocytes form the basis of protective immunity and immunopathology in both diseases. The 
immunological implications of TB/HIV co-infection compared to mono-infections are beginning to be 
elucidated. Observations include rapid depletion and preferential HIV targeting of MTB specific CD4+ T-
cells [12], loss of HIV-specific T-cell functionality [13], increased CD4+CCR5+ expression and consequently 
2 
 
increased HIV susceptibility and enhanced viral replication [14, 15]. Taken together these findings indicate a 
conjoined MTB-HIV pathogenic manipulation of CD4+ T-cells which has not been explored in individual 
subsets.  
The CD4+ T-lymphocytes are a heterogonous population that can be broadly classified according to their 
distinct cytokine and transcription factor profiles. Th17 cells, characterised by the production of IL-17A/F, 
IL-21 and IL-22 together with the expression of CCR6 and RAR-related orphan receptor C, are a pro-
inflammatory subset of effector cells critical in mucosal immunity to bacterial and fungal infections [16]. 
Regulatory T-cells, categorised by the transcription factor Foxp3, are a suppressive subset of immune cells 
which maintain peripheral tolerance and limit pro-inflammatory responses preventing immunopathology 
[17]. An imbalance in Th17 and Treg frequency has been implicated in the pathogenesis of several diseases. 
Evidence shows pathogen driven alterations in Th17 and Treg proportion and function in both TB and HIV 


















STUDY RATIONALE AND AIMS 
 
In order to reduce the incidence and mortality of TB/HIV, improvements are mandatory in diagnostics, 
disease monitoring and treatment [1]. This requires greater understanding of pathogen driven immune 
dysfunction characteristic of both infections. The CD4+ T-cell response is a convergent point in the host 
immune response to MTB and HIV. An investigation into the MTB/HIV manipulation of CD4+ T-cells 
provides clues into the underlying mechanisms mediating pathogenesis of dual infection and gradually lays 
the foundation for novel therapeutic and prophylactic interventions, ultimately benefiting clinical disease 
management. With this aim it is imperative to measure the biological responses in TB/HIV endemic areas 
such as SA.  
 
Although TB most commonly presents as pulmonary disease, with concurrent HIV infection 40-80% of 
active TB cases are extrapulmonary [18, 19], the most common form of which is TB pleurisy [20]. Clinical 
and experimental evidence indicates that TB pleurisy provides an optimum model to elucidate 
immunological mechanisms involved in the defence against MTB in vivo. Immunity is compartmentalised in 
the pleural space [21] and is generally self-limiting, indicating effective anti-MTB activity [21-23]. 
Furthermore, it has been established that TB infection outcome is determined by localised immune responses 
which are not accurately reflected systemically [24].  
 
This study was designed to investigate the implications of TB/HIV co-infection on Th17 and Treg 
lymphocyte responses in PEMCs of a South African population. 
 
Our research objectives were: 
1. To determine the effect of TB/HIV pleurisy on Treg stability and functional characteristics in vitro and 
ex vivo. 
2. To determine the effect of TB/HIV pleurisy on Th17 lymphocyte proportion, functional characteristics 
and the associated cytokine microenvironment in vitro and ex vivo. 
3. To determine the effect of a TB/HIV co-infected micro-environment on monocyte mediated Th17 and 
Treg polarisation and the associated cytokine profile in vitro. 
 
Pleural effusion fluid samples were obtained by diagnostic pleural tap from TB pleurisy patients with 
concurrent HIV infection and compared to that from confirmed HIV seronegative patients with non-
infectious pleural effusions. The results of ex vivo assays were confirmed in vitro by treating healthy CD4+ 











1.1   Tuberculosis 
 
1.1.1  Overview of tuberculosis 
Tuberculosis (TB) was declared a global health emergency in 1994 by the World Health Organisation 
(WHO) and has remained a major public health challenge since [25].  
 
Tuberculosis is spread by the airborne Mycobacterium tuberculosis (MTB) and acquired by inhalation of 
infected droplets. MTB passes to the lungs where the co-ordinated activity of macrophages, dendritic cells 
(DC) and cluster differentiation (CD) 4+ T-cells results in the formation of the granuloma and clinically silent 
infection. Due to host and/or MTB factors, excessive bacterial replication within the granuloma results in its 
break down with dissemination and transmission of the bacilli via the respiratory route, characteristic of 
active infection [7]. Although MTB is capable of causing primary disease, the most common manifestation 
in adults is reactivation of a pre-existing latent infection, termed post primary TB [26], with a life time risk 
of 10% [27].  
 
Most organs can be infected with MTB; however, the predominant clinical manifestation is pulmonary TB. 
When MTB has disseminated to other areas of the body, via the blood or lymphatic system, it is referred to 
as extrapulmonary TB [7].  
 
1.1.2 Epidemiology of tuberculosis 
According to WHO, in 2013 there were approximately 9 million new cases of active TB infection and 1.5 
million deaths globally. Over 95% of these deaths occurred in low- and middle- income developing countries 
such as South Africa (SA) [1]. South Africa is considered a high burden TB country with an incidence of 
450,000 in 2013, the third highest incidence rate globally and the highest rate of drug susceptible and 
resistant TB in Africa [1, 3] (Figure 1.1). It is estimated that in SA 1 person out every 100 develops active 





Figure 1.1: Estimated tuberculosis incidence rates (2013) depicting the high burden in South Africa [1]. 
 
1.1.3 Morphology of Mycobacterium tuberculosis 
Mycobacterium tuberculosis is a large, non-motile rod shaped bacterium (Figure 1.2). It is a facultative, 
obligate aerobe with a slow replication rate of 16-20 hours. The bacterium ranges in length from 2-4 microns 




Figure 1.2: Scanning electron micrograph of Mycobacterium tuberculosis (15549×) [28]. 
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The cell envelope; the cell wall together with the mycobacterial inner cell membrane, is the major 
determinant of MTB virulence. The cell wall is made up of two layers - the lower layer adjacent to the cell 
membrane is composed of peptidoglycan covalently attached to arabinogalactan which in turn is esterified to 
mycolic acids, forming the mycolylarabinogalactan-peptidoglycan (mAGP) complex. The insoluble mAGP 
complex is essential for structural integrity and forms a hydrophobic barrier responsible for the viability of 
MTB and resistance to chemotherapy [29, 30] (Figure 1.3). 
 
In the upper layer, also termed the mycobacterial outer membrane, and intercalated within the mycolic acids 
of the mAGP complex are interspersed cell wall proteins and the major pathogenic free lipids. Most 
significantly these include; phthiocerol dimycocerosates (PDIM), cord factor/trehalose dimycolates or 
monomycolates (TDM/TMM), sulfolipids, phthiocerol-containing lipids, phosphatidylinositol mannosides 
(PIM), lipomannan (LM) and lipoarabinomannan (LAM). A defining feature of mycobacterium species is 
this presence of a wide diversity of these complex lipids constructing approximately 60% of the cell 
envelope [31]. Simplistically, the lipids are the signalling and effector molecules of the bacterium-host 
interaction and contribute significantly to the success of the pathogen [29, 30] (Figure 1.3).  
 
 
Figure 1.3: Two-dimensional representation of the Mycobacterium tuberculosis cell wall. Mycobacterial 
inner membrane (MIM), mycobacterial outer membrane (MOM) [30]. 
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1.1.4 The pathogenesis of tuberculosis 
Mycobacterium tuberculosis infection follows a well described set of events. Briefly, bacilli are inhaled as 
droplets from the atmosphere with the infectious dose estimated at a single bacterium. The innate immune 
response is initiated when MTB in the alveolar space is recognised by pattern recognition receptors (PRRs), 
predominantly Toll-like receptors (TLRs) on alveolar and interstitial monocytes/macrophages as well as 
local DCs, and subsequently engulfed. These antigen presenting cells (APCs) present antigen in association 
with major histocompatibility complex (MHC) class II molecules to CD4+ T-helper (Th) lymphocytes, and to 
a lesser extent in association with MHC-I and CD1 to CD8+ T-cells [7, 32].  
Up to the initiation of acquired immunity, macrophages remain relatively permissive to intracellular MTB. 
Experimental host studies identify this as a period of exponential bacterial replication [33]. Primed T-cells 
then recognise and activate macrophages to institute anti-mycobacterial killing mechanisms through the 
secretion of interferon (IFN)-γ and tumor necrosis factor (TNF)-α bringing bacterial replication under 
control, but not eradication. These pro-inflammatory cascades culminate in the remodelling of the infection 
site into the characteristic tissue nodule, the granuloma. The result is a chronic infection associated with slow 
or non-replicating bacilli and potentially progressive pathology [7, 34].  
 
1.1.4.1 Macrophages 
Macrophages play a dual role in TB infection. Mycobacterium tuberculosis targets and replicates within 
modified phagosomes of macrophages, employing a multitude of strategies to evade clearance by both the 
innate and adaptive immune systems, yet macrophages are the predominant cell responsible for MTB killing.  
 
Infected macrophages initially respond with a vigorous pro-inflammatory and anti-microbial response 
mediated by TLR signalling [35]. TLRs are key recognition molecules in the host’s innate immune system, 
TLR-2 being one of the major PRRs for detecting MTB [36, 37]. MTB has a diverse range of TLR-2 ligands 
including MTB heat shock protein 65 and 70, several types of lipoproteins (LpqH, LprA, LprG, PhoS1), 
LAM, LM, PIMs and TDM [38-40].  
 
Following MTB engulfment, alveolar macrophages enter the lung interstitium establishing a site of infection 
[41, 42]. This consequently leads to a localised pro-inflammatory cascade with production of TNF-α, 
interleukin (IL)-1, IL-6, and IL-12, together with inflammatory chemokines C-C motif ligand (CCL) 2 and 
C-X-C motif ligand (CXCL) 10 by the infected macrophage. The chemokine gradient recruits waves of 
neutrophils, natural killer (NK) cells, CD4+, CD8+ and γö T- and B-lymphocytes each producing their own 
complement of chemokines and cytokines which amplify cellular recruitment and remodelling of the 
infection site into the granuloma [26, 41-44]. Tumor necrosis factor-α, produced by macrophages and 
lymphocytes, acts in a positive feedback manner to accentuate macrophage chemokine production thereby 
emphasising immune cell accumulation and granuloma formation. Persistent TNF-α production is required to 
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sustain the chemokine gradient and therefore maintain the structure of the granuloma. Once the bacilli have 
been successfully contained and latency established, the chemokine cascade is down regulated by IFN-γ, 
produced by lymphocytes at the site of infection, through a negative feedback loop [26].  
 
1.1.4.2 Dendritic cells 
Dendritic cells play a central role in the switch from an innate immune response to acquired specific 
immunity. Bacilli are phagocytosed by DCs surveying the airways resulting in DC production of IL-12, 
upregulation of MHC class I, II and CD1 associated antigens as well as co-stimulatory molecules 
CD40/54/80/86. In conjunction, the acquisition of a motile phenotype results in the migration of DCs to the 
proximal lymph nodes where they prime naïve T-cells [45].   
 
Antigen specific T-cell responses are noted in the mediastinal lymph nodes approximately 10 days following 
aerogenic murine infection at the earliest [46, 47]. This is the rate limiting step of T-cell priming, the reasons 
for which are still unclear [48, 49]. This lag permits exponential bacterial replication producing a high 
pulmonary bacterial load at the onslaught of T-cell immunity [50]. Recent evidence shows that MTB 
infection of DCs inhibits their migration through the CCL19- C-C motif receptor (CCR) 7 gradient [51]. 
Furthermore, MTB proteins, Hip1 [52] and mannose capped LAM (ManLAM) [53, 54], have been shown to 
inhibit DC maturation, cytokine secretion and antigen presentation resulting in impaired T-cell priming and 
sub optimal inflammatory responses.  
 
1.1.4.3 CD4+ T-lymphocytes 
The specialisation of T-lymphocyte responses to produce characteristic cytokine profiles plays a central role 
in co-ordinating host immunity against MTB infection. CD4+ T-cells are essential for the control of primary 
infection and the ongoing immune surveillance of the reservoir of persistent bacilli within the granuloma 
from which reactivation originates [40]. This is illustrated by the fact that selective depletion of CD4+ T-cells 
by the human immunodeficiency virus (HIV) significantly increases TB reactivation rates to 5-10% per life 
year [27] and incidence to 25.7 per 100 persons per year, in patients with CD4+ T-cell counts below 50 
cells/μl [55]. 
 
Classically, innate immunity to MTB is superseded by an antigen specific Th1/IFN-γ response, the nature of 
which is well described. IFN-γ is a critical mediator of macrophage activation and bactericidal mechanisms. 
The induction of inducible nitric oxide synthase (iNOS) in macrophages and downstream production of 
reactive nitrogen intermediates, together with reactive oxygen species, are toxic to MTB [56-58]. 
Additionally, IFN-γ stimulates autophagic pathways in infected macrophages resulting in maturation of the 




More recently studies have shown that the newly identified CD4+ T-cell subtypes; pro-inflammatory Th17 
and anti-inflammatory T-regulatory lymphocytes (Tregs) are associated with immunity against MTB in 
addition to Th1. These subsets will be discussed in detail below. 
 
1.1.4.4 CD8+ T-lymphocytes 
The role of cytotoxic T-cells has been overshadowed by that of Th cells. It has been demonstrated that CD8+ 
T-cells partake in MTB infection in several ways [60, 61]: (1) Cytokine production; CD8+ T-lymphocytes 
have been identified as a source of IFN-γ and therefore mediate macrophage activation and bactericidal 
mechanisms [58, 62-64]. (2) Granule dependent cytotoxicity; both granulysin and perforin mediated 
cytotoxic activities have been implicated in the lysis of infected cells and extracellular MTB [62, 65-67]. The 
bacteria are released into the extracellular environment to be taken up by activated macrophages capable of 
killing the bacilli. However, CD8+ T-cell dysfunction has been frequently associated with active TB disease 
[68, 69].  
 
1.1.4.5 B-lymphocytes 
Classically, B lymphocytes and associated antibodies are considered to be insignificant role players in TB. 
However, humoral immunity is involved in shaping the cellular immune response to MTB including direct 
antigen presentation to T-cells, direct effects of antibody on mycobacteria, cytokine production and 
granuloma organisation [70-73], binding of antibody complex to APC Fcγ receptors influencing subsequent 
Th1/IFN-γ responses [8], macrophage activation and bactericidal mechanisms [8, 73] in an organ specific 
manner [73]. 
 
Follicle like B-cell aggregates have been demonstrated in the lungs of human and murine pulmonary TB 
infections associated with granulomatous inflammation [74-76]. The role of these B-cell centres have not 
been fully elucidated but are hypothesised to perpetuate local immune responses through cellular 
proliferation [77] as well as involvement in both B-cell maturation and antigen presentation to T-cells, 
augmenting the immune response [8, 75].  
 
1.1.5 The granuloma 
The granuloma serves to physically contain the bacilli preventing dissemination and provide a 
microenvironment of optimum and localised immune communication. This leads to inhibition of bacterial 
growth by activating macrophage bactericidal mechanisms and creating an oxygen and nutrient deprived 
environment [44].  
 
According to the central dogma, the initial granuloma consists of a core of infected macrophages surrounded 
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by additional macrophages displaying distinct morphology; multi-nucleated giant cells, epitheloid cells and 
foamy macrophages [78, 79] as well as granulocytes and other mononuclear phagocytes [9, 26, 33, 42]. In 
the early stages of granuloma development, the nodule undergoes marked neovascularisation due to the 
production of pro-angiogenic vascular epithelial growth factor by activated macrophages [80]. The blood 
vessels denote extensive lymphocyte cuffing indicating a recruitment of lymphocytes as well as dendritic 
cells and macrophages to the site of infection [80]. As the structure matures it develops a significant fibrous 
sheath of collagen and other extracellular matrix components around the macrophage rich centre. The 
lymphocytic infiltrate is excluded and aggregates around the fibrous cuff defining the periphery of the nodule 
[9, 26, 33, 42] (Figure 1.4). 
 
The granuloma has several morphologically distinct forms: solid (composed of dense aggregates of infected 
and uninfected macrophages and lymphocytes without central necrosis), neutrophilic (extensive granulocytic 
infiltrates and/or central core of suppuration) and caseous (enlarged necrosis and liquefaction of dead cells in 
the core of the granuloma which can progress to cavities, surrounded by a cuff of macrophages and 
lymphocytes) with or without fibrosis or calcification [26, 33, 81].  
 
This solid granuloma characterises the containment or clinically silent stage of infection; a period of 
stalemate when bacillary load remains constant and the infection enters latency [26, 33, 81]. As the 
granuloma progresses from solid non-progressive to active cavitary lesions, there is a decrease in the number 
of blood vessels penetrating the nodule, facilitating caseation in the hypoxic environment [26, 75, 82]. In 
addition, the killing of MTB within macrophages is suggested to be severely limited as superoxide and nitric 
oxide production by macrophages is inhibited by hypoxia resulting in uncontrolled bacterial replication 






Figure 1.4: The life cycle of Mycobacterium tuberculosis [84].  
 
Retrospective histological studies of patients with active disease show marked heterogeneity in granuloma 
progression seen in a single host. This indicates differential immunological processes occurring separately at 
each site [26, 85-87] and suggesting that TB progression from latent to active infection is a dynamic 
evolution determined locally at the granuloma [33].  
 
An alternate school of thought suggests that MTB drives the development of the granuloma in order to 
physically separate its self within the infected macrophages at the centre from the activated lymphocytes on 
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the outskirts of the fibrous capsule. In this way the isolated central core serves as a site of bacterial expansion 
[76, 88-92]. The core of the granuloma is not considered to be the dominant site of immune action but the 
peripheral cellular infiltrates composed of APCs and lymphocytes, resembling secondary lymphoid organs, 
potentially orchestrate the immune response [33, 77] (Figure 1.4).  
 
The mycobacterial proteins and lipids have an established granulomatous effect; MTB 6-kDa early secretory 
antigenic target (ESAT-6) [88] and PIM2 [93], induce matrix metalloproteinase (MMP)-9 expression in 
pulmonary epithelial cells neighbouring infected macrophages promoting recruitment of macrophages [94]. 
In addition LM, LAM, TDM/TMM and PIMs are known to induce chemokine and pro-inflammatory 
cytokine production from mononuclear cells through pattern recognition receptors such as TLR-2 [90, 95-
100]. These granulomatous effects provide an accumulation of uninfected host macrophages with suboptimal 
activation, allowing for continued mycobacterial persistence in the core while physically separated from the 
bactericidal activity of lymphocytes [89, 90]. 
 
1.1.6 Immune evasion strategies 
Mycobacterium tuberculosis survives and replicates within macrophages establishing chronic persistent 
infection. This is achieved by arresting phagolysosome biogenesis thereby restricting the unfavourable 
intracellular environment, preventing host effector mechanisms and shielding MTB from antigen processing 
pathways.  
 
A feature of phagosome maturation is acidification (pH5.0 and lower) of the phagosome lumen. The acidic 
environment inhibits bacterial activity, optimises the activity of hydrolytic proteases, ensures correct 
vesicular trafficking and phagosome-lysosome fusion events and degradation of the pathogen into 
components for antigen processing and presentation, ultimately resulting in activation of the cell mediated 
immune response. Acidification is achieved by the recruitment of V-ATPases to the phagosome which 
actively pump hydrogen ions across the phagosome membrane. In vitro and in vivo studies observed that 
MTB containing phagosomes acidify to a minimum of pH6.4 and subsequently fail to fuse with lysosomes 
[101-104]; MTB has been shown to exclude V-ATPases from the phagosome membrane preventing 
acidification [105]. This is mediated by a MTB protein tyrosine phosphatase, PtpA, which binds to subunit H 
of the macrophage V-ATPase inhibiting the trafficking of vesicles containing the V-ATPase complex to the 
phagosome [106].   
 
Arrest of phagosome-lysosome fusion has been shown to occur due to a failure in early endosomal Rab5 to 
late endosomal Rab7 conversion, preventing completion of endosomal sorting and membrane trafficking. 
Rab conversion occurs through a calcium/calmodulin/calmodulin kinase II dependent phosphatidylinositol-3-
kinase (PI3K)/phosphatidylinositol-3-phosphate (PI3P) pathway. This cascade mediates the recruitment of 
the Rab5 effector early endosomal antigen 1 (EEA1) to the phagosome triggering the fusion of phagosomes 
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with late endosomes. Several bacterial products are observed to be involved; LAM has been shown to 
interfere in the calcium fluxes required for this pathway consequently inhibiting it [107]. ManLAM has been 
shown to block the calcium/calmodulin recruitment of PI3K to the phagosome preventing PIP3 generation 
and EEA1 acquisition [102, 108-110]. A bacterial PI3P phosphatase, SapM, degrades any PI3P which evades 
the ManLAM block [102, 111, 112]. The combined effect is inhibition of phagolysosome biogenesis.  
 
Macrophage lysosomes are the convergent step between phagocytic and biosynthetic pathways where 
antigens are processed and complexed with MHC molecules for presentation to T-cells [113]. Accumulation 
of MTB components in acidic late endosomal compartments optimises processing. The MTB phagosome has 
limited acidification and hydrolytic activity and therefore a suboptimal capacity to process antigens [114]. 
The inhibition of phagolysosome biogenesis not only avoids MTB destruction by hydrolytic proteases but 
also presentation and recognition by primed T-cells [115, 116]. Despite this, cytokine mediated activation of 
the macrophage is sufficient to overcome MTB mediated phagosome modulation; the phagosome acidifies to 
pH5.2 with subsequent bactericidal actions and fusion with the lysosome mediated by members of the IFN-
inducible p47 GTPase family [117, 118]. 
 
1.1.7 Transmission 
Several factors affecting T-cell and/or macrophage function have been associated with an increased risk of 
developing active TB [25] including HIV co-infection [119], diabetes mellitus [120], renal impairment [121], 
TNF-α antagonist therapy [122], cancer [123], alcohol abuse [124] and tobacco use [125].  
 
1.1.7.1 Breakdown of the granuloma 
Preceding research dictates that active infection advances from failure to contain infection within the 
granuloma due to impairment of the host immune response, specifically CD4+ T-cell responses. In 
accordance, HIV co-infection is the strongest known risk factor for immediate (primary) and delayed (post 
primary) progression from latent to active disease [119]. By this model, excessive bacterial replication 
results in progressive necrosis followed by caseation, liquidation of the granuloma and cavitation into the 
bronchi releasing bacilli. This necessitates development of a productive cough resulting in aerosol 
transmission of infectious MTB [7, 26].  
 
Mycobacterium tuberculosis evades the immune response to allow persistent infection but simultaneously 
promotes sufficient immunopathology to ensure its transmission [126]. A more recent school of thought 
suggests that MTB dysregulation of host lipid synthesis and lipid accumulation is pivotal in transition from 
latent to active infection, magnified by dysregulation of CD4+ T-cell responses. Histological analysis of 
biopsies from patients with untreated TB demonstrated that reactivation originated from areas of lipoid 
pneumonia. Within these areas there was sequestration of abundant lipid rich macrophages, termed foamy 
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macrophages (FMs) [79, 127, 128]. Furthermore, infection was restricted to the FM and bacilli were 
predominantly found within the lipid droplets. Cavities originated from tuberculosis pneumonia in 
individuals who had no histological evidence of caseating granulomas [79, 127, 128]. Whereas previously, 
tuberculosis pneumonia was regarded as a consequence of cavitation, it is now considered as the origin 
[127]. 
 
Mycolic acids form a significant and characteristic component of MTB, constituting 40-60% of its dry 
weight [129]. Recently it has been demonstrated that FM generation is specifically induced by oxygenated 
mycolic acids (oxygenated ketomycolic) and hydroxyl mycolic acids, of virulent mycobacterial strains [79].  
 
The FM is in its self a pro-inflammatory cell [130]. It is indicated as a key player in sustaining persistent 
bacterial infection and dysregulating T-cell responses driving pathology leading to necrotic cavitation and 
transmission [33]. FMs show reduced ability to mediate phagocytosis, accompanied by diminished anti-
mycobacterial mechanisms [79], lowered antigen processing capacity through down regulation of CD40 and 
MHC II expression [131], increased Fas/Fas ligand mediated Th1 apoptosis [132], as well as production of 
high levels of iNOS resulting in T-cell hypo-responsiveness [133].  
  
Mycobacterium tuberculosis induced FMs displayed an elevated continual secretion of TNF-α, a strong 
inducer of necrosis [79]. In a series of human biopsy samples FMs were only observed in necrotic lesions 
and their presence correlated to the onset of necrosis, systematically located at the interface between the 
histiocytes and the necrotic core [33, 79, 127, 128]. The spatial and temporal relationship between FMs and 
the necrotic centre of the granuloma suggests a causal association.  
 
Together these findings indicate a bacterial driven role of FMs preventing macrophage intracellular killing 
with simultaneous suppression of T-cell responses resulting in sheltering of MTB and facilitating 
persistence. This MTB mediated suppression of cell mediated immunity accentuates necrotic loss of 
granuloma structure leading to excessive bacterial replication and transmission [79, 128]. 
 
1.1.7.2 Host cell death 
Virulent MTB survive within macrophages by preventing apoptosis, phagosome maturation and antigen 
processing creating a niche where bacteria remain metabolically active and capable of replication [134]. 
However, MTB would benefit from cell death once a high intracellular bacterial load has been reached 
allowing for dissemination of the bacilli. Necrosis is the preferred MTB exit strategy, promoting 
inflammation and disease progression [135-137].  
 
MTB has been shown to cause plasma membrane microdisruptions in the infected macrophage. Repair of 
these lesions by exocytosis of endomembranes is required for preventing necrosis and promoting apoptosis. 
This is achieved by the fusion of golgi and lysosome derived vesicles with the plasma membrane, the process 
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being dependent on prostaglandin E2 (PGE2) [138]. In the late stages of infection, macrophages infected 
with virulent MTB strains preferentially synthesise lipoxin A4 (LXA4) which inhibits apoptosis and 
promotes necrosis shielding the MTB from the innate immune system. The production of LXA4, which 
blocks PGE2 biosynthesis by down regulation of cyclooxygenase 2, is a natural anti-inflammatory immune 
mechanism. This is exploited by pathogenic MTB at the infection site, inhibiting plasma membrane repair, 
driving inflammation and necrosis [138, 139]. Necrotic death of FMs within the granuloma leads to the 
accumulation of lipid debris at the core of the liquefying granuloma forming the caseum [33]. 
 
1.1.8 Tuberculosis pleurisy 
Although TB most commonly presents as pulmonary disease, with concurrent HIV infection, 40-80% of TB 
is extrapulmonary [18, 19]. TB pleurisy is considered an early manifestation of TB [18], the initial presenting 
factor in approximately 25% of cases [140] and the most common form of HIV-related extrapulmonary TB 
[20]. Furthermore, TB pleurisy is the most common cause of pleural effusions in TB endemic areas [20, 141, 
142] such as SA. 
 
A TB pleural effusion (TPE) is a consequence of MTB infection of the pleura characterised by a chronic 
accumulation of inflammatory cells in the pleural cavity [143]. This can be the result of either primary 
infection or reactivation and is thought to be due to the breakdown of small subpleural caseous granulomas 
that release their contents into the pleural space. This is followed by acute inflammation resulting from a 
delayed hypersensitivity reaction to MTB antigens mediated by CD4+ T-lymphocytes. This 
compartmentalised inflammatory reaction increases the permeability of pleural capillaries which, together 
with reduced lymphatic drainage, results in the formation and accumulation of pleural fluid in the pleural 
cavity. In the initial stages of this process neutrophils dominate the pleural space; however, soon after T-
lymphocytes become the chief cell type [143, 144]. TB pleurisy may cause the localised deposition of 
inelastic fibrotic tissue on the visceral pleura hindering lung expansion and resulting in a negative pleural 
space pressure permitting the development of a chronic pleural effusion [143].  
 
The TPE most commonly manifests as an acute or sub-acute condition with pyrexia, cough (productive or 
non-productive potentially with the expectoration of blood), shortness of breath and pleuritic chest pain in 
over 70% of patients [145]. Other constitutional symptoms include night sweats, weight loss, generalised 
weakness, malaise and dyspnoea varying in grade according to the magnitude of the effusion [143]. Upon 
examination of chest radiographs, TPEs are typically unilateral, small to moderate in size, loculated and 
serous in appearance with or without pulmonary parenchymal changes [18, 146]. This may be associated 
with tracheal and mediastinal shift away from the TPE, decreased chest movement and dullness on 




Definitive diagnosis of TPE is based on the demonstration of bacilli in the sputum, pleural fluid or pleural 
biopsy specimens [147, 148] by acid fast staining (Ziehl-Neelsen, Auramine) and mycobacterial culture 
regardless of parenchymal or pulmonary involvement [143, 148]. Within the appropriate clinical context a 
reasonably certain diagnosis can also be based on the demonstration of granulomas in the parietal pleura 
[143] and a raised pleural fluid adenosine deaminase level above 30-40U/L [20, 143, 149], even among HIV 
positive individuals with low CD4+ T-cell counts [150]. Frequently pleural fluid analysis allows for the 
presumptive diagnosis of TPE, this invariably demonstrates a straw coloured exudative effusion with a 
lymphocytic predominance [148, 151], a protein concentration greater than 3-5g/dl (more than 70% of cases) 
[20, 140], glucose level below 60mg/dl (greater than 25% of cases) and a pH of less than 7.2 (greater than 
10% of cases) [140]. 
 
TB/HIV co-infected patients may present with typical TB symptoms; however, more often these patients are 
minimally symptomatic, with less specific symptoms or asymptomatic [152].  
 
1.1.9 Treatment of tuberculosis 
According to the South African National Tuberculosis Treatment Guidelines 2014 and the WHO guidelines 
2010, uncomplicated extrapulmonary TB is generally treated in the same manner as pulmonary TB: For 
newly and previously treated adults and children older than 8 years of age and above 30kg in weight, TB 
treatment is started with four first line drugs – isoniazid, rifampicin, pyrazinamide and ethambutol for a two 
month intensive phase. This reduces the number of viable bacilli and renders the patient non-infectious 
within 10-14 days. Approximately 90% of mycobacteria are killed within the first week of treatment. With 
fewer bacilli the risk of acquired drug resistance decreases and so a 4 month continuation phase is instituted 
with two drugs – isoniazid and rifampicin. The sterilising activities of these drugs eliminate remaining bacilli 
preventing relapse (Figure 1.5). This regime is also instituted in TB/HIV co-infection in antiretroviral (ARV) 















Figure 1.5: First line drugs in the treatment of drug susceptible tuberculosis [154]. 
 
1.1.10 Drug Resistance  
Mycobacterium tuberculosis acquires drug resistant mutations in a sequential manner due to cellular 
mechanisms and external factors. Most significantly, suboptimal therapy predominantly due to monotherapy, 
inadequate dosage, treatment interruptions and drug interactions [25].  
 
Multi-drug resistant TB (MDR-TB) is defined as resistance to two of the four first line drugs, isoniazid and 
rifampicin. Extensively drug resistant TB (XDR-TB) is defined as resistance to any fluoroquinolone and at 
least one of the 3 of the second line drugs (capreomycin, kanamycin and amikacin) in addition to isoniazid 
and rifampicin [155, 156]. Totally drug resistant TB (T/XX DR-TB) is a strain of MTB showing resistance to 
all first and second line TB drugs used, although the terminology is still to be fully defined [25, 157, 158]. 
Treatment and clinical management is complicated by lengthier, prohibitively expensive, more toxic and less 
effective treatment regimens with inadequate success rates [159]. 
 
According to WHO, drug resistant TB is rising with approximately 210,000 deaths and 480,000 new MDR-
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TB cases in 2013. An estimated 9.6% of these are XDR-TB with a mortality rate of 44-49% [1]. However, 
these figures are thought to be significantly underestimated across sub-Saharan Africa, Asia and Eastern 
Europe due to the lack of capacity and availability of drug resistance testing facilities, inconsistent testing 
methods and inadequate treatment [25, 159-161]. During 2013, in SA 1.8% of new cases and 6.7% of 
retreatment cases were reported to have MDR-TB, with the second highest number of reported XDR-TB 
cases globally [1]. Furthermore, in 2013 SA became one of four countries reporting cases of T/XXDR-TB 
[162].  
 
Drug resistant TB is exacerbated by convergence with HIV infection. In a South African study by Gandhi et 
al, of 53 patients diagnosed with XDR-TB 44 were tested for HIV and all were co-infected, 52 of which died 
with a median survival of 16 days from diagnosis [155]. Further studies have shown a 70-90% HIV co-
infection in MDR-TB patients [163-165] and 98-100% in XDR-TB [165] with 80% [166] and 98% [155] 
mortality in XDR-TB reported.  
 
1.2 Human immunodeficiency virus infection 
 
1.2.1 Overview of  human immunodeficiency virus infection 
HIV is a retrovirus of the lentivirus genus and Retroviridae family, transmitted in certain bodily fluids. The 
virion was identified in 1983 as the causative agent of acquired immunodeficiency syndrome (AIDS) [167, 
168]. Infection is characterised by progressive CD4+ T-cell depletion and chronic immune activation 
resulting in immunodeficiency, immune exhaustion and the onset of opportunistic infections and 
malignancies [10].  
 
1.2.2 Epidemiology of human immunodeficiency virus/acquired immunodeficiency syndrome 
As of 2014 an estimated 36.9 million individuals were living with HIV infection worldwide, with 
approximately 2 million new infections (5,480 daily) and a mortality of 1.2 million during this period. Sub-
Saharan Africa is the most affected accounting for 70% of infections globally [169]. In 2013, SA had the 
highest number of individuals living with HIV infection (6.8 million), new infections (340,000), and the 






Figure 1.6: Prevalence of human immunodeficiency virus infection (2014) depicting the high burden in 
South Africa [169]. 
 
1.2.3 Human immunodeficiency virus strains and subtypes  
HIV is a zoonotic virus originating in West and Central Africa from multiple transmissions of the simian 
immunodeficiency virus from non-human primates [170]. HIV-1 and HIV-2 are two distinct viruses; HIV-1 
predominates globally while HIV-2 is relatively uncommon, mainly restricted to West Africa, is less 
infectious and presents with slower disease progression [10, 171]. In this thesis, HIV refers to HIV-1. 
 
There are four strains of HIV-1 originating from three individual transmission events from chimpanzees (M, 
N and O) and one event from gorillas (P). Strains N, O and P are restricted to West Africa. Strain M is 
responsible for the global HIV pandemic and is composed of nine genetically distinct subtypes: A-D, F-H, J 
and K. In addition, the subtypes can combine genetic material to form a hybrid virus termed a circulating 
recombinant form, the frequency of which is increasing worldwide. Subtype C is prevalent in Africa and 
India accounting for approximately 48% of infections globally during 2004-2007. Subtype B is 
predominately found in Western Europe, North and South America and Australia accounting for 11% of 
infections in the same period [10, 171].  
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HIV-1 displays marked genetic diversity and rapid evolution, contributing in a large part to the success of the 
virus. This is a result of a high rate of replication and mutations caused by the error prone viral reverse 
transcriptase [172], transcriptional inaccuracy by host ribonucleic acid (RNA) polymerase II and 
ABOBEC3G/F mediated G-to-A hyper mutation [173]. An infected and untreated individual has a plasma 
viral load of approximately 104-105copies/ml with a turnover rate of ~1010/day [174]. This results in 10 
mutations with every replication cycle of the viral genome repeated in thousands of generations over the 
course of infection in a large quasi-species population. Consequently, the virus can evolve rapidly in 
response to selective pressures with the rise of a genetically distinct HIV-1 population every few years [173, 
175, 176].  
 
1.2.4 Morphology, morphogenesis and replication of human immunodeficiency virus-1 
Mature HIV-1 is spherical virion with a diameter of approximately 120nm. It consists of a lipid bilayer 
membrane, with envelope (Env) glycoprotein (gp) spikes and an inner layer of matrix proteins (MA). This 
surrounds a characteristic conical fullerene core housing the rinonucleoprotein (RNP) complex of 
nucleocapsid (NC), viral RNA and viral enzymes (protease (PR), reverse transcriptase (RT), integrase (IN), 
Vpu, Vif, Vpr, Nef, Tat and Rev ) [175, 177]. The viral genome consists of two identical single-stranded 
RNA molecules (9.2kb) within the viral particle and a pro-viral double stranded deoxyribonucleic acid 
(DNA) within the infected host cell [177] (Figure 1.7). 
 
 
Figure 1.7: The structure of the mature human immunodeficiency virus-1 virion [178]. 
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The initial step in the HIV-1 replication cycle (Figure 1.8) is host cell attachment and viral entry, for which 
HIV-1 uses a two-receptor model. The Env glycoprotein is a heterodimer of external gp120 covalently linked 
to the transmembrane domain, gp41, organised in triangular symmetry [179]. Env has an affinity for CD4 
receptors and traffics HIV-1 to CD4+ T-cells. The binding of the extracellular domain of gp120 to CD4 
initiates a conformational change in gp120 allowing subsequent binding to a chemokine co-receptor; CCR5 
or C-X-C motif receptor (CXCR) 4 [180]. The expression of these receptors on the surface of lymphocytes, 
monocytes, macrophages and DCs are the major determinants of tropism and target cell populations. 
CD4/co-receptor ligation triggers additional conformational changes in Env permitting gp41 to fuse with the 
host cell membrane Following fusion, the viral core is released into the cytoplasm of the newly infected cell 
to initiate replication [176, 177]. 
 
Uncoating of the viral capsid is facilitated by MA, Nef and Vif together with host-derived cellular factors. 
The single stranded viral RNA is then reverse transcribed by HIV-1 RT, a RNA-dependent DNA 
polymerase, into full length double stranded pro-viral DNA. The pro-viral DNA is transported in the pre-
integration complex to the nuclear envelope and is actively transported through the nuclear pore under the 
guidance of Vpr [181]. Before integration, the pro-viral DNA is present in the host cell nucleus in three 
forms – linear, 1-long terminal repeat (LTR) or 2-LTR circles. Nef, Tat and Rev are produced in basal 
amounts by the activation of the LTR promoter region by host cellular factors, including nuclear factor –κB 
(NF-κB) [182]. In the host cell nucleus HIV-1 IN catalyses the integration of the viral genome into the host 
chromosomes [176].  
 
Following integration, cellular RNA polymerase II transcribes pro-viral DNA. However, elongation of the 
viral transcript requires binding of HIV-1 Tat to the HIV-1 trans-activation response element (TAR) [183]. 
In the early stages of replication only multiply-spliced messenger ribonucleic acids (mRNAs) are generated 
together with the expression of Tat, Nef and Rev. Once sufficient levels of Rev are achieved, non- or singly-
spliced mRNAs are produced. HIV-1 mRNAs are then transported to and translated by cytoplasmic 
polysomes to produce viral proteins and RNA [184].  
 
Genomic env is translated into the precursor protein gp160, glycosylated within the endoplasmic reticulum, 
transported to and inserted into the host cell membrane. Gag-pol is translated to produce Gag polyprotein, 
and a ribosomal -1 frameshift during translation produces the Gag-Pol polyprotein. Gag is the source of 
structural proteins for the assembly of the mature virion while Gag-Pol contains the viral enzymes PR, RT 
and IN. At this point Gag and Gag-Pol polyproteins traffic to the plasma membrane for assembly and 










Figure 1.8: The life cycle of human immunodeficiency virus-1 [185]. 
 
In the process of replication HIV-1 assembles into two morphologically distinct immature and mature forms 
(Figure 1.9). HIV-1 is initially budded and released from the infected host cell as a non-infectious donut 
shaped immature virion. The immature virion is composed of a cellular derived bilayer lipid envelope, and 
an inner layer of radially extended Gag poly-proteins. Gag is the construction machine of HIV-1 which 
performs and integrates all of the activities required for HIV-1 assembly [173]. Following translation, the N-
terminal MA domain targets Gag to the host cell plasma membrane and binds directly to the inner leaflet by 
insertion of myristoyl group into the lipid bilayer and by the basic patch which binds acidic phospholipids, 
notably phosphatidylinositol-(4,5)-biphosphate [186]. During viral assembly and budding Nef, Env and Vpu 
are involved in the downregulation of CD4 on the host cell membrane preventing interaction with newly 




During budding or immediately after release, HIV-1 reorganises the inner morphology of the immature 
virion through a process of maturation, RNA dimer stabilisation and acquisition of infectivity [173, 175, 
187]. Mature HIV-1 structural proteins are derived from the Gag poly-protein which is composed of four 
domains (MA (matrix protein or p17), CA (capsid protein or p24), NC (nucleocapsid or p7) and p6) and two 
spacer peptides (SP1, SP2)) thus containing 5 proteolytic cleavage sites (Figure 1.9). Budding results in 
activation of viral PR which cleaves Gag at these sites to produce a new set of viral proteins. These proteins 
then reassemble to form the characteristic morphology a mature HIV-1 virion. The MA remains associated 
with the inner viral membrane to form the matrix layer, NC coats the stabilises the dimeric viral RNA and 
condenses at the centre of the core to form the nucleocapsid, and approximately 1500 copies of CA assemble 








HIV-1 is transmitted in certain bodily fluids (blood, pre-seminal fluid and semen, rectal fluids, vaginal fluids 
and breast milk) when the source comes into contact with a mucous membrane, damaged tissue or direct 
contact with the blood stream. The routes of exposure include first and foremost sexual, vertical mother-to-
child (during pregnancy, delivery and breastfeeding) and intravenous transmission (shared needles such as in 
intravenous drug use, needle stick injuries, infected blood transfusion). Generally HIV-1 transmission rates 
are low ranging from 0.001 to 10% per exposure [189, 190]. Viral load is the most significant factor 




1.2.6 The course of human immunodeficiency virus-1 infection 
The pathogenesis of HIV-1 can be divided into four stages; an eclipse phase, acute infection, asymptomatic 
chronic infection and AIDS (Figure 1.10).  
Infection begins with the transmission of a single founder virus. During the eclipse phase (~1-2 weeks), HIV-
1 initiates focal replication in proximal CD4+ T-cells moving to proximal lymphoid organs and then 
establishing systemic infection through extracellular diffusion, DC transport or T-cell migration. Viremia is 
undetectable without presentation of an immune response or clinical symptoms [190, 192].  
 
This is followed by acute infection (~2-4 weeks) during which there is a spike in viral replication with 
plasma viral loads reaching up to 108 copies/ml, and consequently the highest risk of transmission during the 
course of infection [193]. This period is characterised by high numbers of infected cells in the blood and 
lymph nodes, a transient decrease in peripheral CD4+ T-cells, a significant increase in markers of immune 
activation as well as marked induction of inflammatory cytokines and chemokines. Killing of productively 
infected cells is mediated by HIV-specific CD8+ T-cells (cytolysis and Fas mediated apoptosis) in response 
to HIV-1 antigens expressed on infected cells in association with MHC-I [10, 192]. The advantage of the two 
step replication model employed by Tat and Rev is the postponement of viral protein synthesis to minimize 
exposure to CD8+ T-cells and maximise viral production per cell [192]. At approximately three months there 
is production of HIV neutralising antibodies mediating phagocytosis of infected cells. The innate immune 
response is also essential for viral control during this time and is largely meditated by NK cells. Both the 
adaptive and innate immune responses select for the emergence of mutations in key viral epitopes leading to 
immune escape [10, 192]. 
 
The control of replication and exhaustion of activated target cells results in a temporal sharp decrease in 
plasma viral load by 100-fold or more to a set-point [10, 11, 192]. This value varies from below detectable 
limits of <40 copies/ml in elite controllers (patients who naturally control viral replication similar to the 
levels of patients on ARVs) to >10,0000 copies/ml [11, 194]. Clinically, in approximately half of infected 
individuals, this period can be characterised by flu-like symptoms termed acute retroviral syndrome [10, 
192]. 
 
This is followed by asymptomatic chronic infection or clinical latency (~1-20 years) where HIV-1 exists in a 
quasi-steady state with the host. This period is represented by a constant or gradually rising level of viremia 
with concurrent progressive exhaustion of HIV-specific T-cells; characterised by increased expression of 
programmed death 1 (PD-1) and loss of effector function [192]. Without treatment, HIV generally progresses 
to AIDS within 7-10 years. As the final stage, AIDS is diagnosed when a patient has a CD4+ T-cell count 
below 200 cells/μl and is characterised by opportunistic infections (predominately TB) and viral-related 
malignancies (non-Hodgkin’s lymphoma and Kaposi’s sarcoma). There is loss of control over viral 




Figure 1.10 The natural history of untreated human immunodeficiency virus-1 infection [10]. 
 
1.2.7 CD4+ T-cell depletion and immune dysfunction 
The initiating HIV-1 founder virus has distinct phenotypic characteristics including CCR5 tropism and the 
requirement of high surface expression levels of CD4. This lends CD4+CCR5+ central and effector memory 
T-cells as the preferred target population. As the infection progresses the HIV-1 Env protein undergoes 
mutational and conformational evolution allowing HIV-1 to enter cells using CXCR4 and lower expression 
levels of CD4 representing the extension of infection into new cell types [195].  
 
A characteristic hallmark of HIV infection is the progressive reduction in circulating CD4+ T-cells by a 
combinatorial effect of reduced capacity to generate and support T-cell function and increased destruction 
[11, 190]. 
 
CD4+ T-cells are eradicated by direct cytopathic infection, HIV-specific CD8+ T-cell and antibody mediated 
killing of infected cells as well as bystander effects including syncytia formation, chronic immune activation 
and subsequent senescence [10, 190, 192]. Several viral proteins have been attributed apoptotic effects; host 
cell surface expression of Env mediates syncytium formation [190] and a proteolytic fragment of caspase 8, 
Casp8p41 produced by viral proteases induces apoptosis through the Bcl-2 associated X protein (Bax)/Bcl-2 
homologous antagonist/killer (Bak) and caspase 9 mitochondrial pathway [196]. 
 
Concurrently, HIV-1 replication causes the activation of APCs through ligation of innate immune receptors 
and the consequent production of pro-inflammatory cytokines and the recruitment and accumulation of HIV-
specific effector cells. This pro-inflammatory environment promotes central memory T-cell proliferation 
increasing the HIV target cell population [11]. Finally, chronic inflammation results in collagen deposition 
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and progressive fibrotic damage to the fibroblastic reticular cell network, the predominant source of T-cell 
survival factor IL-7 further accentuating CD4+ T-cell destruction [197]. 
 
In contrast to the progressive loss of circulating CD4+ T-cells, the most notable effect on T-cell homeostasis 
occurs in the gut associated lymphoid tissue, the largest lymphoid organ in the body containing 
approximately 40% of all lymphocytes. Here, HIV results in the rapid and massive elimination of resting and 
activated CCR5+CD4+ T-cells early after infection that is not restored following ARV therapy [11, 198] 
(Figure 1.10). Further to the loss of total CD4+ T-cells, there is preferential depletion of Th17 cells essential 
in the immune defence to bacteria and critical in maintenance of the mucosal barrier [199-201]. In the 
gastrointestinal tract (GIT), T-cell depletion is accompanied by enterocyte apoptosis, breakdown of the 
intestinal epithelial barrier and enhanced barrier permeability resulting in the increased translocation of 
microbial products from the GIT into the systemic circulation contributing to systemic immune activation 
[202].  
 
1.2.8 Chronic immune activation 
A key correlate of HIV-1 progression is the chronic activation of the innate and adaptive immune systems 
with the expression of activation (CD38/HLA-DR) [203], senescence (CD57) [204] and exhaustion (PD-1) 
markers [205], hyperglobulinemia, increased circulating pro-inflammatory cytokines and activation of IFN 
responsive genes [206]. Several mechanisms have been suggested to drive this biological phenomenon 
including: (1) Direct actions of HIV as a ligand for TLR-7 and TLR-8 on plasmacytoid DCs and consequent 
IFN-α production [207]. (2) Activation of other innate receptors through capsid protein [208] or viral DNA 
[209]. (3) Microbial translocation across the GIT into the systemic circulation – lipopolysaccharide is a 
potent TLR-4 stimulator resulting in the production of pro-inflammatory cytokines IL-6 and TNF-α [202]. 
(4) Co-infection with viruses that expand activated T-cells [210]. (5) A reduced ratio of pro-inflammatory 
Th17 to anti-inflammatory Tregs [200], as well as (6) homeostatic mechanisms driving proliferation to 
restore depleted lymphocyte populations [11].  
 
1.2.9 Antiretroviral therapy 
Antiretroviral treatment suppresses viral replication and facilitates reconstitution of the immune system. 
Expanding access to ARVs has significantly changed the epidemiology of HIV/AIDS; raising prevalence due 
to the increase in life span but simultaneously decreasing incidence due to the reduced risk of transmission 
[169]. These drugs are grouped into 6 classes based on the mechanism of action and resistance profiles – 
nucleoside-analog reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors 
(NNRTI), protease inhibitors, fusion inhibitors, integrase inhibitors and chemokine co-receptor agonists 
(Figure 1.11). Triple drug therapy, termed highly active antiretroviral treatment (HAART) is the most 




Figure 1.11: The human immunodeficiency virus-1 life cycle illustrating the mechanisms of action of 
different classes of antiretroviral drugs [10]. 
 
The South African National Consolidated Guidelines recommend HAART initiation when the patient’s 
CD4+ T-cell count is below 500cells/μl, WHO clinical stage 3 or 4, pregnant, breastfeeding, or the co-
presence of Hepatitis B or active TB. A standard first line combined ARV regimen for adults is composed of 
two NRTIs (TDF/Tenofovir and 3TC/Lamivudine or FTC/Emtricitabine), as well as a NNRTI 
(EFV/Efavirenz) provided in a fixed dose combination. This regime is also recommended in HIV/TB co-
infection [211]. Following the initiation of ARVs, plasma viral load typically decreases to concentrations 
below the minimum detection limit of many commercial assays within three months, with a variable 
restoration of CD4+ T-cell counts [10]. 
 
The ability of HIV to mutate and replicate in the presence of ARVs is termed HIV drug resistance (HIVDR). 
The there is a steady increase in the prevalence of HIVDR in low- and middle-income countries such as SA. 
The consumption of ARVs despite continued viral replication results in the selection of HIV sub-populations 
with HIVDR mutations. This is largely a consequence of sub-optimal treatment regimens, poor adherence 
28 
 
and the ability of the drug to select for resistant mutations. This results in the transmission of HIVDR strains, 
treatment failure and requirement of more expensive second and third line HAART regimes [10, 212].  
 
Despite their success in controlling HIV replication, HAART is unable to eradicate HIV pre-empting lifelong 
treatment. HIV can survive HAART due to latent infection of long lived memory T-cells, integration of HIV 
DNA into the host genome without viral replication [192, 213], and anatomical reservoirs poorly accessible 
to HAART such as the GIT, lymphoid tissue and central nervous system [214, 215]. 
 
1.3 Tuberculosis and human immunodeficiency virus co-infection 
 
1.3.1 Overview of tuberculosis and human immunodeficiency virus co-infection 
Infection with HIV is the most significant risk factor in the progression of TB disease; an HIV positive 
individual has a 26-31 times greater risk of developing active TB infection. In turn, TB expedites the 
pathogenesis of HIV, with TB being the most common presenting illness and the leading cause of mortality 
in this group [1, 169].  
 
1.3.2 Epidemiology of tuberculosis and human immunodeficiency virus co-infection 
According to WHO, in 2013 at least one third of HIV infected individuals were co-infected with MTB 
globally. During this time, 1.1 million new TB cases were reported in HIV positive individuals and 1 in 4 
HIV-related deaths were attributed to TB. In this same period, 62% of South African TB patients were noted 
to be HIV positive [1]. Furthermore, SA had the second highest number of TB-related deaths among HIV 













Figure 1.12: Estimated tuberculosis and human immunodeficiency virus co-infection prevalence (2013) 
depicting the high burden of co-infection in South Africa [1]. 
 
1.3.3 CD4+ T-cell responses in tuberculosis and human immunodeficiency virus co-infection 
Recent studies have begun to elucidate the effect of TB/HIV co-infection on T-cell responses. MTB specific 
CD4+ T-cells are rapidly depleted from the periphery following HIV infection, partly due to preferential HIV 
targeting of these cells [12]. In addition, HIV infected patients with latent TB infection show a loss of 
peripheral and broncho-alveolar lavage (BAL) fluid mono-, bi- [216, 217] and polyfunctional MTB specific 
CD4+ T-cell responses [216-219]. IL-2 producing MTB-specific CD4+ T-cells correlate inversely to viral 
load [218], and this is not corrected with ARV treatment [220]. In a macaque model, the peripheral depletion 
of CD4+ T-cells has been linked to TB reactivation [221].  
 
Both active and latent TB have been associated with lower HIV-specific T-cell functionality in co-infected 
compared to mono-infected patients. A stronger effect is noted in active infection indicating that MTB load 
may amplify HIV mediated T-cell dysregulation accounting for expedited HIV progression [13, 222]. 
Several studies have observed that active TB enhances CCR5 expression and/or the frequency of 
CCR5+CD4+ T-cells during HIV co-infection [14, 15], this suggests that TB mediated chronic immune 




Furthermore, it has been shown that a strong CD4+ T-cell response to MTB may simultaneously result in 
enhanced HIV replication [224], dependent on the MTB strain: Less virulent strains drive potent pro-
inflammatory cytokine production and heightened viral replication. More virulent strains, which produce a 
less immunogenic response, promote lower levels of HIV replication [225]. These findings indicate that 
MTB antigen specific responses enhance HIV viral replication in line with the higher viral loads observed in 
co-infected patients compared to HIV non-infected patients who express similar levels of 
immunosuppression [14, 226]. 
 
1.4 T-regulatory lymphocytes 
 
1.4.1 Overview of T-regulatory lymphocytes 
T-regulatory lymphocytes are a suppressive subset of CD4+ T-lymphocytes (5-10%) characterised by the 
expression of lineage specific transcription factor forkhead box P3 (Foxp3) [17]. Tregs regulate effector 
lymphocyte function to maintain immunological tolerance and suppress pro-inflammatory pathways [227, 
228]. In the context of TB/HIV co-infection, an imbalance in Treg proportion can either lead to uncontrolled 
inflammation and consequent immunopathology or down regulation of antigen specific CD4+ T-cells, 
ultimately resulting in pathogen persistence and establishment of chronic infection [229].  
 
1.4.2 T-regulatory lymphocyte polarisation 
Under physiological conditions the vast majority of Tregs are generated in the thymus (tTregs), responsible 
for the maintenance of immune homeostasis and peripheral tolerance. Upon pathological challenge the tTreg 
T-cell receptor (TCR) repertoire is complemented by peripheral (p)Tregs derived from naïve CD4+ 
conventional T-cells (Tconv) [229-231]. Together with epigenetic changes, Tregs are polarised by the 
combination of several transcriptional signals including TCR/CD28 co-stimulation, transforming growth 
factor-β (TGF-β)/IL-2 cytokine signaling and an autocrine Foxp3 dependent feedback loop. These signals 
culminate in the activation of a host of transcription factors binding to the Foxp3 promoter as well as three 
highly conserved non-coding sequence regions (CNS1-3) in the genomic Foxp3 region [230] (Figure 1.13). 
 
With regard to cytokine signalling, Treg polarisation is mediated by exposure to low-dose antigen in the 
presence of TGF-β and IL-2 [230, 232]. TGF-β receptor ligation results in SMAD3 binding to CNS1, a 
prerequisite for Foxp3 induction in CD4+ Tconvs [233]. This is reinforced by IL-2; Tregs constitutively 
express CD25 (IL-2 receptor (R) α) [228], ligation of which results in activation of Janus activated kinase 
(Jak)1/3 and subsequent phosphorylation and activation of signal transducer and activator of transcription 
(STAT) 5 [234]. In turn, STAT5 binds to the promoter region and CNS2 in the Foxp3 gene inducing Foxp3 






Figure 1.13: Transcriptional regulation of forkhead box P3 expression [230].  
 
Forkhead box P3, a transcription factor of the winged helix family, is indispensable for Treg lineage 
specification and suppressive function by acting at transcriptional, epigenetic and post transcriptional levels 
[17, 236]. It maintains the expression of CD25 at the cell surface by binding the CD25 promoter both 
directly [237] and indirectly [238, 239]. In this way, IL-2 creates a positive feedback loop for CD25 
expression through STAT5 and Foxp3 [240]. Regulatory T-cells do not produce IL-2 [241] but are reliant on 
IL-2 produced by CD4+ Tconvs [242]. This dependence sets up a negative feedback loop whereby the 
proliferation of Tregs is directly controlled by the degree of Tconv activation [243]. 
 
1.4.3 Mechanisms of T-regulatory lymphocyte function 
T-regulatory lymphocytes can be divided into subpopulations with disparate suppressive functions and 
heterogeneous chemokine receptors that promote their differential tissue homing and localisation [244, 245]. 
Through a broad array of contact dependent and independent mechanisms, Tregs can inhibit the generation 
and function of effector cells at any point in the inflammatory process [243] including initial activation 
[246], migration [247] or at the target site [248]. 
 
These mechanisms include: (1) The production of inhibitory cytokines (TGF-β, IL-10, IL-35) which suppress 
T-cell activation and proliferation. (2) The deprivation of cytokines of the common receptor γ-chain family 
from effector T-cells (particularly IL-2 via expression of CD25) which induces pro-apoptotic protein 
expression and cell death. (3) The direct killing of DCs and effector cells by granzyme A/B and perforin 
cytolysis or the TNF-related apoptosis inducing ligand death receptor 5 (TRAIL-DR5) pathway. (4) 
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Suppression of DC maturation via lymphocyte activation gene 3 (LAG3) and MHC II interactions. (5) 
Blocking of co-stimulatory molecule expression (CD80/CD86) on DCs via cytotoxic T-lymphocyte antigen 
4 (CTLA4), thereby weakening the APC-T-cell interaction. (6) The expression of ectonucleosidases 
CD39/CD73 which mediate enzymatic hydrolysis of extracellular adenosine triphosphate to inhibitory 
adenosine thereby disrupting the metabolic state of effector cells via 3’, 5’- cyclic adenosine monophosphate. 
(7) The deprivation of tryptophan from effector T-cells through indoleamine 2,3-dioxygenase induction in 
DCs, inhibiting T-cell proliferation [243, 249-251] (Figure 1.14). The mechanism of action employed is most 




Figure 1.14: Immunosuppressive mechanisms used by T-regulatory lymphocytes [252]. 
 
1.4.4 T-regulatory lymphocytes in tuberculosis 
The reported proportion of Tregs in active TB infection is conflicting. Previous studies have noted a reduced 
[253] or unchanged [254, 255] frequency of Tregs in the peripheral blood of untreated active TB patients 
compared to healthy controls. Others have identified Treg expansion at both the disease site and in the 
peripheral blood in an MTB antigen-specific manner, with a correlation to disease severity and an inverse 
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correlation to MTB specific immune responses [256-261]. Notably, there is no evidence on the frequency of 
Tregs in TB/HIV co-infection. 
 
T-regulatory lymphocytes have been shown to down regulate the immune response to MTB preventing tissue 
injury by resolving granulomatous inflammation. However, impairment of antigen specific T-cell responses 
simultaneously prevents bacterial clearance and reduces inflammation at the infection site paving the way for 
chronic infection. More specifically, Treg mediated suppression results in impaired macrophage activation 
and killing of intracellular bacteria, reduced antigen presenting capacity and pro-inflammatory cytokine 
production, including MTB specific IFN-γ production by Th1 cells, as well as reduced MTB specific CD8+ 
and CD4+ T-cell activation, expansion and recruitment to the infection site [223, 255, 258-260, 262-264].  
 
In addition to limiting inflammation, Tregs have also been implicated in the reactivation of latent infection 
and dissemination of bacilli. During active TB infection Tregs have a higher capacity to inhibit Th1 than 
Th17 responses. It has been suggested that this differential inhibition of Th1/IFN-γ mediated suppression of 
bacterial replication while permitting Th17/IL-17 mediated recruitment of pro-inflammatory cells to the site 
of infection results in chronic inflammatory caseating tubercles and the transmission of bacilli. This indicates 
that Tregs exert a selective suppression on specific components of the adaptive immune response to MTB 
[258]. 
 
1.4.5 T-regulatory lymphocytes in human immunodeficiency virus infection 
The majority of HIV studies have reported lower absolute cell counts but increased relative frequency of 
lymph node [265], mucosa [266] and peripheral [267-271] Tregs compared to healthy controls, resulting in a 
greater suppressor to effector ratio [272]. Interestingly, HIV controllers and long term non-progressors 
display tissue and peripheral Treg frequencies similar to or lower than healthy controls [266, 270, 271], 
indicating that the selective expansion of Tregs is non-protective [273].  
 
Regulatory T-cell functionality is maintained during untreated chronic HIV infection with anti-proliferative 
capacity similar to that of HIV controllers [274] and significant down regulation of HIV specific CD4+ T-cell 
immune responses, particularly the inhibition of cytokine production [229, 275-277]. Furthermore, HIV-1 
binding to the Treg CD4 enhances Treg survival and suppressive activity particularly the ability to inhibit 
CD4+ T-cell proliferation and IL-2 production [277]. This is potentially beneficial; suppressing chronic T-
cell activation reducing the pool of susceptible CD4+ T-cells [278]. However, this would also inhibit HIV-
specific T-cell responses contributing to immune deficiency, heightened virulence and an overall poor 





1.5 T-helper 17 lymphocytes 
 
1.5.1 Overview of T-helper 17 lymphocytes  
T-helper 17 cells are a pro-inflammatory subset of CD4+` effector T-cells [280] characterised by the 
production of IL-17A/F, IL-21 and IL-22, surface expression of CCR6 and lineage specific transcription 
factor RAR-related orphan receptor C (RORC) [16]. Under immune homeostasis, Th17 cells predominantly 
reside at the mucosal surfaces where they play a pivotal role in inflammatory reactions and protective 
immunity against intra-[281, 282] and extracellular [283, 284] bacterial and fungal infections. 
 
1.5.2 T-helper 17 lymphocyte polarisation 
Classically, Th17 cells are generated from naïve CD4+ Tconvs under TGF-β/IL-21 [285] or TGF-β/IL-6 and 
IL-21 or IL-23 [286] conditions (Figure 1.15). This leads to Th17 lineage commitment via the activation of 
STAT3 and downstream transcription factor RORC, which in turn binds to the promoter region of IL17A/F 
[287-290].  
 
Further to this, IL-1β and IL-6 are essential in the expansion and amplification of differentiated and memory 
Th17 cells and IL-23 is essential for the stabilisation and maintenance of the Th17 phenotype and effector 
functions [291]. Naive CD4+ Tconvs do not express IL-1R and IL-23R; these receptors are induced after 
exposure to TGF-β and IL-6/IL-21 [285, 292, 293]. Subsequently, IL-1β acts synergistically with IL-6 and 
IL-23 towards Th17 polarisation by regulating the expression of interferon regulatory factor 4 which then 





Figure 1.15: Representation of T-helper 17 lymphocyte differentiation [296].  
 
In addition to the key regulators discussed above, other transcription factors such as Baft [297], IκBζ [298] 
and Runx1 [299] are essential for enhancing Th17 differentiation and production of effector molecules [300]. 
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1.5.3 Functions of T-helper 17 effector cytokines 
T-helper 17 cells characteristically produce IL-17A/F, IL21 and IL-22. Th17 cells also produce CCL20, 
granulocyte-macrophage-colony stimulating factor (GM-CSF), IL-8, IL-26 and IL-10, although these are not 
Th17 specific [300].  
 
1.5.3.1 Interleukin-17A and F 
IL-17A is the prototypic member of the IL-17 family consisting of 6 cytokines; IL-17A-F. IL-17A and IL-
17F share 44% homology and can form homodimers or heterodimers. They are presumably expressed by 
induction of the same gene locus and are commonly co-expressed at the level of the single cell [301]. Both 
IL-17A and F bind to the receptor heterodimer; IL-17RA/IL-17RC [302, 303]. Ligation of this receptor 
recruits adaptor protein ACT1 which in turn stimulates TNF receptor-associated factor 6 (TRAF6) to activate 
the canonical NF-κB, and to a lesser extent the mitogen activated protein kinase (MAPK) pathways in target 
cells [301, 304, 305]. This results in pro-inflammatory gene expression by transcriptional activation [306] 
and target mRNA stabilisation [307].  
 
IL-17A and F are pivotal in the recruitment, activation and migration of neutrophils and CCR5+ lymphocytes 
to the site of inflammation [308]. In addition, these cytokines target non-immune cells including epithelial 
and endothelial cells, fibroblasts and airway smooth muscle cells to produce pro-inflammatory mediators 
such as antimicrobial molecules (CCL20 and defensin-β4), adhesion molecules, cytokines (IL-6, IL-8, IL-26, 
TNF-α, IL-1β, granulocyte-CSF, GM-CSF, chemokines (CXCL1, CXCL2, CXCL8, CCL2, CCL7, CCL20, 
CCL28) as well as PGE2, nitric oxide and MMPs [280, 300, 301, 309, 310] (Figure 1.16).  
 
CCL20 mediates Th17 tissue homing to the site of inflammation via its cognate receptor CCR6, highly 
expressed on Th17 cells. The autocrine production of CCL20 allows Th17 cells to autonomously regulate 
their recruitment to inflamed tissues and sustain the Th7 mediated inflammatory cascade [295, 311].  
 
1.5.3.2 Interleukin-21 
IL-21, of the IL-2 cytokine family, mediates its actions through a heterodimer of IL-21R and the common 
cytokine receptor γ chain found on B- and T-lymphocytes as well as other cells of the myeloid lineage. 
Ligation of the IL-21R complex activates the Jak3/STAT3 pathway resulting in Th17 differentiation [301]. 
In addition, IL-21 causes proliferation and differentiation of CD8+ T-cells [312] and B-lymphocytes [313], 
immunoglobulin class switching [314], differentiation and cytotoxic activities of NK cells [315] and IL-8 






IL-22, of the IL-10 cytokine family, is produced in response to IL-23/STAT3 signalling [316]. The IL-22R is 
composed of IL-22R1 and IL-10R2 chains expressed on epithelial cells, keratinocytes and fibroblasts, but 
not immune cells. Ligation of this receptor activates STAT3 and MAPK pathways resulting in the expression 
of genes and proteins involved in tissue remodelling and wound healing, epidermal hyperplasia and epithelial 
barrier function, inflammation, chemotaxis, acute phase reactants and antimicrobial substances, which in turn 
enhance the inflammatory properties of TNF-α, IL-1β and IL-17A/F [301, 316, 317]. In chronic 
inflammation, IL-22 exerts either cytoprotective or pro-inflammatory effects depending on the tissue location 




Figure 1.16: The functions of T-helper 17 effector cytokines. Adapted from Maddur et al [300]. 
 
1.5.4 T-helper 17 lymphocytes in tuberculosis 
A distinct subset of MTB specific pro-inflammatory Th17 memory T-cells have been identified [320]; 
however, their frequency and contribution to the immune response is conflicting. Several studies have noted 
an expansion of Th17 cells and elevated levels of IL-17A in the peripheral blood [253, 321, 322] and pleural 
fluid [253, 322, 323] during MTB infection with correlation to disease severity [322]. Others have noted a 
higher frequency of Th17 cells in peripheral blood [320, 324-329] and BAL fluid [320, 328] of latently 
infected or healthy donors. This suggests that the Th17/IL-17A axis may be associated with either pathology 
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and/or protection [308]. Furthermore, other studies have found no significant difference in the systemic Th17 
count between active, latent and non-infected patients [330, 331]. Notably, there is no evidence on the 
frequency and function of Th17 cells in TB/HIV co-infection. 
 
Th17/IL-17 axis is suggested to provide protective immunity against MTB by contributing to granuloma 
formation and maintenance [332-335]. Early expression of pulmonary IL-17 in TB infection is pivotal in 
granulomatous cellular recruitment by inducing chemokine secretion from non-haematopoietic cells. This 
predominantly results in neutrophil and CCR5+ lymphocyte recruitment, through the induction of IL-8 and 
CXCL13 respectively, to form lung lymphoid follicles for optimal macrophage activation and bacterial 
clearance [308, 336-340]. However, there is a disadvantage to this protective granulomatous strategy. During 
the chronic stages of infection, Th17 hyperactivity can lead to immunopathology via IL-17-CXCL mediated 
influx of immune cells and extensive tissue destruction [332, 339, 341-343]. 
 
In this way, Th17 cells can take part in both protective and pathological mechanisms in TB infection, not 
only contributing to the development and organisation of the granuloma but also its breakdown and 
progression to cavitation and eventual transmission [333, 344]. Th17 immunity has also been shown to 
contribute to mucosal TB vaccine immunity where CXCL13 induction by IL-17A was critical in protection 
[308]. 
 
1.5.5 T-helper 17 lymphocytes in human immunodeficiency virus infection  
During HIV infection there is preferential loss of Th17 cells from the mucosa and peripheral blood with 
reduced levels of IL-17A that is not completely restored by ARV therapy [345-350]. This suggests that HIV 
infection interferes with the generation of Th17 cells [349, 351]. Interestingly, this phenomenon is absent in 
HIV-1 infected long-term non-progressors [346] and elite controllers [352]. The loss of Th17 cells has been 
noted to contribute to HIV pathogenesis [353], correlate highly with immune hyper-activation [354] and 
negatively correlate with raised viral loads.  
 
Th17 cells show greater HIV susceptibility than other T-cell subsets [354-356]. In addition, this subset is a 
highly permissive environment for HIV replication in vitro and in vivo, in both CCR5 and CXCR4 tropic 
HIV [354, 356, 357]. This has been associated with a significant impairment of Th17 generation from CD4+ 
Tconvs in the peripheral blood [349]. Th17 targeting correlates with a higher expression of HIV envelope 
receptors CD4, CXCR4, CCR5 and α4β7 and low levels of autocrine production of CCR5 ligands CCL3 and 
CCL4, potent mediators of HIV self-protection, resulting in higher gp120 binding [356] and providing a 
potential reason for their preferential depletion [349, 354, 356]. Furthermore, the over expression of Th17 
negative regulators (phosphatase SHP2, suppressor of cytokine signalling 3, and protein inhibitor of 
activated STAT3) have been observed during HIV infection [358]. 
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1.5.6 T-regulatory and T-helper 17 lymphocyte antagonism 
There is a cell intrinsic reciprocal relationship between Th17 and Treg developmental pathways. This 
influences the nature of the immune response with a significant effect on the development and outcome of 
inflammatory diseases [359].  
Th17 cells and Tregs arise from common precursors and carry out opposing functions driven by the cytokine 
milieu and its effect on specific transcription factors. TGF-β is a common element in Treg and Th17 
development by inducing the expression of Foxp3 and RORC in naïve CD4+ Tconv through SMAD2 and 3 
respectively. TGF-β alone advances Foxp3 expression and Treg differentiation to maintain peripheral 
tolerance; the N-terminal domain of Foxp3 interacts with RORC inhibiting IL-17A promoter activation 
preventing Th17 differentiation [359]. However, TGF-β in combination with IL-21, IL-6/IL-21 or IL-6/IL-23 
reduces TGF-β induced Foxp3 expression through the activation of STAT3, this in turn overcomes Foxp3 
mediated RORC inhibition [296, 360]. In addition, IL-1 inhibits TGF-β induced Foxp3 expression resulting 
in the enhancement of Th17 differentiation under Th17 polarising conditions [361]. 
 
In counterpart to IL-1, IL-6, IL-21 and IL-23; IL-2, secreted by CD4+ Tconv cells, further enforces this 
reciprocal relationship. IL-2 mediated STAT5 activation opposes Th17 differentiation by STAT5 binding of 
the IL17 gene thereby acting as a repressor [362]. IL-2 can also inhibit Th17 polarisation through the 
transcription factor E26-transformation specific 1 [363] and down regulating IL-6R expression in CD4+ T-


















1. World Health Organisation. 2014. Global tuberculosis report. Geneva, Switzerland. 
2. UNAIDS. 2014. AIDSinfo online database. Accessed on 2015-10-14 [http://aidsinfo.unaids.org/]. 
3. Chatterjee D, Pramanik AK. 2015. Tuberculosis in the African continent: A comprehensive review. 
Pathophysiology. 22(1):73-83. 
4. World Health Organisation. 2014. Tuberculosis country profiles online database. Accessed on 2015-
10-14 [http://www.who.int/tb/country/data/profiles/en/]. 
5. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. 2012. Tuberculosis and HIV co-
infection. PLoS Pathogens. 8(2):e1002464. 
6. Andrews JR, Hatherill M, Mahomed H, Hanekom WA, Campo M, Hawn TR, Wood R, Scriba TJ. 
2015. The dynamics of QuantiFERON-TB Gold in-tube conversion and reversion in a cohort of South 
African adolescents. American Journal of Respiratory and Critical Care Medicine. 191(5):584-591. 
7. Philips JA, Ernst JD. 2012. Tuberculosis pathogenesis and immunity. Annual Review of Pathology: 
Mechanisms of Disease. 7:353-384. 
8. Maglione PJ, Chan J. 2009. How B cells shape the immune response against Mycobacterium 
tuberculosis. European Journal of Immunology. 39(3):676-686. 
9. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. 2005. Lung remodeling in 
pulmonary tuberculosis. Journal of Infectious Diseases. 192(7):1201-1210. 
10. Maartens G, Celum C, Lewin SR. 2014. HIV infection: Epidemiology, pathogenesis, treatment and 
prevention. The Lancet. 384(9939):258-271. 
11. Lackner A, Lederman MM, Rodriguez B. 2012. HIV pathogenesis: The host. Cold Spring Harbor 
Perspectives in Medicine. 2(9):a007005. 
12. Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Reither K, Heeregrave EJ, Casazza JP, 
Ambrozak DR, Louder M, Ampofo W. 2010. Preferential infection and depletion of Mycobacterium 
tuberculosis–specific CD4 T-cells after HIV-1 infection. Journal of Experimental Medicine. 
207(13):2869-2881. 
13. Chetty S, Govender P, Zupkosky J, Pillay M, Ghebremichael M, Moosa M-YS, Ndung'u T, Porichis F, 
Kasprowicz VO. 2015. Co-Infection with Mycobacterium tuberculosis impairs HIV-specific CD8+ and 
CD4+ T-cell functionality. PloS One. 10(3):e0118654. 
40 
 
14. Haridas V, Pean P, Jasenosky LD, Madec Y, Laureillard D, Sok T, Sath S, Borand L, Marcy O, Chan 
S. 2015. TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly 
immunosuppressed HIV-infected patients with TB. AIDS. 29(3):263-273. 
15. Kabue JP, de Swardt D, de Beer C, Glashoff RH. 2013. Short-term antiretroviral therapy fails to 
reduce the expanded activated CCR5-expressing CD4+ T-lymphocyte population or to restore the 
depleted naive population in chronically HIV-infected individuals with active pulmonary tuberculosis. 
AIDS Research and Human Retroviruses. 29(5):769-777. 
16. Huber S, Gagliani N, Flavell RA. 2012. Life, death, and miracles: Th17 cells in the intestine. European 
Journal of Immunology. 42(9):2238-2245. 
17. Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T-cell development by the transcription 
factor Foxp3. Science. 299(5609):1057-1061. 
18. Barker RD. 2012. Clinical tuberculosis. Medicine. 40(6):340-345. 
19. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. 1987. 
Tuberculosis in patients with the acquired immunodeficiency syndrome: Clinical features, response to 
therapy and survival. American Review of Respiratory Disease. 136(3):570-574. 
20. TB DOTS Strategy Co-ordination Directorate. 2014. National Tuberculosis Management Guidelines. 
National Department of Health, Republic of South Africa. 
21. Barnes PF, Mistry SD, Cooper CL, Pirmez C, Rea TH, Modlin RL. 1989. Compartmentalization of a 
CD4+ T-lymphocyte subpopulation in tuberculous pleuritis. Journal of Immunology. 142(4):1114-
1119. 
22. Roper W, Waring J. 1955. Primary serofibrinous pleural effusion in military personnel. American 
Review of Tuberculosis. 71(5):616-634. 
23. Balboa L, Romero MM, Basile JI, y García CAS, Schierloh P, Yokobori N, Geffner L, Musella RM, 
Castagnino J, Abbate E. 2011. Paradoxical role of CD16+CCR2+CCR5+ monocytes in tuberculosis: 
Efficient APC in pleural effusion but also mark disease severity in blood. Journal of Leukocyte 
Biology. 90(1):69-75. 
24. Gideon HP, Phuah J, Myers AJ, Bryson BD, Rodgers MA, Coleman MT, Maiello P, Rutledge T, 
Marino S, Fortune SM. 2015. Variability in tuberculosis granuloma T-cell responses exists, but a 




25. Parida S, Axelsson‐Robertson R, Rao M, Singh N, Master I, Lutckii A, Keshavjee S, Andersson J, 
Zumla A, Maeurer M. 2015. Totally drug‐resistant tuberculosis and adjunct therapies. Journal of 
Internal Medicine. 277(4):388-405. 
26. Russell DG. 2007. Who puts the tubercle in tuberculosis? Nature Reviews Microbiology. 5(1):39-47. 
27. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. 2003. The growing 
burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal 
Medicine. 163(9):1009-1021. 
28. Carr JH, Butler R. 2006. Scanning Electron Micrograph of Mycobacterium tuberculosis. Centres for 
Disease Control and Prevention. Accessed on 2015-10-15 
[http://phil.cdc.gov/phil/details.asp?pid=9997#modalIdString_CDCImage_0] 
29. Brennan P. 2003. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. 
Tuberculosis. 83(1):91-97. 
30. Minnikin DE, Lee OY, Wu HH, Nataraj V, Donoghue HD, Ridell M, Watanabe M, Alderwick L, 
Bhatt A, Besra GS. 2015. Pathophysiological implications of cell envelope structure in Mycobacterium 
tuberculosis and related taxa. In: Tuberculosis - Expanding Knowledge. 7:145-175. Edited by Ribón 
DW. InTech. ISBN 978-953-51-2139-8. 
31. Kolattukudy P, Fernandes ND, Azad A, Fitzmaurice AM, Sirakova TD. 1997. Biochemistry and 
molecular genetics of cell‐wall lipid biosynthesis in mycobacteria. Molecular Microbiology. 
24(2):263-270. 
32. Jo EK, Yang CS, Choi CH, Harding CV. 2007. Intracellular signalling cascades regulating innate 
immune responses to Mycobacteria: Branching out from Toll‐like receptors. Cellular Microbiology. 
9(5):1087-1098. 
33. Russell DG, Cardona P-J, Kim M-J, Allain S, Altare F. 2009. Foamy macrophages and the progression 
of the human tuberculosis granuloma. Nature Immunology. 10(9):943-948. 
34. Pandey AK, Sassetti CM. 2008. Mycobacterial persistence requires the utilization of host cholesterol. 
Proceedings of the National Academy of Sciences USA. 105(11):4376-4380. 
35. Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, Barnes PF, Röllinghoff 
M, Bölcskei PL, Wagner M. 2001. Induction of direct antimicrobial activity through mammalian Toll-
like receptors. Science. 291(5508):1544-1547. 
42 
 
36. Underhill DM, Ozinsky A, Smith KD, Aderem A. 1999. Toll-like receptor-2 mediates mycobacteria-
induced proinflammatory signaling in macrophages. Proceedings of the National Academy of Sciences 
USA. 96(25):14459-14463. 
37. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. 1999. Human Toll-like 
receptors mediate cellular activation by Mycobacterium tuberculosis. Journal of Immunology. 
163(7):3920-3927. 
38. Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV. 2006. Mycobacterium tuberculosis 
LprA is a lipoprotein agonist of TLR-2 that regulates innate immunity and APC function. Journal of 
Immunology. 177(1):422-429. 
39. Sutcliffe IC, Harrington DJ. 2004. Lipoproteins of Mycobacterium tuberculosis: An abundant and 
functionally diverse class of cell envelope components. FEMS Microbiology Reviews. 28(5):645-659. 
40. Harding CV, Boom WH. 2010. Regulation of antigen presentation by Mycobacterium tuberculosis: A 
role for Toll-like receptors. Nature Reviews Microbiology. 8(4):296-307. 
41. Flynn JL, Chan J. 2005. What's good for the host is good for the bug. Trends in Microbiology. 
13(3):98-102. 
42. Ulrichs T, Kaufmann SH. 2006. New insights into the function of granulomas in human tuberculosis. 
Journal of Pathology. 208(2):261-269. 
43. Slight SR, Khader SA. 2013. Chemokines shape the immune responses to tuberculosis. Cytokine and 
Growth Factor Reviews. 24(2):105-113. 
44. Algood HMS, Chan J, Flynn JL. 2003. Chemokines and tuberculosis. Cytokine and Growth Factor 
Reviews. 14(6):467-477. 
45. Gonzalez-Juarrero M, Orme IM. 2001. Characterization of murine lung dendritic cells infected with 
Mycobacterium tuberculosis. Infection and Immunity. 69(2):1127-1133. 
46. Dorhoi A, Reece ST, Kaufmann SH. 2011. For better or for worse: The immune response against 
Mycobacterium tuberculosis balances pathology and protection. Immunological Reviews. 240(1):235-
251. 
47. Reiley WW, Calayag MD, Wittmer ST, Huntington JL, Pearl JE, Fountain JJ, Martino CA, Roberts 
AD, Cooper AM, Winslow GM. 2008. ESAT-6-specific CD4 T-cell responses to aerosol 
Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proceedings of the 
National Academy of Sciences USA. 105(31):10961-10966. 
43 
 
48. Cooper AM. 2009. Cell-mediated immune responses in tuberculosis. Annual Review of Immunology. 
27:393-422. 
49. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. 2010. Eicosanoid pathways 
regulate adaptive immunity to Mycobacterium tuberculosis. Nature Immunology. 11(8):751-758. 
50. Reece ST, Kaufmann SH. 2012. Floating between the poles of pathology and protection: Can we pin 
down the granuloma in tuberculosis? Current Opinion in Microbiology. 15(1):63-70. 
51. Blomgran R, Ernst JD. 2011. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T-
cells during Mycobacterium tuberculosis Infection. Journal of Immunology. 186(12):7110-7119. 
52. Madan-Lala R, Sia JK, King R, Adekambi T, Monin L, Khader SA, Pulendran B, Rengarajan J. 2014. 
Mycobacterium tuberculosis impairs dendritic cell functions through the serine hydrolase Hip1. 
Journal of Immunology. 192(9):4263-4272. 
53. Srivastava V, Manchanda M, Gupta S, Singla R, Behera D, Das G, Natarajan K. 2009. Toll-like 
receptor 2 and DC-SIGNR1 differentially regulate suppressors of cytokine signaling 1 in dendritic 
cells during Mycobacterium tuberculosis infection. Journal of Biological Chemistry. 284(38):25532-
25541. 
54. Geijtenbeek TB, van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, 
Appelmelk B, van Kooyk Y. 2003. Mycobacteria target DC-SIGN to suppress dendritic cell function. 
Journal of Experimental Medicine. 197(1):7-17. 
55. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina 
E. 2006. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: 
Implications for prophylaxis and treatment. Journal of Acquired Immune Deficiency Syndromes. 
42(4):464-469. 
56. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. 1993. An essential role for 
interferon-γ in resistance to Mycobacterium tuberculosis infection. Journal of Experimental Medicine. 
178(6):2249-2254. 
57. Cooper AM, Dalton DK, Stewart TA, Griffin J, Russell D, Orme I. 1993. Disseminated tuberculosis in 
interferon-γ gene-disrupted mice. Journal of Experimental Medicine. 178(6):2243-2247. 
58. Green AM, Difazio R, Flynn JL. 2013. IFN-γ from CD4 T-cells is essential for host survival and 




59. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. 2004. Autophagy is a 
defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected 
macrophages. Cell. 119(6):753-766. 
60. Lazarevic V, Flynn J. 2002. CD8+ T-cells in tuberculosis. American Journal of Respiratory and 
Critical Care Medicine. 166(8):1116-1121. 
61. Stenger S. 2001. Cytolytic T-cells in the immune response to Mycobacterium tuberculosis. 
Scandinavian Journal of Infectious Diseases. 33(7):483-487. 
62. Serbina NV, Lazarevic V, Flynn JL. 2001. CD4+ T-Cells are required for the development of cytotoxic 
CD8+ T-Cells during Mycobacterium tuberculosis infection. Journal of Immunology. 167(12):6991-
7000. 
63. Qiao D, Li L, Guo J, Lao S, Zhang X, Zhang J, Wu C. 2011. Mycobacterium tuberculosis culture 
filtrate protein 10-specific effector/memory CD4+ and CD8+ T-cells in tubercular pleural fluid, with 
biased usage of T-cell receptor Vβ chains. Infection and Immunity. 79(8):3358-3365. 
64. Li L, Yang B, Zhang X, Lao S, Wu C. 2014. Mycobacterium tuberculosis-specific polyfunctional 
cytotoxic CD8+ T-cells express CD69. Tuberculosis. 94(3):219-225. 
65. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, 
Melián An, Bogdan C. 1998. An antimicrobial activity of cytolytic T-cells mediated by granulysin. 
Science. 282(5386):121-125. 
66. Pitabut N, Sakurada S, Tanaka T, Ridruechai C, Tanuma J, Aoki T, Kantipong P, Piyaworawong S, 
Kobayashi N, Dhepakson P et al. 2013. Potential function of granulysin, other related effector 
molecules and lymphocyte subsets in patients with TB and HIV/TB co-infection. International Journal 
of Medical Sciences. 10(8):1003-1014. 
67. Serbina NV, Liu C-C, Scanga CA, Flynn JL. 2000. CD8+ CTL from lungs of Mycobacterium 
tuberculosis-infected mice express perforin in vivo and lyse infected macrophages. Journal of 
Immunology. 165(1):353-363. 
68. Axelsson-Robertson R, Loxton AG, Walzl G, Ehlers MM, Kock MM, Zumla A, Maeurer M. 2013. A 
broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific 
CD8+ T-cell immune response in South African patients with active tuberculosis. PloS One. 
8(3):e58309. 
69. Day CL, Moshi ND, Abrahams DA, van Rooyen M, O'rie T, de Kock M, Hanekom WA. 2014. 
Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T-cells with a pro-
45 
 
apoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. 
PloS One. 9(4):e94949. 
70. Maglione PJ, Xu J, Chan J. 2007. B-cells moderate inflammatory progression and enhance bacterial 
containment upon pulmonary challenge with Mycobacterium tuberculosis. Journal of Immunology. 
178(11):7222-7234. 
71. Maglione PJ, Xu J, Casadevall A, Chan J. 2008. Fcγ receptors regulate immune activation and 
susceptibility during Mycobacterium tuberculosis infection. Journal of Immunology. 180(5):3329-
3338. 
72. Junqueira‐Kipnis AP, Kipnis A, Henao Tamayo M, Harton M, Gonzalez Juarrero M, Basaraba RJ, 
Orme IM. 2005. Interleukin‐10 production by lung macrophages in CBA xid mutant mice infected 
with Mycobacterium tuberculosis. Immunology. 115(2):246-252. 
73. Torrado E, Fountain JJ, Robinson RT, Martino CA, Pearl JE, Rangel-Moreno J, Tighe M, Dunn R, 
Cooper AM. 2013. Differential and site specific impact of B-cells in the protective immune response 
to Mycobacterium tuberculosis in the mouse. PLoS One. 8(4):e61681. 
74. Bosio CM, Gardner D, Elkins KL. 2000. Infection of B-cell deficient mice with CDC 1551, a clinical 
isolate of Mycobacterium tuberculosis: Delay in dissemination and development of lung pathology. 
Journal of Immunology. 164(12):6417-6425. 
75. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, Koch C, Tufariello J, Flynn J, Chan J. 2006. 
Characterization of the tuberculous granuloma in murine and human lungs: Cellular composition and 
relative tissue oxygen tension. Cellular Microbiology. 8(2):218-232. 
76. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. 2001. Temporal and 
spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with 
Mycobacterium tuberculosis. Infection and Immunity. 69(3):1722-1728. 
77. Ulrichs T, Kosmiadi GA, Trusov V, Jörg S, Pradl L, Titukhina M, Mishenko V, Gushina N, Kaufmann 
SH. 2004. Human tuberculous granulomas induce peripheral lymphoid follicle‐like structures to 
orchestrate local host defence in the lung. Journal of Pathology. 204(2):217-228. 
78. Cáceres N, Tapia G, Ojanguren I, Altare F, Gil O, Pinto S, Vilaplana C, Cardona P-J. 2009. Evolution 
of foamy macrophages in the pulmonary granulomas of experimental tuberculosis models. 
Tuberculosis. 89(2):175-182. 
79. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffé M, Emile J-F, Marchou 
B, Cardona P-J. 2008. Foamy macrophages from tuberculous patients' granulomas constitute a 
nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathogens. 4(11):e1000204. 
46 
 
80. Alatas F, Alatas O, Metintas M, Ozarslan A, Erginel S, Yildirim H. 2004. Vascular endothelial growth 
factor levels in active pulmonary tuberculosis. CHEST Journal. 125(6):2156-2159. 
81. Flynn JL, Chan J. 2001. Immunology of tuberculosis. Annual Review of Immunology. 19(1):93-129. 
82. Ulrichs T, Kosmiadi GA, Jörg S, Pradl L, Titukhina M, Mishenko V, Gushina N, Kaufmann SH. 2005. 
Differential organization of the local immune response in patients with active cavitary tuberculosis or 
with non-progressive tuberculoma. Journal of Infectious Diseases. 192(1):89-97. 
83. Robinson MA, Baumgardner JE, Good VP, Otto CM. 2008. Physiological and hypoxic O2 tensions 
rapidly regulate NO production by stimulated macrophages. American Journal of Physiology-Cell 
Physiology. 294(4):1079-1087. 
84. Russell DG, Barry CE, Flynn JL. 2010. Tuberculosis: What we don’t know can, and does, hurt us. 
Science. 328(5980):852-856. 
85. Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA, Capuano SV, Klein E, Flynn JL. 2006. 
Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infection and 
Immunity. 74(7):3790-3803. 
86. Capuano SV, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, Bissel S, Fuhrman C, Klein E, Flynn 
JL. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely 
resembles the various manifestations of human M. tuberculosis infection. Infection and Immunity. 
71(10):5831-5844. 
87. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, Mathema B, 
Ramaswamy SV, Walther G, Steyn LM. 2003. Mycobacterium tuberculosis growth at the cavity 
surface: A microenvironment with failed immunity. Infection and Immunity. 71(12):7099-7108. 
88. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. 2010. Tuberculous 
granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science. 
327(5964):466-469. 
89. Agarwal N, Bishai WR. 2010. Subversion from the sidelines. Science. 327(5964):417-418. 
90. Rhoades E, Hsu F, Torrelles J, Turk J, Chatterjee D, Russell D. 2003. Identification and macrophage‐
activating activity of glycolipids released from intracellular Mycobacterium bovis BCG. Molecular 
Microbiology. 48(4):875-888. 
91. Russell DG. 2001. Mycobacterium tuberculosis: Here today, and here tomorrow. Nature Reviews 
Molecular Cell Biology. 2(8):569-586. 
47 
 
92. Russell DG, Mwandumba HC, Rhoades EE. 2002. Mycobacterium and the coat of many lipids. 
Journal of Cell Biology. 158(3):421-426. 
93. Bansal K, Kapoor N, Narayana Y, Puzo G, Gilleron M, Balaji KN. 2009. PIM2 induced COX-2 and 
MMP-9 expression in macrophages requires PI3K and Notch1 signaling. PLoS One. 4(3):e4911. 
94. Taylor JL, Hattle JM, Dreitz SA, Troudt JM, Izzo LS, Basaraba RJ, Orme IM, Matrisian LM, Izzo 
AA. 2006. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary 
Mycobacterium tuberculosis infection. Infection and Immunity. 74(11):6135-6144. 
95. Dao D, Kremer L, Guérardel Y, Molano A, Jacobs W, Porcelli S, Briken V. 2004. Mycobacterium 
tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages. Infection 
and Immunity. 72(4):2067-2074. 
96. Dahl KE, Shiratsuchi H, Hamilton BD, Ellner JJ, Toossi Z. 1996. Selective induction of transforming 
growth factor-β in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infection 
and Immunity. 64(2):399-405. 
97. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, Fenton MJ. 2001. Different Toll-
like receptor agonists induce distinct macrophage responses. Journal of Leukocyte Biology. 
69(6):1036-1044. 
98. Gilleron M, Ronet C, Mempel M, Monsarrat B, Gachelin G, Puzo G. 2001. Acylation state of the 
phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette Guerin and ability to 
induce granuloma and recruit natural killer T-cells. Journal of Biological Chemistry. 276(37):34896-
34904. 
99. Perez RL, Roman J, Roser S, Little C, Olsen M, Indrigo J, Hunter RL, Actor JK. 2000. Cytokine 
message and protein expression during lung granuloma formation and resolution induced by the 
mycobacterial cord factor trehalose-6, 6'-dimycolate. Journal of Interferon and Cytokine Research. 
20(9):795-804. 
100. Yamagami H, Matsumoto T, Fujiwara N, Arakawa T, Kaneda K, Yano I, Kobayashi K. 2001. 
Trehalose 6, 6′-dimycolate (cord factor) of Mycobacterium tuberculosis induces foreign body and 
hypersensitivity type granulomas in mice. Infection and Immunity. 69(2):810-815. 
101. Russell D, Purdy G, Owens R, Rohde K, Yates R. 2005. Mycobacterium tuberculosis and the four-
minute phagosome: By arresting the maturation of phagosomes, M-tuberculosis avoids being delivered 
to lysosomes. ASM News. 71(10):459-463. 
48 
 
102. Deretic V, Singh S, Master S, Harris J, Roberts E, Kyei G, Davis A, De Haro S, Naylor J, Lee HH. 
2006. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host 
defence mechanism. Cellular Microbiology. 8(5):719-727. 
103. Vergne I, Chua J, Singh SB, Deretic V. 2004. Cell biology of Mycobacterium tuberculosis 
phagosome. Annual Reviews of Cell and Developmental Biology. 20:367-394. 
104. Mwandumba HC, Russell DG, Nyirenda MH, Anderson J, White SA, Molyneux ME, Squire SB. 
2004. Mycobacterium tuberculosis resides in non-acidified vacuoles in endocytically competent 
alveolar macrophages from patients with tuberculosis and HIV infection. Journal of Immunology. 
172(7):4592-4598. 
105. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, Allen RD, 
Gluck SL, Heuser J, Russell DG. 1994. Lack of acidification in mycobacterium phagosomes produced 
by exclusion of the vesicular proton-ATPase. Science. 263(5147):678-681. 
106. Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y. 2011. Mycobacterium tuberculosis protein tyrosine 
phosphatase (PtpA) excludes host vacuolar H+–ATPase to inhibit phagosome acidification. 
Proceedings of the National Academy of Sciences USA. 108(48):19371-19376. 
107. Vergne I, Chua J, Deretic V. 2003. Tuberculosis toxin blocking phagosome maturation inhibits a novel 
Ca2+/calmodulin-PI3K hVPS34 cascade. Journal of Experimental Medicine. 198(4):653-659. 
108. Fratti RA, Backer JM, Gruenberg J, Corvera S, Deretic V. 2001. Role of phosphatidylinositol 3-kinase 
and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. Journal 
of Cell Biology. 154(3):631-644. 
109. Purdy GE, Owens RM, Bennett L, Russell DG, Butcher BA. 2005. Kinetics of phosphatidylinositol‐3‐
phosphate acquisition differ between IgG bead‐containing phagosomes and Mycobacterium 
tuberculosis‐containing phagosomes. Cellular Microbiology. 7(11):1627-1634. 
110. Shukla S, Richardson E, Athman J, Shi L, Wearsch P, McDonald D, Banaei N, Boom W, Jackson M, 
Harding C. 2014. Mycobacterium tuberculosis lipoprotein LprG binds lipoarabinomannan and 
determines its localization in the cell wall envelope and affects phagolysosomal fusion. PloS  
Pathogens. 10(12):e1004596. 
111. Saleh MT, Belisle JT. 2000. Secretion of an acid phosphatase (SapM) by Mycobacterium tuberculosis 
that is similar to eukaryotic acid phosphatases. Journal of Bacteriology. 182(23):6850-6853. 
112. Vergne I, Chua J, Lee H-H, Lucas M, Belisle J, Deretic V. 2005. Mechanism of phagolysosome 
biogenesis block by viable Mycobacterium tuberculosis. Proceedings of the National Academy of 
Sciences USA. 102(11):4033-4038. 
49 
 
113. Harding CV, Geuze HJ. 1992. Class II MHC molecules are present in macrophage lysosomes and 
phagolysosomes that function in the phagocytic processing of Listeria monocytogenes for presentation 
to T-cells. Journal of Cell Biology. 119(3):531-542. 
114. Ramachandra L, Noss E, Boom WH, Harding CV. 2001. Processing of Mycobacterium tuberculosis 
antigen 85B involves intraphagosomal formation of peptide–major histocompatibility complex II 
complexes and is inhibited by live bacilli that decrease phagosome maturation. Journal of 
Experimental Medicine. 194(10):1421-1432. 
115. Beatty WL, Ullrich H-J, Russell DG. 2001. Mycobacterial surface moieties are released from infected 
macrophages by a constitutive exocytic event. European Journal of Cell Biology. 80(1):31-40. 
116. Ullrich H-J, Beatty WL, Russell DG. 2000. Interaction of Mycobacterium avium-containing 
phagosomes with the antigen presentation pathway. Journal of Immunology. 165(11):6073-6080. 
117. MacMicking JD, Taylor GA, McKinney JD. 2003. Immune control of tuberculosis by IFN-γ-inducible 
LRG-47. Science. 302(5645):654-659. 
118. Via L, Fratti R, McFalone M, Pagan-Ramos E, Deretic D, Deretic V. 1998. Effects of cytokines on 
mycobacterial phagosome maturation. Journal of Cell Science. 111(7):897-905. 
119. Kwan CK, Ernst JD. 2011. HIV and tuberculosis: A deadly human syndemic. Clinical Microbiology 
Reviews. 24(2):351-376. 
120. Jeon CY, Murray MB. 2008. Diabetes mellitus increases the risk of active tuberculosis: A systematic 
review of 13 observational studies. PLoS Medicine. 5(7):e152. 
121. Wu V-C, Wang C-Y, Shiao C-C, Chang C-H, Huang H-Y, Huang T-M, Lai C-F, Lin M-C, Ko W-J, 
Wu K-D. 2013. Increased risk of active tuberculosis following acute kidney injury: A nationwide, 
population-based study. PloS One. 8(7):e69556. 
122. Dixon W, Watson K, Lunt M, Hyrich K, Silman A, Symmons D. 2006. Rates of serious infection, 
including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving 
anti–tumor necrosis factor therapy: Results from the British society for rheumatology biologics 
register. Arthritis and Rheumatism. 54(8):2368-2376. 
123. Vento S, Lanzafame M. 2011. Tuberculosis and cancer: A complex and dangerous liaison. The Lancet 
Oncology. 12(6):520-522. 
124. Stoffels K, Allix-Béguec C, Groenen G, Wanlin M, Berkvens D, Mathys V, Supply P, Fauville-
Dufaux M. 2013. From multidrug-to extensively drug-resistant tuberculosis: Upward trends as seen 
from a 15-year nationwide study. PLoS One. 8(5):e63128. 
50 
 
125. Maurya V, Vijayan V, Shah A. 2002. Smoking and tuberculosis: An association overlooked. 
International Journal of Tuberculosis and Lung Disease. 6(11):942-951. 
126. Rath P, Huang C, Wang T, Wang T, Li H, Prados-Rosales R, Elemento O, Casadevall A, Nathan CF. 
2013. Genetic regulation of vesiculogenesis and immunomodulation in Mycobacterium tuberculosis. 
Proceedings of the National Academy of Sciences USA. 110(49):4790-4797. 
127. Hunter RL, Jagannath C, Actor JK. 2007. Pathology of postprimary tuberculosis in humans and mice: 
Contradiction of long-held beliefs. Tuberculosis. 87(4):267-278. 
128. Welsh KJ, Risin SA, Actor JK, Hunter RL. 2011. Immunopathology of postprimary tuberculosis: 
Increased T-regulatory cells and DEC-205-positive foamy macrophages in cavitary lesions. Clinical 
and Developmental Immunology. 2011:e307631. 
129. Brennan PJ, Nikaido H. 1995. The envelope of mycobacteria. Annual Review of Biochemistry. 
64(1):29-63. 
130. Baldán Á, Gomes AV, Ping P, Edwards PA. 2008. Loss of ABCG1 results in chronic pulmonary 
inflammation. Journal of Immunology. 180(5):3560-3568. 
131. Ordway D, Henao-Tamayo M, Orme IM, Gonzalez-Juarrero M. 2005. Foamy macrophages within 
lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic 
of dendritic cells and anti-apoptotic markers of the TNF receptor-associated factor family. Journal of 
Immunology. 175(6):3873-3881. 
132. Ríos‐Barrera VA, Campos‐Peña V, Aguilar‐León D, Lascurain LR, Meraz‐Ríos MA, Moreno J, 
Figueroa‐Granados V, Hernández‐Pando R. 2006. Macrophage and T-lymphocyte apoptosis during 
experimental pulmonary tuberculosis: Their relationship to mycobacterial virulence. European Journal 
of Immunology. 36(2):345-353. 
133. Nabeshima S, Nomoto M, Matsuzaki G, Kishihara K, Taniguchi H, Yoshida S-i, Nomoto K. 1999. T-
cell hyporesponsiveness induced by activated macrophages through nitric oxide production in mice 
infected with Mycobacterium tuberculosis. Infection and Immunity. 67(7):3221-3226. 
134. Gan H, Lee J, Ren F, Chen M, Kornfeld H, Remold HG. 2008. Mycobacterium tuberculosis blocks 
crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain 
virulence. Nature Immunology. 9(10):1189-1197. 
135. Gil O, Guirado E, Gordillo S, Díaz J, Tapia G, Vilaplana C, Ariza A, Ausina V, Cardona P-J. 2006. 
Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is 




136. Lee J, Hartman M, Kornfeld H. 2009. Macrophage apoptosis in tuberculosis. Yonsei Medical Journal. 
50(1):1-11. 
137. Behar SM, Divangahi M, Remold HG. 2010. Evasion of innate immunity by Mycobacterium 
tuberculosis: Is death an exit strategy? Nature Reviews Microbiology. 8(9):668-674. 
138. Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM, Fortune S, Behar SM, Remold 
HG. 2009. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane 
repair. Nature Immunology. 10(8):899-906. 
139. Chen M, Divangahi M, Gan H, Shin DS, Hong S, Lee DM, Serhan CN, Behar SM, Remold HG. 2008. 
Lipid mediators in innate immunity against tuberculosis: Opposing roles of PGE2 and LXA4 in the 
induction of macrophage death. Journal of Experimental Medicine. 205(12):2791-2801. 
140. Porcel-Perez J, Vives SM, Esquerda SA, Jover SA. 2004. Cuttoff values of biochemical tests on 
pleural fluid: Their usefulness in differential diagnosis of 1,040 patients with pleural effusion. Anales 
de Medicina Interna. 21(3):113-117. 
141. Liam CK, Lim KH, Wong CMM. 2000. Causes of pleural exudates in a region with a high incidence 
of tuberculosis. Respirology. 5(1):33-38. 
142. Valdes L, Alvarez D, Valle JM, Pose A, San Jose E. 1996. The etiology of pleural effusions in an area 
with high incidence of tuberculosis. CHEST Journal. 109(1):158-162. 
143. Porcel JM. 2009. Tuberculous pleural effusion. Lung. 187(5):263-270. 
144. Light RW. 2007. Tuberculosis pleural effusions. In: Pleural diseases. 5th edn. 13:211-224. Lippincott 
Williams and Wilkins. Philadelphia, Pennsylvania. ISBN 9780781769570. 
145. Perez-Rodriguez E, Light RW. 2008. Effusions from infections: Tuberculosis. In: Textbook of pleural 
diseases. 2nd edn. 27:367-378. Edited by Light R, Lee Y. CRC Press. Boca Raton, Florida. ISBN 
9780340940174. 
146. Viedma EC, Dus MJL, González-Molina A, Aldás JLS. 2006. A study of loculated tuberculous pleural 
effusions treated with intrapleural urokinase. Respiratory Medicine. 100(11):2037-2042. 
147. Gopi A, Madhavan SM, Sharma SK, Sahn SA. 2007. Diagnosis and treatment of tuberculous pleural 
effusion in 2006. CHEST Journal. 131(3):880-889. 
148. Ruan S-Y, Chuang Y-C, Wang J-Y, Lin J-W, Chien J-Y, Huang C-T, Kuo Y-W, Lee L-N, Chong-Jen 
JY. 2012. Revisiting tuberculous pleurisy: Pleural fluid characteristics and diagnostic yield of 
mycobacterial culture in an endemic area. Thorax. 67(9):822-827. 
52 
 
149. Liang Q-L, Shi H-Z, Wang K, Qin S-M, Qin X-J. 2008. Diagnostic accuracy of adenosine deaminase 
in tuberculous pleurisy: A meta-analysis. Respiratory Medicine. 102(5):744-754. 
150. Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. 2008. Adenosine deaminase activity is a 
sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS 
One. 3(7):e2788. 
151. Lin M-T, Wang J-Y, Yu C-J, Lee L-N, Yang P-C, Group T. 2009. Mycobacterium tuberculosis and 
polymorphonuclear pleural effusion: Incidence and clinical pointers. Respiratory Medicine. 
103(6):820-826. 
152. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, 
Freedberg KA. 2010. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral 
therapy in Durban, South Africa. Clinical Infectious Diseases. 51(7):823-829. 
153. World Heath Organisation. 2010. Guidelines for the treatment of tuberculosis 4th edition. Geneva, 
Switzerland. 
154. Butler R, Carr J, Townsend K. 2012. First-line treatment of tuberculosis (TB) for drug-Sensitive TB. 
National Institute of Allergy and Infectious Diseases (NIAID). Accessed on 2015-10-20 
[https://www.niaid.nih.gov/topics/tuberculosis/understanding/whatistb/visualtour/pages/firstline.aspx] 
155. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland 
G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with 
tuberculosis and HIV in a rural area of South Africa. The Lancet. 368(9547):1575-1580. 
156. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova O, Ferrara G, Cirillo D, Gori 
A, Matteelli A. 2007. Clinical and operational value of the extensively drug-resistant tuberculosis 
definition. European Respiratory Journal. 30(4):623-626. 
157. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, ZiaZarifi AH, Hoffner SE. 2009. 
Emergence of new forms of totally drug-resistant tuberculosis bacilli: Super extensively drug-resistant 
tuberculosis or totally drug-resistant strains in Iran. CHEST Journal. 136(2):420-425. 
158. Velayati AA, Farnia P, Masjedi MR. 2013. The totally drug resistant tuberculosis (TDR-TB). 
International Journal of Clinical and Experimental Medicine. 6(4):307-309. 
159. Günther G. 2014. Multidrug-resistant and extensively drug-resistant tuberculosis: A review of current 
concepts and future challenges. Clinical Medicine. 14(3):279-285. 
160. Zumla A, George A, Sharma V, Herbert RHN, Oxley A, Oliver M. 2015. The WHO 2014 Global 
tuberculosis report—further to go. The Lancet Global Health. 3(1):10-12. 
53 
 
161. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox H, Ford N, 
McNerney R et al. 2012. Drug-resistant tuberculosis: Current dilemmas, unanswered questions, 
challenges, and priority needs. Journal of Infectious Diseases. 205(suppl 2):228-240. 
162. Klopper M, Warren RM, Hayes C, van Pittius NCG, Streicher EM, Müller B, Sirgel FA, Chabula-
Nxiweni M, Hoosain E, Coetzee G. 2013. Emergence and spread of extensively and totally drug-
resistant tuberculosis, South Africa. Emerging Infectious Diseases. 19(3):449-455. 
163. Buthelezi S. Situational analysis of TB drug resistance in KwaZulu-Natal province, Republic of South 
Africa. In: 2nd Meeting of the WHO Global XDR-TB Task Force. 2008. World Health Organisation. 
Geneva, Switzerland.  
164. Brust J, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber 
SA, Lalloo UG. 2011. Culture conversion among HIV co-infected multidrug-resistant tuberculosis 
patients in Tugela Ferry, South Africa. PloS One. 6(1):e15841. 
165. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, 
Friedland GH. 2010. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results 
in high early mortality. American Journal of Respiratory and Critcal Care Medicine. 181(1):80-86. 
166. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. 1993. The 
emergence of drug-resistant tuberculosis in New York City. New England Journal of Medicine. 
328(8):521-526. 
167. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A. 1981. Pneumocystis 
carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new 
acquired cellular immunodeficiency. New England Journal of Medicine. 305(24):1425-1431. 
168. Barré-Sinoussi F, Chermann J-C, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin 
C, Vézinet-Brun F, Rouzioux C. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk 
for acquired immune deficiency syndrome (AIDS). Science. 220(4599):868-871. 
169. UNAIDS. 2015. How AIDS Changed Everything - MDG 6: 15 Years, 15 Lessons of Hope from the 
AIDS Response. Geneva, Switzerland. 
170. Hahn BH, Shaw GM, De KM, Sharp PM. 2000. AIDS as a zoonosis: Scientific and public health 
implications. Science. 287(5453):607-614. 




172. Roberts JD, Bebenek K, Kunkel TA. 1988. The accuracy of reverse transcriptase from HIV-1. Science. 
242(4882):1171-1173. 
173. Ganser-Pornillos BK, Yeager M, Sundquist WI. 2008. The structural biology of HIV assembly. 
Current Opinion in Structural Biology. 18(2):203-217. 
174. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: 
Virion clearance rate, infected cell life-span and viral generation time. Science. 271(5255):1582-1586. 
175. Sakuragi J-i. 2011. Morphogenesis of the infectious HIV-1 virion. Frontiers in Microbiology. 2:242-
246. 
176. Arts EJ, Hazuda DJ. 2012. HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspectives in 
Medicine. 2(4):a007161. 
177. Sierra S, Kupfer B, Kaiser R. 2005. Basics of the virology of HIV-1 and its replication. Journal of 
Clinical Virology. 34(4):233-244. 
178. Robinson HL. 2002. New hope for an AIDS  vaccine. Nature Reviews Immunology. 2(4):239-250. 
179. Gelderblom HR. 1991. Assembly and morphology of HIV: Potential effect of structure on viral 
function. AIDS. 5(6):617-638. 
180. Clapham PR, McKnight Á. 2002. Cell surface receptors, virus entry and tropism of primate 
lentiviruses. Journal of General Virology. 83(8):1809-1829. 
181. Le Rouzic E, Benichou S. 2005. The Vpr protein from HIV-1: Distinct roles along the viral life cycle. 
Retrovirology. 2(1):11-24. 
182. Wu Y. 2004. HIV-1 gene expression: Lessons from provirus and non-integrated DNA. Retrovirology. 
1(1):13-22. 
183. Karn J, Stoltzfus CM. 2012. Transcriptional and post transcriptional regulation of HIV-1 gene 
expression. Cold Spring Harbor Perspectives in Medicine. 2(2):a006916. 
184. Pollard VW, Malim MH. 1998. The HIV-1 rev protein. Annual Reviews in Microbiology. 52(1):491-
532. 
185. Pasternak AO, Lukashov VV, Berkhout B. 2013. Cell-associated HIV RNA: A dynamic biomarker of 
viral persistence. Retrovirology. 10(1):41-55. 
55 
 
186. Chukkapalli V, Hogue IB, Boyko V, Hu W-S, Ono A. 2007. Interaction between HIV-1 Gag matrix 
domain and phosphatidylinositol-(4, 5)-bisphosphate is essential for efficient Gag-membrane binding. 
Journal of Virology. 82:2405–2417. 
187. Frankel AD, Young JA. 1998. HIV-1: Fifteen proteins and an RNA. Annual Review of Biochemistry. 
67(1):1-25. 
188. Monroe EB, Kang S, Kyere SK, Li R, Prevelige PE, Jr. 2010. Hydrogen/deuterium exchange analysis 
of HIV-1 capsid assembly and maturation. Structure. 18(11):1483-1491. 
189. Boily M-C, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M. 2009. Heterosexual risk 
of HIV-1 infection per sexual act: Systematic review and meta-analysis of observational studies. The 
Lancet Infectious Diseases. 9(2):118-129. 
190. Swanstrom R, Coffin J. 2012. HIV-1 pathogenesis: The virus. Cold Spring Harbor Perspectives in 
Medicine. 2(12):a007443. 
191. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo 
T, Gray RH. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. 
New England Journal of Medicine. 342(13):921-929. 
192. Coffin J, Swanstrom R. 2013. HIV pathogenesis: Dynamics and genetics of viral populations and 
infected cells. Cold Spring Harbor Perspectives in Medicine. 3(1):a012526. 
193. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. 2011. Acute HIV-1 infection. New England 
Journal of Medicine. 364(20):1943-1954. 
194. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard 
JA, Bangham C, Rizza CR. 1991. Human immunodeficiency virus genetic variation that can escape 
cytotoxic T-cell recognition. Nature. 354(6353):453-459. 
195. Wilen CB, Tilton JC, Doms RW. 2012. HIV: Cell binding and entry. Cold Spring Harbor Perspectives 
in Medicine. 2(8):a006866. 
196. Sainski AM, Natesampillai S, Cummins NW, Bren GD, Taylor J, Saenz DT, Poeschla EM, Badley 
AD. 2011. The HIV-1-specific protein Casp8p41 induces death of infected cells through Bax/Bak. 
Journal of Virology. 85(16):7965-7975. 
197. Zeng M, Southern PJ, Reilly CS, Beilman GJ, Chipman JG, Schacker TW, Haase AT. 2012. 
Lymphoid tissue damage in HIV-1 infection depletes naive T-cells and limits T-cell reconstitution 
after antiretroviral therapy. PLoS Pathogens. 8(1):e1002437. 
56 
 
198. Mehandru S, Poles MA, Tenner-Racz K, Manuelli V, Jean-Pierre P, Lopez P, Shet A, Low A, Mohri 
H, Boden D. 2007. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early 
human immunodeficiency virus type 1 infection. Journal of Virology. 81(2):599-612. 
199. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. 2006. 
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of 
antimicrobial peptides. Journal of Experimental Medicine. 203(10):2271-2279. 
200. Prendergast A, Prado JG, Kang Y-H, Chen F, Riddell LA, Luzzi G, Goulder P, Klenerman P. 2010. 
HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in 
regulatory T-cells. AIDS. 24(4):491-502. 
201. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, Scheinberg P, Price DA, Hage 
CA, Kholi LM. 2008. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic 
lentiviral infections. Blood. 112(7):2826-2835. 
202. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, 
Lambotte O, Altmann D. 2006. Microbial translocation is a cause of systemic immune activation in 
chronic HIV infection. Nature Medicine. 12(12):1365-1371. 
203. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. 1993. Elevated levels of 
CD38+CD8+ T-cells in HIV infection add to the prognostic value of low CD4+ T-cell levels: Results of 
6 years of follow-up. Journal of Acquired Immune Deficiency Syndromes. 6(8):904-912. 
204. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, 
Migueles SA, Connors M. 2003. Expression of CD57 defines replicative senescence and antigen-
induced apoptotic death of CD8+ T cells. Blood. 101(7):2711-2720. 
205. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie 
AJ, DePierres C. 2006. PD-1 expression on HIV-specific T-cells is associated with T-cell exhaustion 
and disease progression. Nature. 443(7109):350-354. 
206. Hyrcza MD, Kovacs C, Loutfy M, Halpenny R, Heisler L, Yang S, Wilkins O, Ostrowski M, Der SD. 
2007. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T-cells are established early in human 
immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well 
as extensive transcriptional changes in CD8+ T-cells. Journal of Virology. 81(7):3477-3486. 
207. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Lindsay RJ, Orellana L, 
Mildvan D. 2009. Sex differences in the Toll-like receptor–mediated response of plasmacytoid 
dendritic cells to HIV-1. Nature Medicine. 15(8):955-959. 
57 
 
208. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. 2010. A cryptic sensor for HIV-1 
activates antiviral innate immunity in dendritic cells. Nature. 467(7312):214-217. 
209. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. 2010. The cytosolic 
exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. 
Nature Immunology. 11(11):1005-1013. 
210. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, Hoh R, Martin JN, McCune JM, 
Waters DD. 2006. Increased carotid intima-media thickness in HIV patients is associated with 
increased cytomegalovirus-specific T-cell responses. AIDS. 20(18):2275-2283. 
211. South African Department of Health. 2014. National Consolidated Guidelines: For the prevention of 
mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents 
and adults. Department of Health. Pretoria, South Africa. 
212. World Health Organisation. 2012. HIV drug resistance report. Geneva, Switzerland. 
213. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori 
F, Flexner C. 1999. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of 
HIV-1, even in patients on effective combination therapy. Nature Medicine. 5(5):512-517. 
214. Chun T-W, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican 
JM, Mullins JI. 2008. Persistence of HIV in gut-associated lymphoid tissue despite long-term 
antiretroviral therapy. Journal of Infectious Diseases. 197(5):714-720. 
215. Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, 
Hirschel B, Gaudenz R. 2013. Higher CNS penetration-effectiveness of long-term combination 
antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal 
of Acquired Immune Deficiency Syndromes. 62(1):28-35. 
216. Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, Dawson R, Hanekom WA, Lange C, Wilkinson 
RJ. 2009. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. American 
Journal of Respiratory and Critical Care Medicine. 180(12):1262-1270. 
217. Jambo KC, Sepako E, Fullerton DG, Mzinza D, Glennie S, Wright AK, Heyderman RS, Gordon SB. 
2011. Bronchoalveolar CD4+ T-cell responses to respiratory antigens are impaired in HIV-infected 
adults. Thorax. 66(5):375-382. 
218. Day CL, Mkhwanazi N, Reddy S, Mncube Z, van der Stok M, Klenerman P, Walker BD. 2008. 
Detection of polyfunctional Mycobacterium tuberculosis–specific T-cells and association with viral 
load in HIV-1–infected persons. Journal of Infectious Diseases. 197(7):990-999. 
58 
 
219. Sutherland JS, Young JM, Peterson KL, Sanneh B, Whittle HC, Rowland-Jones SL, Adegbola RA, 
Jaye A, Ota MO. 2010. Polyfunctional CD4+ and CD8+ T-cell responses to tuberculosis antigens in 
HIV-1 infected patients before and after antiretroviral treatment. Journal of Immunology. 
184(11):6537-6544. 
220. Jambo KC, Banda DH, Afran L, Kankwatira AM, Malamba RD, Allain TJ, Gordon SB, Heyderman 
RS, Russell DG, Mwandumba HC. 2014. Asymptomatic HIV-infected individuals on antiretroviral 
therapy exhibit impaired lung CD4+ T-cell responses to mycobacteria. American Journal of 
Respiratory and Critical Care Medicine. 190(8):938-947. 
221. Diedrich CR, Mattila JT, Klein E, Janssen C, Phuah J, Sturgeon TJ, Montelaro RC, Lin PL, Flynn JL. 
2010. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with 
early peripheral T-cell depletion and not virus load. PloS One. 5(3):e9611. 
222. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O’rie T, Pienaar B, de Kock M, 
Kaplan G, Mahomed H et al. 2011. Functional capacity of Mycobacterium tuberculosis-specific T-cell 
responses in humans is associated with mycobacterial load. Journal of Immunology. 187(5):2222-
2232. 
223. Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE. 2015. T-cells and adaptive immunity to 
Mycobacterium tuberculosis in humans. Immunological Reviews. 264(1):74-87. 
224. Ranjbar S, Ly N, Thim S, Reynes J-M, Goldfeld AE. 2004. Mycobacterium tuberculosis recall 
antigens suppress HIV-1 replication in anergic donor cells via CD8+ T-cell expansion and increased 
IL-10 levels. Journal of Immunology. 172(3):1953-1959. 
225. Ranjbar S, Boshoff HI, Mulder A, Siddiqi N, Rubin EJ, Goldfeld AE. 2009. HIV-1 replication is 
differentially regulated by distinct clinical strains of Mycobacterium tuberculosis. PLoS One. 
4(7):e6116. 
226. Barnabas RV, Webb EL, Weiss HA, Wasserheit JN. 2011. The role of co-infections in HIV epidemic 
trajectory and positive prevention: A systematic review and meta-analysis. AIDS. 25(13):1559-1573. 
227. Josefowicz SZ, Lu L-F, Rudensky AY. 2012. Regulatory T-cells: Mechanisms of differentiation and 
function. Annual Review of Immunology. 30:531-564. 
228. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 1995. Immunologic self-tolerance maintained 
by activated T-cells expressing IL-2 receptor alpha-chains (CD25): Breakdown of a single mechanism 
of self-tolerance causes various autoimmune diseases. Journal of Immunology. 155(3):1151-1564. 
229. Holmes D, Jiang Q, Zhang L, Su L. 2008. Foxp3 and Treg cells in HIV-1 infection and immuno-
pathogenesis. Immunological Research. 41(3):248-266. 
59 
 
230. Huehn J, Beyer M. 2015. Epigenetic and transcriptional control of Foxp3+ regulatory T-cells. 
Seminars in Immunology. 27(1):10-18. 
231. Whiteside TL. 2014. Regulatory T-cell subsets in human cancer: Are they regulating for or against 
tumor progression? Cancer Immunology, Immunotherapy. 63(1):67-72. 
232. Nelson BH. 2004. IL-2, regulatory T-cells and tolerance. Journal of Immunology. 172(7):3983-3988. 
233. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. 2008. Smad3 and NFAT 
cooperate to induce Foxp3 expression through its enhancer. Nature Immunology. 9(2):194-202. 
234. Bensinger SJ, Walsh PT, Zhang J, Carroll M, Parsons R, Rathmell JC, Thompson CB, Burchill MA, 
Farrar MA, Turka LA. 2004. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T-
cells. Journal of Immunology. 172(9):5287-5296. 
235. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, 
Soiffer RJ. 2006. IL-2 regulates Foxp3 expression in human CD4+CD25+ regulatory T-cells through a 
STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 108(5):1571-
1579. 
236. Fontenot JD, Gavin MA, Rudensky AY. 2003. Foxp3 programs the development and function of 
CD4+CD25+ regulatory T-cells. Nature Immunology. 4(4):330-336. 
237. Camperio C, Caristi S, Fanelli G, Soligo M, Del Porto P, Piccolella E. 2012. Forkhead transcription 
factor Foxp3 upregulates CD25 expression through cooperation with RelA/NF-κB. PLoS One. 
7(10):e48303. 
238. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler 
SF et al. 2006. Foxp3 controls regulatory T-cell function through cooperation with NFAT. Cell. 
126(2):375-387. 
239. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T, 
Sakaguchi S. 2007. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. 
Nature. 446(7136):685-689. 
240. Lin JX, Li P, Liu D, Jin HT, He J, Ata Ur Rasheed M, Rochman Y, Wang L, Cui K, Liu C et al. 2012. 
Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune 
function. Immunity. 36(4):586-599. 
241. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. 1998. Regulatory CD4 T-cells: 




242. Amado IF, Berges J, Luther RJ, Mailhe MP, Garcia S, Bandeira A, Weaver C, Liston A, Freitas AA. 
2013. IL-2 coordinates IL-2-producing and regulatory T-cell interplay. Journal of Experimental 
Medicine. 210(12):2707-2720. 
243. Benoist C, Mathis D. 2012. Treg cells, life history and diversity. Cold Spring Harbor Perspectives in 
Biology. 4(9):a007021. 
244. Feuerer M, Hill JA, Kretschmer K, von Boehmer H, Mathis D, Benoist C. 2010. Genomic definition of 
multiple ex vivo regulatory T-cell subphenotypes. Proceedings of the National Academy of Sciences 
USA. 107(13):5919-5924. 
245. Feuerer M, Hill JA, Mathis D, Benoist C. 2009. Foxp3+ regulatory T-cells: Differentiation, 
specification, subphenotypes. Nature Immunology. 10(7):689-695. 
246. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, 
Bluestone JA. 2006. Visualizing regulatory T-cell control of autoimmune responses in non-obese 
diabetic mice. Nature Immunology. 7(1):83-92. 
247. Davidson TS, Shevach EM. 2011. Polyclonal Treg cells modulate T-effector cell trafficking. European 
Journal of Immunology. 41(10):2862-2870. 
248. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. 2009. How punctual ablation of regulatory T-
cells unleashes an autoimmune lesion within the pancreatic islets. Immunity. 31(4):654-664. 
249. Vignali DA, Collison LW, Workman CJ. 2008. How regulatory T-cells work. Nature Reviews 
Immunology. 8(7):523-532. 
250. Huang C-T, Dutta A, Miaw S-C, Drake C, Powell J, Pardoll D. 2015. Infectious tolerance of LAG-3+ 
regulatory T-cells with attenuated T-bet induction Journal of Immunology. 194(suppl 1):197-215. 
251. Shevach EM. 2009. Mechanisms of Foxp3+ T-regulatory cell mediated suppression. Immunity. 
30(5):636-645. 
252. Rochman Y, Spolski R, Leonard WJ. 2009. New insights into the regulation of T-cells by γc family 
cytokines. Nature Reviews Immunology. 9(7):480-490. 
253. Wang GQ, Yang CL, Yue DF, Pei LH, Zhong H, Niu JX. 2014. The changes and its significance of 
Th17 and Treg cells and related cytokines in patients with tuberculosis pleurisy. Allergy, Asthma and 
Clinical Immunology. 10(1):28-33. 
254. Nemeth J, Winkler H-M, Boeck L, Adegnika AA, Clement E, Mve TM, Kremsner PG, Winkler S. 




255. Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, Di Mitri D, Battistini L, Martini F, 
Borsellino G. 2009. Characterization of regulatory T-cells identified as CD4+CD25highCD39+ in 
patients with active tuberculosis. Clinical and Experimental Immunology. 156(3):463-470. 
256. Pang H, Yu Q, Guo B, Jiang Y, Wan L, Li J, Wu Y, Wan K. 2013. Frequency of regulatory T-cells in 
the peripheral blood of patients with pulmonary tuberculosis from Shanxi Province, China. PLoS One. 
8(6):e65496. 
257. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. 2006. Regulatory T-cells are expanded in 
blood and disease sites in patients with tuberculosis. American Journal of Respiratory and Critical 
Care Medicine. 173(7):803-810. 
258. Marin ND, Paris SC, Velez VM, Rojas CA, Rojas M, Garcia LF. 2010. Regulatory T-cell frequency 
and modulation of IFN-γ and IL-17 in active and latent tuberculosis. Tuberculosis. 90(4):252-261. 
259. Ribeiro-Rodrigues R, Resende Co T, Rojas R, Toossi Z, Dietze R, Boom WH, Maciel E, Hirsch CS. 
2006. A role for CD4+CD25+ T-cells in regulation of the immune response during human tuberculosis. 
Clinical and Experimental Immunology. 144(1):25-34. 
260. Chen X, Zhou B, Li M, Deng Q, Wu X, Le X, Wu C, Larmonier N, Zhang W, Zhang H. 2007. 
CD4+CD25+FoxP3+ regulatory T-cells suppress Mycobacterium tuberculosis immunity in patients 
with active disease. Clinical Immunology. 123(1):50-59. 
261. He X-Y, Xiao L, Chen H-B, Hao J, Li J, Wang Y-J, He K, Gao Y, Shi B-Y. 2010. T-regulatory cells 
and Th1/Th2 cytokines in peripheral blood from tuberculosis patients. European Journal of Clinical 
Microbiology and Infectious Diseases. 29(6):643-650. 
262. de Waal Malefyt R, Haanen J, Spits H, Roncarolo M-G, Te Velde A, Figdor C, Johnson K, Kastelein 
R, Yssel H, De Vries JE. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific 
human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via 
downregulation of class II major histocompatibility complex expression. Journal of Experimental 
Medicine. 174(4):915-924. 
263. Ding L, Shevach E. 1992. IL-10 inhibits mitogen-induced T-cell proliferation by selectively inhibiting 
macrophage costimulatory function. Journal of Immunology. 148(10):3133-3139. 
264. Fiorentino DF, Zlotnik A, Mosmann T, Howard M, O'garra A. 1991. IL-10 inhibits cytokine 
production by activated macrophages. Journal of Immunology. 147(11):3815-3822. 
265. Bandera A, Ferrario G, Saresella M, Marventano I, Soria A, Zanini F, Sabbatini F, Airoldi M, 
Marchetti G, Franzetti F et al. 2010. CD4+ T-cell depletion, immune activation and increased 
production of regulatory T-cells in the thymus of HIV-infected individuals. PLoS One. 5(5):e10788. 
62 
 
266. Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, 
Shacklett BL. 2011. Increased frequency of regulatory T-cells accompanies increased immune 
activation in rectal mucosa of HIV-positive non-controllers. Journal of Virology. 85(21):11422-11434. 
267. Montes M, Sanchez C, Lewis DE, Graviss EA, Seas C, Gotuzzo E, White AC, Jr. 2011. Normalization 
of FoxP3+ regulatory T-cells in response to effective antiretroviral therapy. Journal of Infectious 
Diseases. 203(4):496-499. 
268. Bi X, Suzuki Y, Gatanaga H, Oka S. 2009. High frequency and proliferation of CD4+Foxp3+ Treg in 
HIV-1-infected patients with low CD4 counts. European Journal of Immunology. 39(1):301-309. 
269. Suchard MS, Mayne E, Green VA, Shalekoff S, Donninger SL, Stevens WS, Gray CM, Tiemessen 
CT. 2010. Foxp3 expression is upregulated in CD4+ T-cells in progressive HIV-1 infection and is a 
marker of disease severity. PLoS One. 5(7):e11762. 
270. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, Norris PJ, Busch MP, Martin JN, 
Brooks C et al. 2011. A low T-regulatory cell response may contribute to both viral control and 
generalized immune activation in HIV controllers. PLoS One. 6(1):e15924. 
271. Schulze zur Wiesch J, Thomssen A, Hartjen P, Tóth I, Lehmann C, Meyer-Olson D, Colberg K, Frerk 
S, Babikir D, Schmiedel S et al. 2011. Comprehensive analysis of frequency and phenotype of T-
regulatory cells in HIV Infection: CD39 expression of Foxp3+ T-regulatory cells correlates with 
progressive disease. Journal of Virology. 85(3):1287-1297. 
272. Presicce P, Orsborn K, King E, Pratt J, Fichtenbaum CJ, Chougnet CA. 2011. Frequency of circulating 
regulatory T-cells increases during chronic HIV infection and is largely controlled by highly active 
antiretroviral therapy. PLoS One. 6(12):e28118. 
273. Chevalier MF, Weiss L. 2013. The split personality of regulatory T-cells in HIV infection. Blood. 
121(1):29-37. 
274. Angin M, Kwon DS, Streeck H, Wen F, King M, Rezai A, Law K, Hongo TC, Pyo A, Piechocka-
Trocha A. 2012. Preserved function of regulatory T-cells in chronic HIV-1 infection despite decreased 
numbers in blood and tissue. Journal of Infectious Diseases. 205(10):1495-1500. 
275. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. 2004. Human 
immunodeficiency virus–driven expansion of CD4+CD25+ regulatory T-cells, which suppress HIV-
specific CD4 T-cell responses in HIV-infected patients. Blood. 104(10):3249-3256. 
276. Kinter A, McNally J, Riggin L, Jackson R, Roby G, Fauci AS. 2007. Suppression of HIV-specific T-
cell activity by lymph node CD25+ regulatory T-cells from HIV-infected individuals. Proceedings of 
the National Academy of Sciences USA. 104(9):3390-3395. 
63 
 
277. Ji J, Cloyd MW. 2009. HIV-1 binding to CD4 on CD4+CD25+ regulatory T-cells enhances their 
suppressive function and induces them to home to, and accumulate in, peripheral and mucosal 
lymphoid tissues: An additional mechanism of immunosuppression. International Immunology. 
21:283–294. 
278. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. 2009. Decreased immune 
activation in resistance to HIV-1 infection is associated with an elevated frequency of 
CD4+CD25+Foxp3+ regulatory T-cells. Journal of Infectious Diseases. 199(9):1318-1322. 
279. Munier CM, Kelleher AD, Kent SJ, De Rose R. 2013. The role of T-cell immunity in HIV-1 infection. 
Current Opinion in Virology. 3(4):438-446. 
280. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, Wang Y, Hood L, Zhu Z, Tian Q et al. 
2005. A distinct lineage of CD4 T-cells regulates tissue inflammation by producing interleukin 17. 
Nature Immunology. 6(11):1133-1141. 
281. Zhou X, Chen Q, Moore J, Kolls JK, Halperin S, Wang J. 2009. Critical role of the interleukin-
17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with chlamydia 
species. Infection and Immunity. 77(11):5059-5070. 
282. Zhang X, Gao L, Lei L, Zhong Y, Dube P, Berton MT, Arulanandam B, Zhang J, Zhong G. 2009. A 
MyD88-dependent early IL-17 production protects mice against airway infection with the obligate 
intracellular pathogen Chlamydia muridarum. Journal of Immunology. 183(2):1291-1300. 
283. Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, Khader SA, Dubin PJ, Enelow 
RI, Kolls JK. 2011. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in 
mice. Journal of Immunology. 186(3):1666-1674. 
284. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, Schwarzenberger P, Shellito JE, Kolls 
JK. 2001. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. American 
Journal of Respiratory Cell and Molecular Biology. 25(3):335-340. 
285. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler 
DA. 2008. IL-21 and TGF-β are required for differentiation of human Th17 cells. Nature. 
454(7202):350-352. 
286. Manel N, Unutmaz D, Littman DR. 2008. The differentiation of human Th17 cells requires 




287. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. 2006. 
The orphan nuclear receptor ROR-γt directs the differentiation program of proinflammatory IL-17+ T-
helper cells. Cell. 126(6):1121-1133. 
288. Mudter J, Yu J, Zufferey C, Brüstle A, Wirtz S, Weigmann B, Hoffman A, Schenk M, Galle PR, Lehr 
HA. 2011. IRF4 regulates IL‐17A promoter activity and controls ROR-γt‐dependent Th17 colitis in 
vivo. Inflammatory Bowel Diseases. 17(6):1343-1358. 
289. Brüstle A, Heink S, Huber M, Rosenplänter C, Stadelmann C, Yu P, Arpaia E, Mak TW, Kamradt T, 
Lohoff M. 2007. The development of inflammatory Th17 cells requires interferon-regulatory factor 4. 
Nature Immunology. 8(9):958-966. 
290. Hirahara K, Ghoreschi K, Laurence A, Yang X-P, Kanno Y, O'Shea JJ. 2010. Signal transduction 
pathways and transcriptional regulation in Th17 cell differentiation. Cytokine and Growth Factor 
Reviews. 21(6):425-434. 
291. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, 
Schluns KS et al. 2008. T-helper 17 lineage differentiation is programmed by orphan nuclear receptors 
ROR-α and ROR-γ. Immunity. 28(1):29-39. 
292. Lee W-W, Kang SW, Choi J, Lee S-H, Shah K, Eynon EE, Flavell RA, Kang I. 2010. Regulating 
human Th17 cells via differential expression of IL-1 receptor. Blood. 115(3):530-540. 
293. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, Soumelis V. 2008. A critical 
function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving 
and modulating human Th17 responses. Nature Immunology. 9(6):650-657. 
294. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, 
Tian Q. 2009. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. 
Immunity. 30(4):576-587. 
295. Sundrud MS, Trivigno C. 2013. Identity crisis of Th17 cells: Many forms, many functions, many 
questions. Seminars in Immunology. 25(4):263-272. 
296. Noack M, Miossec P. 2014. Th17 and regulatory T-cell balance in autoimmune and inflammatory 
diseases. Autoimmunity Reviews. 13(6):668-677. 
297. Schraml BU, Hildner K, Ise W, Lee W-L, Smith WA-E, Solomon B, Sahota G, Sim J, Mukasa R, 




298. Okamoto K, Iwai Y, Oh-Hora M, Yamamoto M, Morio T, Aoki K, Ohya K, Jetten AM, Akira S, Muta 
T. 2010. IκBζ regulates Th17 development by cooperating with ROR nuclear receptors. Nature. 
464(7293):1381-1385. 
299. Zhang F, Meng G, Strober W. 2008. Interactions among the transcription factors Runx1, ROR-γt and 
Foxp3 regulate the differentiation of interleukin 17–producing T-cells. Nature Immunology. 
9(11):1297-1306. 
300. Maddur MS, Miossec P, Kaveri SV, Bayry J. 2012. Th17 cells: Biology, pathogenesis of autoimmune 
and inflammatory diseases, and therapeutic strategies. The American Journal of Pathology. 181(1):8-
18. 
301. Korn T, Bettelli E, Oukka M, Kuchroo VK. 2009. IL-17 and Th17 Cells. Annual Review of 
Immunology. 27:485-517. 
302. Toy D, Kugler D, Wolfson M, Bos TV, Gurgel J, Derry J, Tocker J, Peschon J. 2006. Cutting edge: 
Interleukin 17 signals through a heteromeric receptor complex. Journal of Immunology. 177(1):36-39. 
303. Shen F, Gaffen SL. 2008. Structure-function relationships in the IL-17 receptor: Implications for 
signal transduction and therapy. Cytokine. 41(2):92-104. 
304. Hot A, Zrioual S, Toh M-L, Lenief V, Miossec P. 2011. IL-17A- versus IL-17F-induced intracellular 
signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in 
rheumatoid synoviocytes. Annals of the Rheumatic Diseases. 70(2):341-348. 
305. Sønder SU, Saret S, Tang W, Sturdevant DE, Porcella SF, Siebenlist U. 2011. IL-17-induced NF-κB 
activation via CIKS/Act1 physiologic significance and signaling mechanisms. Journal of Biological 
Chemistry. 286(15):12881-12890. 
306. Kao C-Y, Huang F, Chen Y, Thai P, Wachi S, Kim C, Tam L, Wu R. 2005. Up-regulation of CC 
chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but 
MEK/NF-κB-dependent signaling pathway. Journal of Immunology. 175(10):6676-6685. 
307. Datta S, Novotny M, Pavicic PG, Zhao C, Herjan T, Hartupee J, Hamilton T. 2010. IL-17 regulates 
CXCL1 mRNA stability via an AUUUA/tristetraprolin-independent sequence. Journal of 
Immunology. 184(3):1484-1491. 
308. Gopal R, Rangel-Moreno J, Slight S, Lin Y, Nawar HF, Junecko BF, Reinhart TA, Kolls J, Randall 
TD, Connell TD. 2013. Interleukin-17-dependent CXCL13 mediates mucosal vaccine–induced 
immunity against tuberculosis. Mucosal Immunology. 6(5):972-984. 
66 
 
309. Linden A, Laan M, Anderson G. 2005. Neutrophils, interleukin-17A and lung disease. European 
Respiratory Journal. 25(1):159-172. 
310. Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, Cosmi L, Lunardi C, 
Annunziato F, Romagnani S. 2010. Evidence for a cross-talk between human neutrophils and Th17 
cells. Blood. 115(2):335-343. 
311. Yu Q, Lou X-m, He Y. 2015. Preferential recruitment of Th17 cells to cervical cancer via CCR6-
CCL20 pathway. PLoS One. 10(3):e0120855. 
312. Tian Y, Cox M, Kahan S, Ingram J, Bakshi R, Zajac A. 2015. IL-21 signaling modulates the 
differentiation, distribution, and abundance of CD8 T-cell subsets. Journal of Immunology. 194(suppl 
1):200-208. 
313. Diehl SA, Schmidlin H, Nagasawa M, Blom B, Spits H. 2012. IL-6 Triggers IL-21 production by 
human CD4+ T-cells to drive STAT3-dependent plasma cell differentiation in B-cells. Immunology 
and Cell Biology. 90(8):802-811. 
314. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. 2008. IL-21 induced isotype 
switching to IgG and IgA by human naive B-cells is differentially regulated by IL-4. Journal of 
Immunology. 181(3):1767-1779. 
315. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton 
L, Maiti SN, Huls MH et al. 2012. Membrane-bound IL-21 promotes sustained ex vivo proliferation of 
human natural killer cells. PLoS One. 7(1):e30264. 
316. Wolk K, Sabat R. 2006. Interleukin-22: A novel T- and NK-cell derived cytokine that regulates the 
biology of tissue cells. Cytokine and Growth Factor Reviews. 17(5):367-380. 
317. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, Vom Baur E, Witte K, Warszawska K, 
Philipp S. 2009. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-
17 and IFN-γ are not. Journal of Molecular Medicine. 87(5):523-536. 
318. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. 2010. Biology of interleukin-22. Seminars in 
Immunopathology. 32(1):17-31. 
319. Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, Artis D. 2010. Pathological versus protective 
functions of IL-22 in airway inflammation are regulated by IL-17A. Journal of Experimental 
Medicine. 207(6):1293-1305. 
320. Scriba TJ, Kalsdorf B, Abrahams D-A, Isaacs F, Hofmeister J, Black G, Hassan HY, Wilkinson RJ, 
Walzl G, Gelderbloem SJ. 2008. Distinct, specific IL-17-and IL-22-producing CD4+ T-cell subsets 
67 
 
contribute to the human anti-mycobacterial immune response. Journal of Immunology. 180(3):1962-
1970. 
321. Marín ND, París SC, Rojas M, García LF. 2012. Reduced frequency of memory T-cells and increased 
Th17 responses in patients with active tuberculosis. Clinical and Vaccine Immunology. 19(10):1667-
1676. 
322. Jurado JO, Pasquinelli V, Alvarez IB, Peña D, Rovetta AI, Tateosian NL, Romeo HE, Musella RM, 
Palmero D, Chuluyán HE. 2012. IL-17 and IFN-γ expression in lymphocytes from patients with active 
tuberculosis correlates with the severity of the disease. Journal of Leukocyte Biology. 91(6):991-1002. 
323. Wang T, Lv M, Qian Q, Nie Y, Yu L, Hou Y. 2011. Increased frequencies of T-helper type 17 cells in 
tuberculous pleural effusion. Tuberculosis. 91(3):231-237. 
324. Bandaru A, Devalraju KP, Paidipally P, Dhiman R, Venkatasubramanian S, Barnes PF, Vankayalapati 
R, Valluri V. 2014. Phosphorylated STAT3 and PD‐1 regulate IL‐17 production and IL‐23 receptor 
expression in Mycobacterium tuberculosis infection. European Journal of Immunology. 44(7):2013-
2024. 
325. Cowan J, Pandey S, Filion L, Angel J, Kumar A, Cameron D. 2012. Comparison of interferon‐γ, 
interleukin (IL)‐17‐and IL‐22‐expressing CD4 T-cells, IL‐22 expressing granulocytes and 
proinflammatory cytokines during latent and active tuberculosis infection. Clinical and Experimental 
Immunology. 167(2):317-329. 
326. Kumar NP, Anuradha R, Suresh R, Ganesh R, Shankar J, Kumaraswami V, Nutman TB, Babu S. 
2011. Suppressed type 1, type 2, and type 17 cytokine responses in active tuberculosis in children. 
Clinical and Vaccine Immunology. 18(11):1856-1864. 
327. Chen X, Zhang M, Liao M, Graner MW, Wu C, Yang Q, Liu H, Zhou B. 2010. Reduced Th17 
response in patients with tuberculosis correlates with IL-6R expression on CD4+ T-cells. American 
Journal of Respiratory and Critical Care Medicine. 181(7):734-742. 
328. Perreau M, Rozot V, Welles HC, Belluti‐Enders F, Vigano S, Maillard M, Dorta G, Mazza‐Stalder J, 
Bart PA, Roger T. 2013. Lack of Mycobacterium tuberculosis–specific interleukin 17A producing 
CD4+ T-cells in active disease. European Journal of Immunology. 43(4):939-948. 
329. Hur Y-G, Gorak-Stolinska P, Ben-Smith A, Lalor MK, Chaguluka S, Dacombe R, Doherty TM, 
Ottenhoff TH, Dockrell HM, Crampin AC. 2013. Combination of cytokine responses indicative of 
latent TB and active TB in Malawian adults. PLoS One. 8(11):e79742. 
330. Marín ND, París SC, Rojas M, García LF. 2013. Functional profile of CD4+ and CD8+ T-cells in 
latently infected individuals and patients with active TB. Tuberculosis. 93(2):155-166. 
68 
 
331. Peng M, Wang Z, Yao C, Jiang L, Jin Q, Wang J, Li B. 2008. Interleukin 17-producing γδ T-cells 
increased in patients with active pulmonary tuberculosis. Cellular and Molecular Immunology. 
5(3):203-208. 
332. Torrado E, Cooper AM. 2010. IL-17 and Th17 cells in tuberculosis. Cytokine and Growth Factor 
Reviews. 21(6):455-462. 
333. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, Kawakami K, Suda T, Sudo K, Nakae 
S, Iwakura Y. 2007. IL-17 mediated regulation of innate and acquired immune response against 
pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. Journal of Immunology. 
178(6):3786-3796. 
334. Redford PS, Boonstra A, Read S, Pitt J, Graham C, Stavropoulos E, Bancroft GJ, O'Garra A. 2010. 
Enhanced protection to Mycobacterium tuberculosis infection in IL‐10 deficient mice is accompanied 
by early and enhanced Th1 responses in the lung. European Journal of Immunology. 40(8):2200-2210. 
335. Yoshida YO, Umemura M, Yahagi A, O’Brien RL, Ikuta K, Kishihara K, Hara H, Nakae S, Iwakura 
Y, Matsuzaki G. 2010. Essential role of IL-17A in the formation of a mycobacterial infection-induced 
granuloma in the lung. Journal of Immunology. 184(8):4414-4422. 
336. Seiler P, Aichele P, Bandermann S, Hauser AE, Lu B, Gerard NP, Gerard C, Ehlers S, Mollenkopf HJ, 
Kaufmann SH. 2003. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is 
regulated by neutrophils via CXCR3-signaling chemokines. European Journal of Immunology. 
33(10):2676-2686. 
337. Silva MT. 2010. When two is better than one: Macrophages and neutrophils work in concert in innate 
immunity as complementary and cooperative partners of a myeloid phagocyte system. Journal of 
Leukocyte Biology. 87(1):93-106. 
338. Miossec P, Kolls JK. 2012. Targeting IL-17 and Th17 cells in chronic inflammation. Nature Reviews 
Drug Discovery. 11(10):763-776. 
339. Freches D, Korf H, Denis O, Havaux X, Huygen K, Romano M. 2013. Mice genetically inactivated in 
interleukin‐17A receptor are defective in long‐term control of Mycobacterium tuberculosis infection. 
Immunology. 140(2):220-231. 
340. Gopal R, Monin L, Slight S, Uche U, Blanchard E, Junecko BAF, Ramos-Payan R, Stallings CL, 
Reinhart TA, Kolls JK. 2014. Unexpected role for IL-17 in protective immunity against hypervirulent 
Mycobacterium tuberculosis HN878 infection. PLoS  Pathogens. 10(5):e1004099. 
341. Torrado E, Robinson RT, Cooper AM. 2011. Cellular response to mycobacteria: Balancing protection 
and pathology. Trends in Immunology. 32(2):66-72. 
69 
 
342. Etna MP, Giacomini E, Severa M, Coccia EM. 2014. Pro-and anti-inflammatory cytokines in 
tuberculosis: A two-edged sword in TB pathogenesis. Seminars in Immunology. 26(6):543-551. 
343. Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, Saraiva M, Pereira DR, Randall TD, 
Pedrosa J, Cooper AM. 2010. Pathological role of interleukin 17 in mice subjected to repeated BCG 
vaccination after infection with Mycobacterium tuberculosis. Journal of Experimental Medicine. 
207(8):1609-1616. 
344. Wozniak TM, Saunders BM, Ryan AA, Britton WJ. 2010. Mycobacterium bovis BCG-specific Th17 
cells confer partial protection against Mycobacterium tuberculosis infection in the absence of 
interferon-γ. Infection and Immunity. 78(10):4187-4194. 
345. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, 
Markowitz M. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4+ T-
lymphocytes from effector sites in the gastrointestinal tract. Journal of Experimental Medicine. 
200(6):761-770. 
346. Ciccone EJ, Greenwald JH, Lee PI, Biancotto A, Read SW, Yao MA, Hodge JN, Thompson WL, 
Kovacs SB, Chairez CL. 2011. CD4+ T-cells, including Th17 and cycling subsets, are intact in the gut 
mucosa of HIV-1-infected long-term nonprogressors. Journal of Virology. 85(12):5880-5888. 
347. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. 2012. Incomplete immune recovery in HIV 
infection: Mechanisms, relevance for clinical care and possible solutions. Clinical and Developmental 
Immunology. 2012:e670957. 
348. He Y, Li J, Zheng Y, Luo Y, Zhou H, Yao Y, Chen X, Chen Z, He M. 2012. A randomized case–
control study of dynamic changes in peripheral blood Th17/Treg cell balance and interleukin-17 levels 
in highly active antiretroviral-treated HIV type 1/AIDS patients. AIDS Research and Human 
Retroviruses. 28(4):339-345. 
349. DaFonseca S, Niessl J, Pouvreau S, Wacleche VS, Gosselin A, Cleret-Buhot A, Bernard N, Tremblay 
C, Jenabian M-A, Routy J-P. 2015. Impaired Th17 polarization of phenotypically naive CD4+ T-cells 
during chronic HIV-1 infection and potential restoration with early ART. Retrovirology. 12(1):38-60. 
350. Singh A, Vajpayee M, Ali SA, Chauhan NK. 2014. Cellular interplay among Th17, Th1, and Treg 
cells in HIV‐1 subtype “C” infection. Journal of Medical Virology. 86(3):372-384. 
351. Bixler SL, Mattapallil JJ. 2013. Loss and dysregulation of Th17 cells during HIV infection. Clinical 
and Developmental Immunology. 2013:e852418. 
70 
 
352. Brandt L, Benfield T, Mens H, Clausen LN, Katzenstein TL, Fomsgaard A, Karlsson I. 2011. Low 
level of regulatory T-cells and maintenance of balance between regulatory T-cells and Th17 cells in 
HIV-1 infected elite controllers. Journal of Acquired Immune Deficiency Syndromes. 57(2):101-108. 
353. Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, Estes JD, Sandler NG, 
Sukhumvittaya S, Marovich M. 2014. Initiation of ART during early acute HIV infection preserves 
mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathogens. 
10(12):e1004543. 
354. El Hed A, Khaitan A, Kozhaya L, Manel N, Daskalakis D, Borkowsky W, Valentine F, Littman DR, 
Unutmaz D. 2010. Susceptibility of human Th17 cells to human immunodeficiency virus and their 
perturbation during infection. Journal of Infectious Diseases. 201(6):843-854. 
355. McKinnon LR, Nyanga B, Chege D, Izulla P, Kimani M, Huibner S, Gelmon L, Block KE, Cicala C, 
Anzala AO. 2011. Characterization of a human cervical CD4+ T-cell subset coexpressing multiple 
markers of HIV susceptibility. Journal of Immunology. 187(11):6032-6042. 
356. Alvarez Y, Tuen M, Shen G, Nawaz F, Arthos J, Wolff MJ, Poles MA, Hioe CE. 2013. Preferential 
HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and 
lack of CCR5 ligands. Journal of Virology. 87(19):10843-10854. 
357. Rodriguez-Garcia M, Barr FD, Crist SG, Fahey JV, Wira CR. 2014. Phenotype and susceptibility to 
HIV infection of CD4+ Th17 cells in the human female reproductive tract. Mucosal Immunology. 
2014(7):1375–1385. 
358. Bixler SL, Sandler NG, Douek DC, Mattapallil JJ. 2013. Suppressed Th17 levels correlate with 
elevated PIAS3, SHP2, and SOCS3 expression in CD4 T-cells during acute simian immunodeficiency 
virus infection. Journal of Virology. 87(12):7093-7101. 
359. Zhou L, Lopes JE, Chong MM, Ivanov, II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky 
AY et al. 2008. TGF-β induced Foxp3 inhibits Th17 cell differentiation by antagonizing ROR-γt 
function. Nature. 453(7192):236-240. 
360. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. 
Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T-
cells. Nature. 441(7090):235-238. 
361. Ikeda S, Saijo S, Murayama MA, Shimizu K, Akitsu A, Iwakura Y. 2014. Excess IL-1 signaling 
enhances the development of Th17 cells by downregulating TGF-β induced Foxp3 expression. Journal 
of Immunology. 192(4):1449-1458. 
71 
 
362. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, 
Hennighausen L. 2007. Interleukin-2 signaling via STAT5 constrains T-helper 17 cell generation. 
Immunity. 26(3):371-381. 
363. Moisan J, Grenningloh R, Bettelli E, Oukka M, Ho I-C. 2007. Ets-1 is a negative regulator of Th17 
differentiation. Journal of Experimental Medicine. 204(12):2825-2835. 
364. Liao W, Lin J-X, Wang L, Li P, Leonard WJ. 2011. Modulation of cytokine receptors by IL-2 broadly 







The Effect of TB/HIV Pleurisy on miR-155 Expression, Stability and IL-35 Production of T-regulatory 
Lymphocytes 
 
Vanessa C Korb a, Alisa Phulukdaree a, 1, Umesh G Lalloo a, Anil A Chuturgoon a, b, and Devapregasan 
Moodley a, 2 
 
aDiscipline of Medical Biochemistry and Chemical Pathology, University of KwaZulu-Natal, Howard 
College Campus, King George V Avenue, Durban, South Africa 
Institutional Mailing Address: University of KZN, Durban, South Africa, 4041 
E-mail adresses:  
VCK : vanessakorb@gmail.com 
AP : Alisa.Phulukdaree@up.ac.za 
UGL : umeshlalloo@gmail.com 
DM : Devan_Moodley@hms.harvard.edu 
AAC : chutur@ukzn.ac.za 
 
1Present address: Department of Physiology, University of Pretoria, Prinshof Campus, Pretoria, South Africa  
2Present address: Department of Microbiology and Immunobiology, Harvard Medical School, 77 Avenue 
Louis Pasteur, Boston, USA  
 
bCorresponding author: A Chuturgoon; chutur@ukzn.ac.za  
Telephone number: +27312604404 
 
Running Title: TB/HIV reduces miR-155 expression and Treg stability 
 





T-regulatory cells (Tregs), characterised by forkhead box P3 (Foxp3), suppress effector lymphocyte function 
through the production of interleukin (IL)-35. MicroRNA (miR)-155 is a direct target of Foxp3 and 
positively regulates Treg stability by repressing translation of suppressor of cytokine signalling 1 (SOCS1), 
conferring Treg IL-2 competitive fitness. There is conflicting data on the frequency of Tregs in both 
tuberculosis (TB) and human immunodeficiency virus (HIV) infection indicating a pathogen-driven effect on 
Treg stability which has not been assessed in co-infection. 
 
Objectives: We investigated Foxp3, miR-155 and SOCS1 expression, Treg stability and IL-35 production in 
TB/HIV pleurisy in vitro and ex vivo. 
 
Methods: Foxp3 mRNA and miR-155 expression by qPCR, SOCS1 protein by western blotting, Foxp3 
protein and Treg frequency by flow cytometry, and IL-35 concentration by ELISA.  
 
Results: TB+HIV+ pleural effusion mononuclear cells showed increased Foxp3 mRNA (p=0.0022 but 
decreased Foxp3 protein expression (p=0.0008), together with reduced miR-155 (p=0.0022) and increased 
SOCS1 expression (p<0.0001). This was associated with a diminished proportion of 
CD4+CD25+Foxp3+STAT5+ Tregs ex vivo (p=0.0084) and confirmed in vitro (p=0.0467). Furthermore, a 
reduced pleural fluid IL-35 concentration (p=0.0258) was observed suggesting a Treg functional deficit.   
 
Conclusions: The TB/HIV microenvironment decreases the stability and functional capacity of Tregs due to 
altered miRNA-155/SOCS1 dynamics. 
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TB and HIV are the leading causes of death due to infectious disease globally. HIV infected individuals have 
a 26-31 times greater risk of developing active TB infection with TB being the leading cause of HIV-related 
mortality (1). South Africa has the second highest TB incidence and the largest number of individuals living 
with HIV/AIDS worldwide (1-3), consequently 62% of TB patients are HIV positive (2). This highlights the 
importance of co-infection research where the immunological consequences of Mycobacterium tuberculosis-
HIV interactions are largely uncharacterised. 
 
Regulatory T-cells, specified by the transcription factor Foxp3, are a suppressive subset of CD4+CD25+ T-
cells (5-10%). Tregs regulate effector lymphocyte function through contact dependent and independent 
mechanisms, such as the production of anti-inflammatory IL-35 (4). Under physiological conditions thymus 
derived (t)Tregs are responsible for the maintenance of immune homeostasis and peripheral tolerance. Upon 
pathological challenge tTregs are predominately replaced by periphery derived (p)Tregs from naïve CD4+ T-
cells to limit immunopathology during inflammation (5-7). Studies have shown that Treg homeostasis is 
regulated by miRNAs (8-10), a class of single stranded non-coding RNAs that post transcriptionally regulate 
gene expression (11, 12). MiR-155 is a direct target of Foxp3 which stabilises Tregs and confers IL-2 
competitive fitness by targeting and repressing SOCS1 (8-10, 13, 14). 
 
An imbalance in Treg stability has been associated with various pathologies. In TB/HIV co-infection Treg 
hyperactivity and down regulation of antigen specific CD4+ T-cells may ultimately result in pathogen 
persistence and establishment of chronic infection. In contrast, loss of a stable Treg pool results in an 
excessive pro-inflammatory response which amplifies chronic immune activation and heightened virulence 
in HIV and drives granulomatous immunopathology in TB (6). There is conflicting data on the frequency 
and function of Tregs in both TB (15-20) and HIV (21-29) indicating a pathogen-driven effect on Treg 
stability which has not been assessed in co-infection. 
 
Studies show that 40-80% of HIV-related TB is extrapulmonary (30, 31), the most common form of which is 
TB pleurisy (32). This is a consequence of M. tuberculosis infection of the pleura characterised by a chronic 
accumulation of inflammatory cells in the pleural space and resultant pleural effusion (PE) (33). TB infection 
outcome is determined by localised immune responses which are not accurately reflected systemically (34). 
Moreover, Tregs are noted to expand and accumulate at the pleural infection site exerting potent localised 
immune suppression (19, 35). Therefore we investigated Foxp3, miR-155 and SOCS1 expression, Treg 









2.2.1 Study population 
This study protocol was approved by the institutional Biomedical Research Ethics Committee (BF170/11). 
Participants were recruited at the Department of Pulmonary and Critical Care, Inkosi Albert Luthuli Central 
Hospital and the Department of Internal Medicine, Prince Mshiyeni Memorial Hospital (Durban, South 
Africa). Newly diagnosed TB patients presenting with a TB pleural effusion and concurrent HIV-infection 
(n=9) were enrolled. Active TB infection was confirmed by clinical diagnosis with bacterial or radiographic 
evidence; AFB culture positive sputum or pleural fluid microscopy (Gram, Zhiel-Neelsen, Auramine), M. 
tuberculosis DNA (Gene Xpert), pleural histology and pleural fluid cytology. The matched control group 
was composed of patients presenting with a non-infectious pleural effusion (malignancy, cardiac failure, end 
stage renal disease) and HIV seronegative (n=9). Exclusion criteria included anti-tuberculosis or anti-
retroviral therapy, immunomodulatory treatment and conditions. Blood and pleural fluid was sampled by 
routine venesection and diagnostic pleural tap respectively, after informed consent was obtained from each 































Age, years, median (range) 58 (32-76) 37 (18-64) 
Gender   
Male 5 (56) 4 (44) 
Female 4 (44) 5 (56) 
Race   
African 5 (56) 9 (100) 
Indian 4 (44) 0 
TB diagnostic criteria   
Culture positive  8 (89) 
Smear positive  2 (22) 
PCR-MTBDR  9 (100) 
Resistance to any one first line TB drug  1 (11) 
MDR-TB  1 (11) 
XDR-TB  0 
CD4 count, mm3, mean (range)  59 (9-153) 
Past history of TB infection 0 1 (11) 
Current smoker 2 (22) 1 (11) 
Ex-smoker 2 (22) 0 
Alcohol use 2 (22) 3 (33) 
Definitive cause of PE   
Tuberculosis 0 9 (100) 
Malignancy 4 (44) 0 
End stage renal disease 2 (22) 0 
Nephrotic syndrome 1 (11) 0 
Heart failure 2 (22) 0 
Co-Morbidities   
Diabetes mellitus 3 (33) 0 
Hypertension 5 (56) 1 (11) 
Hepatitis B 0 1 (11) 






2.2.2 Pleural effusion fluid and mononuclear cell isolation 
Cell free pleural effusion fluid (PEF), pleural effusion mononuclear cells (PEMCs) and peripheral blood 
mononuclear cells (PBMCs) were extracted from heparinised pleural effusion fluid and blood by differential 
gradient centrifugation within 2 hours (h) of pleural tap/venipuncture. Briefly, 5 ml of sample was layered 
onto equivolume Histopaque-1077 (catalogue number 10771-500, Sigma, USA) and centrifuged (1,491rpm, 
30 minutes (min), room temperature (RT)). PEF, represented as the uppermost layer, was aspirated and 
centrifuged (10,000rpm, 10min, 4°C) to remove any cellular constituents. Harvested PEF was pooled from 5 
patients in each group equally and stored at -80°C until further use. Buffy coats containing mononuclear 
cells were aspirated and rinsed in 0.1M phosphate buffered saline (PBS; 1,491rpm, 20min, RT) 
  
2.2.3 CD4+ T-cell isolation 
For the in vitro component of the study, CD4+ conventional T-lymphocytes (Tconvs) were purified by 
negative magnetic selection from PBMCs of a healthy BCG vaccinated volunteer (10ml, EDTA, one blood 
draw), using the Human CD4 T-Lymphocyte Enrichment Set-DM (catalogue number 557939, BD 
Biosciences, USA). PBMCs were labelled with biotinylated monoclonal antibodies (5μl/10×106 cells, 15min, 
RT) against antigens on erythrocytes, platelets and non-CD4+ peripheral leukocytes. The cells were washed 
(iMag Buffer, 1,491rpm, 20min) and incubated with streptavidin conjugated magnetic nanoparticles 
(5μl/10×106 cells, 30min, RT). The cell suspension was placed in a magnetic field (8min, iMagnet; BD 
Biosciences, USA) and the enriched CD4+ T-cell supernatant aspirated. Negative selection of the positive 
fraction was performed three times to increase the yield of the enriched fraction. The purity of the enriched 
fraction was increased by further negative selection and assessed by flow cytometry. 
 
2.2.4 Cell culture and treatment 
Healthy CD4+ Tconvs were seeded in triplicate (8×104cells/well, U-bottomed microplate) in PEF 
conditioned complete culture medium (CCM; RPMI 1640, 10% foetal calf serum (FCS), 1% Penstrep-
Fungizone, 1% L-glutamine, final concentrations) in a 1:1 ratio (24h, 37°C, 5% CO2). Treatments included 
TB-HIV- PEF and TB+HIV+ PEF. Concurrently, cells were activated with Dynabeads Human T-activator 
CD3/CD28 bead solution (catalogue number 11131D, Gibco by Life Technologies, Norway) (2μl/well). 
Following incubation, cells were harvested, washed once (0.1M PBS; 1,491rpm, 20min, RT) and the 
activation beads removed by magnetic selection (1min, iMagnet). The cells were immediately prepared for 







2.2.5 Flow cytometric analysis 
For surface staining, 2.5x105 cells were re-suspended in staining buffer (25μl, PBS containing 1% heat 
inactivated FCS, 0.09% w/v sodium azide) and labelled with the respective antibodies; fluorescein 
isothiocyanate (FitC) anti-CD4 (1:5, catalogue number 555346)  peridin-chlorophyll-cyanin 5.5 (PerCP-
Cy5.5) anti-CD25 (1:20, catalogue number 560503) (20min, 4°c, in the dark). For intracellular staining, cells 
were fixed in 4% paraformaldehyde (500μl, 30min, RT), washed (staining buffer; 1,491rpm, 20min, RT), 
permeabilised in 75% cold methanol (500μl, 10min, -20°C) and washed again. Cells were stained with the 
appropriate intracellular antibody; phycoerythrin (PE) anti-Foxp3 (1:5, catalogue number 560046), Alex 
Flour® 647 anti-STAT5 (1:5, catalogue number 612599) (60min, RT, in the dark). Antibodies were 
purchased from BD Biosciences, USA. Analysis was performed using the Accuri C6 flow cytometer (BD 
Biosciences, USA) and data analysed using FlowJo vX (10.0.7r2). Samples were run in triplicate and 30,000 
events acquired per sample.  
 
2.2.6 Molecular profiling 
Total RNA was extracted from PEMCs using Qiazol Lysis Reagent (Qiagen, USA) following an in-house 
protocol. Briefly, cells were added to Qiazol Lysis Reagent (1:1) and incubated at RT (5min) and 
subsequently frozen (-80°C, overnight). Chloroform (200μl) was added, incubated at RT (3min) and 
centrifuged (8,200rpm, 15min, 4°C). Isopropanol (500μl) was added to the aqueous phase and frozen (-80°C, 
overnight). The samples were centrifuged (8,200rpm, 20min, 4°C) and the RNA pellet washed in cold 
ethanol (75%, 1ml). The samples were then centrifuged (6,400rpm, 15min, 4°C), the ethanol aspirated and 
the RNA pellet re-suspended in 15μl of nuclease free water. Total RNA was quantified on a Nanodrop™ 
2000 UV-Vis Spectrophotometer (Thermoscientific, USA) and purity assessed with the A260/A280 ratio. 
 
Copy DNA (cDNA) was synthesised using the RT2 First Strand Kit (catalogue number 330401, Qiagen, 
USA) according to the manufacturer’s instructions. Briefly, 1μg of RNA pooled equally from 5 patients per 
group was added to a genomic DNA elimination mix (5 × gDNA elimination buffer, H20) to a total volume 
of 10μl and incubated at 42°C (5min) followed by 4°C (1min). Subsequently, reverse transcription mix 
(10μl, 5 × RT buffer 3, primer and external control mix, RT enzyme mix, H20) was added and incubated at 
42°C (15min) followed by 95°C (5min), on the GeneAmp® PCR System 9700 (Applied Biosystems, USA), 
to produce cDNA. 
 
Real time PCR was used to quantify Foxp3 mRNA expression.  A 25μl reaction consisted of 12.5μl RT2 
SYBR Green Mastermix (catalogue number 330500, Qiagen, United States), 8.5μl nuclease free water, 2μl 
cDNA and 1μl sense and anti-sense primers. Foxp3 primer sequence: sense 5’-
ACACGGACAGGATTGACAGA-3’ anti-sense 5’-CAAATCGCTCCACCAACTAA-3’ (450nM). The 
mRNA expression was compared and normalised to a housekeeping gene, 18S sense 5’-
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ACACGGACAGGATTGACAGA-3’ antisense 5’-CAAATCGCTCCACCAACTAA-3’. Cycling conditions 
were as follows: initial denaturation (95°C, 10min) followed by 40 cycles of denaturation (95°C, 30 seconds 
(s)), annealing (64°C, 30s) and extension (72°C, 1min) on a CFX Real-Time PCR Detector (Bio-Rad, USA). 
The quantification and melt curves were analysed using CFX Manager™ Software v3.0 (Bio-Rad, USA). 
The mRNA levels were calculated using the method described by Livak and Schmittgen (2001) (36) and 
represented as fold changes and relative expression to the control. Samples were run in triplicate and the 
experiments were repeated twice. 
 
2.2.7 miRNA expression 
cDNA was synthesised using the miScript II RT Kit (catalogue number 218160, Qiagen, USA) according to 
the manufacturer’s guidelines. Briefly, 1μg of RNA pooled equally from 5 patients per group was added to a 
reverse transcription mastermix (5x miScript HiSpec Buffer, 10x miScript Nucleics Mix, miScript Reverse 
Transcriptase Mix, H20) to a total volume of 20μl and incubated at 37°C (60min) followed by 95°C (5min) 
on the T100™ Thermocycler (Bio-Rad, USA), to produce cDNA. 
 
Quantification of mature miR-155 was performed using miScript Primer Assays (catalogue number 218300, 
Qiagen, USA) in combination with miScript SYBR Green PCR kit (Qiagen, USA) according to the product 
instructions. A 25μl reaction consisted of 12.5μl 2 x QuantiTect SYBR Green PCR Master Mix, 8.5μl 
nuclease free water, 2μl cDNA, 2.5μl 10x miScript Universal Primer and 2.5μl 10 x miScript Primer Assay. 
Human RNU6B (catalogue number 331001, Qiagen, USA) was run as an internal control. The reaction 
underwent an initial activation step at 95°C (15min) followed by 40 cycles of denaturation (94°C, 15s), 
annealing (55°C, 30s) and extension (70°C, 30s) on the CFX96 Touch Real-Time PCR Detection System. 
The quantification and melt curves were analysed using CFX Manager™ Software v3.0. MiR-155 levels 
were calculated using the method described by Livak and Schmittgen (2001) (36) and represented as fold 
changes and relative expression to the control. Samples were run in triplicate and the experiments were 
repeated twice. 
 
2.2.8 Western blotting 
Protein was isolated from fresh PEMCs using Cytobuster Protein Extraction Reagent (catalogue number 
71009, Novagen Merck Millipore, Germany), supplemented with protease and phosphatase inhibitors 
(catalogue numbers 05892791001 and 04906837001 respectively, Roche, USA). Cytobuster (500ul) was 
added to approximately 1x105 cells, vortexed (1min), incubated on ice (10min) and centrifuged (1,491rpm, 
10min, 4°C). The supernatant containing the crude protein extract was aspirated, pooled equally from 5 
patients in each group, and stored at -80°C until further use. Protein concentration was quantified using the 
bicinchoninic acid (BCA) assay (Sigma, Germany) and samples standardised to 0.4mg/ml. Protein extracts 
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were denatured by boiling (5mins) in a 1:1 Laemli buffer (0.5M Tris-HCl (pH 6.8), 3% glycerol, 10% 
sodium dodecyl sulphate (SDS), 1% bromophenol blue, 12% β-mercaptoethanol in dH20).  
 
Protein samples (25μl) were electrophoresed on a 7.5% SDS-polyacrylamide gel (1.5h, 150 volts) and 
transferred to a nitrocellulose membrane using the Trans-Blot® Turbo™ Transfer System (1h, 350mA, Bio-
Rad, USA). Membranes were blocked (1h) with 5% bovine serum albumin (BSA) in Tris-buffered saline and 
Tween 20 (TTBS; 137mM NaCl, 2.7mM KCl, 24mM Tris, 0.5% Tween 20, dH20, pH 7.6).  
 
The membrane was probed overnight (4°C) with rabbit anti-SOCS1 (catalogue number sc-9021, Santa Cruz 
Biotechnology, USA) diluted 1:1,000 in 5% BSA/TTBS. The membrane was then washed (TTBS, 4 x 
10mins) and probed (1h, RT) with horse radish peroxidase (HRP)-conjugated anti-rabbit IgG (catalogue 
number sc-2004, Santa Cruz Biotechnology) diluted 1:5,000 in 5% BSA/TTBS. The membrane was washed 
again (TTBS, 4 x 10mins). A HRP-conjugated goat polyclonal antibody specific for β-actin diluted 1:5,000 
in 5% BSA/TTBS was used as a loading control and for normalisation of protein expression. The membrane 
was developed using LumiGLO® Chemiluminescent Substrate System (catalogue number 51-61-00, KPL, 
USA) and images were captured on an Alliance 2.7 Gel Documentation System (Uvitec, UK). The density of 
the protein bands was quantified using UviBand Advanced Image Analysis Software v12.14 (Uvitec, UK). 
The experiment was performed in triplicate. Results are presented as relative band intensity (RBI) 
normalised against β-actin. 
 
2.2.9 IL-35 ELISA 
Quantification of PEF IL-35 was measured by enzyme-linked immunosorbent assay (ELISA) using the 
Legend Max™ Human IL-35 Heterodimer Kit (catalogue number 439507, Biolegend, USA) according to the 
manufacturer’s protocol. Briefly, cell free PEF (50μl, diluted 1:10 in assay buffer) was added to wells of the 
pre-coated plate and incubated (2h, 350rpm, RT). The plate was washed 4 times (300μl wash buffer), 
detection antibody (100μl/well) added and incubated (1h, 350rpm, RT). The plate was washed 4 times after 
which Avidin-HRP solution (100μl/well) was added and incubated (30min, 350rpm, RT). The plate was 
washed 5 times, substrate solution F (100μl/well) added and the plate incubated (10min, RT, in the dark). 
The reaction was stopped by the addition of stop solution (100μl/well) and the absorbance read at 450nm 
with a reference at 570nm. Standards and samples were run in duplicate. The minimum detection limit was 
0.13 ± 0.01ng/ml. Results were analysed using an 8-point standard curve constructed from recombinant 
protein standards. 
 
2.2.10 Statistical analysis 
Statistical analysis was performed using GraphPad Prism software (v5.0). The unpaired t-test with Welch 
correction was used in in vitro analyses and the non-parametric Mann-Whitney test in ex vivo analyses to 
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avoid the influence of potential outlier values in the small sample size. Outlier values were calculated and 
excluded using the interquartile range. Data is expressed as mean ± standard error of the mean (SEM), p 




























2.3.1 TB/HIV mediated increase in Foxp3 mRNA but decrease in Foxp3 protein expression 
Foxp3 is indispensable for Treg lineage specification and immunosuppressive activities. We performed 
qPCR to evaluate the expression of Foxp3 mRNA. TB+HIV+ co-infection caused a significant 2.345 fold 
increase in the Foxp3 mRNA expression in PEMCs compared to a TB-HIV- conditions (19.140 ± 0.161 vs. 
17.952 ± 0.164 relative expression (relative cycle threshold, ∆Ct), p=0.0022) (Figure 2.1). In contrast 
TB+HIV+ PEMCs showed a significant 1.661 fold decrease in Foxp3 protein (1594.222 ± 86.189 vs. 959.556 




Figure 2.1: Relative expression of forkhead box P3 mRNA. Pooled TB+HIV+ pleural effusion mononuclear 
cells (PEMCs) showed a significant increase in forkhead box P3 (Foxp3) relative mRNA expression 
represented as a lower relative cycle threshold (∆Ct) (n=6 replicates in each group, p=0.0022, Mann-Whiney 





Figure 2.2: Change in forkhead box P3 relative protein expression. (A) TB+HIV+ pleural effusion 
mononuclear cells (PEMCs) showed a significant decrease in forkhead box P3 (Foxp3)-phycoerythrin (PE) 
mean fluorescence intensity (MFI) (TB-HIV- n=5, TB+HIV+ n=5, p=0.0008, Mann Whitney test). Data 














2.3.2 Reduced miR-155 expression in TB+HIV+ pleurisy 
MiR-155 is a direct target of Foxp3, because we observed reduced Foxp3 protein levels in co-infection we 
questioned whether miR-155 expression (using qPCR) was also decreased. Pooled TB+HIV+ PEMCs showed 
a 2.143 fold decrease in miR-155 expression (3.855 ± 0.073 vs. 4.843 ± 0.044 relative expression (∆Ct), 




Figure 2.3: Relative expression of microRNA-155. Pooled TB+HIV+ pleural effusion mononuclear cells 
(PEMCs) showed a significant decrease in relative microRNA (miR)-155 expression represented as a higher 












2.3.3 Increased SOCS1 expression in TB+HIV+ pleurisy 
MiR-155 suppresses the translation of SOCS1, a negative regulator of IL-2 receptor signalling and inhibitor 
of Foxp3 expression. As we found reduced expression of Foxp3 protein and miR-155 mRNA we 
interrogated if this was linked by increased SOCS1 expression using western blotting. TB+HIV+ PEMCs 
showed a significant 3.751 fold increase in SOCS1 relative protein expression (1.481 ± 0.231 RBI vs. 5.555 




Figure 2.4: Relative protein expression of suppressor of cytokine signalling 1. Pooled TB+HIV+ pleural 
effusion mononuclear cells (PEMCs) showed a significantly greater relative protein expression of the 24kDa 
suppressor of cytokine signalling 1 (SOCS1), represented as western blot relative band density (RBI) (n=9 







2.3.4 Reduced Treg proportion in TB+HIV+ pleurisy 
MiR-155 positively regulates Treg stability by suppressing SOCS1 translation and conferring IL-2 
competitive fitness. We questioned whether a decreased expression of miR-155 and increased expression of 
SOCS1 resulted in loss of Treg stability. The number of Tregs in PEF was quantified by flow cytometry. The 
proportion of CD4+CD25+Foxp3+STAT5+ Tregs in TB+HIV+ pleurisy was significantly 21.049% (1.664 fold) 




Figure 2.5: Frequency of T-regulatory lymphocytes ex vivo. The proportion of CD4+CD25+Foxp3+STAT5+ 
T-regulatory cells (Tregs) was significantly lower in TB+HIV+ pleural effusion mononuclear cells (PEMCs) 
















2.3.5 Lower IL-35 concentration in TB+HIV+ pleurisy 
IL-35 is a suppressive Treg characteristic cytokine. We investigated whether a loss of Treg stability was 
associated with a loss of suppressive activity by quantifying IL-35 in PEF by ELISA. There was a significant 
3.442 fold decrease in IL-35 concentration in the TB+HIV+ cohort compared to the control group (18.784 ± 




Figure 2.6: Concentration (ng/ml) of interleukin-35 in pleural effusion fluid. The TB+HIV+ cohort showed 
significantly lower pleural effusion fluid interleukin (IL)-35 levels than the controls (TB-HIV- n=8, TB+HIV+ 
















2.3.6 Loss of Treg stability confirmed in vitro 
To confirm our ex vivo results, we mimicked in vivo conditions by treating CD4+ Tconvs with PEF 
conditioned CCM. In line with the ex vivo results, TB+HIV+ PEF treatment resulted in a significant 5.756% 
(1.206 fold) lower count of CD4+CD25+Foxp3+STAT5+ Tregs compared to TB-HIV- PEF (33.656 ± 1.719% 




Figure 2.7: Frequency of T-regulatory lymphocytes in vitro. The proportion of CD4+CD25+Foxp3+STAT5+ 
T-regulatory cells (Tregs) was significantly lower in CD4+ T-cells treated with TB+HIV+ pleural effusion 
fluid (PEF) conditioned CCM in vitro (n=9 replicates in each group, p=0.0467, unpaired t-test with Welch 












Regulatory T-cells suppress the activation and function of effector T-cells to maintain immune homeostasis 
and limit immunopathology. Previous studies have shown a loss of Treg stability in TB and HIV 
independently; however, the maintenance of a stable and functional Treg pool has not been assessed in co-
infection. Failure to maintain lineage identity can result in a compromised immune response; this is 
significant given the role of Tregs in mitigating dysregulated inflammation characteristic in TB and HIV. 
 
MiRNAs are predominantly negative post transcriptional regulators which destabilise and degrade target 
mRNA or repress translation, fine tuning gene expression in pleiotropic biological pathways, including 
immune cell lineage commitment and homeostasis (12, 37).  Computational analysis indicates that miRNAs 
may regulate up to 60% of all human protein coding genes (38). Altered miRNA patterns have been 
identified in latent and active TB (39-51) as well as HIV infection (52-57). However, a literature search 
shows that there has been no adequate assessment of miRNA expression in TB/HIV co-infection.  
 
Foxp3, a transcription factor of the winged helix family, is indispensable for Treg lineage specification and 
immunosuppressive activities by acting at transcriptional, epigenetic and post transcriptional levels (58, 59). 
Our study shows a 1.661 fold decrease in Foxp3 protein expression in TB/HIV pleurisy. This is in keeping 
with previous studies that observed reduced Foxp3 protein in an inflammatory and infectious micro-
environment (60, 61). 
 
Foxp3 target genes that are critical in Treg homeostasis have been identified, particularly the MIR155 host 
gene (MIR155HG) (62, 63). miR-155 has been implicated in the pathogenesis of several bacterial and viral 
infections (11). MIR155HG has a Foxp3 binding site in intron 2, approximately 500 base pairs upstream of 
the pre-mir-155 sequence (62, 63). Foxp3-driven miR-155 expression drives the size and stability of the Treg 
subset through modulation of the IL-2 receptor (IL-2R) pathway (8, 10, 13). MiR-155 knockout mice exhibit 
a reduced frequency of Tregs in both the thymus and peripheral lymphoid tissues (8). 
 
IL-2 is critical in Treg stabilisation, survival and maintenance in the periphery (7, 58, 64). Signalling is 
mediated by CD25 (IL-2Rα), constitutively expressed on Tregs, activation of Janus activated kinase (Jak)1/3 
and subsequent phosphorylation of signal transducer and activator of transcription (STAT) 5 (65). In turn 
pSTAT5 binds to the promoter region and conserved non-coding sequence 2 (CNS2) element in the Foxp3 
locus (66), directly controlling Foxp3 heritable expression and transcriptional initiation (7). MiR-155 
stabilises Tregs by binding to the 3’UTR of SOCS1, a negative regulator of IL-2R signalling, and 
suppressing its translation. This in turn confers competitive fitness to the Treg population allowing 




In support of previous TB (67) and HIV (55, 57) studies, our work showed a significant 2.143 fold reduction 
in miR-155 expression and 3.751 fold increase in SOCS1 protein expression during TB+HIV+ pleurisy, a 
novel observation in TB/HIV co-infection. Continuous Foxp3 expression has been shown to be indispensable 
for miR-155 expression (10) therefore reduced miR-155 levels are likely a result of diminished Foxp3 
protein and MIR155HG targeting. Based on this, we propose that decreased miR-155 expression facilitates 
SOCS1 mediated loss of Treg stability by increasing the threshold of IL-2 signalling resulting in a reduced 
proportion of Tregs. A significant 21.049% lower proportion of Tregs was observed in TB+HIV+ pleurisy ex 
vivo indicating that the TB+HIV+ microenvironment is not conducive to Treg stability. This was validated by 
mimicking in vivo conditions resulting in a significant 5.756% lower frequency of Tregs in vitro confirming 
that the TB+HIV+ micro-environment does not maintain a stable Treg pool. These observations provide 
mechanistic insight into the loss of Treg stability during co-infection. 
 
We next questioned whether a loss of Treg stability was associated with diminished suppressive activity as 
Tregs from miR-155 knock out models retained suppressive capacity in vivo and in vitro (8, 13, 37, 68, 69); 
however, the amount of Foxp3 protein has been shown to directly correlate to Treg suppressive function (70, 
71). IL-35, a heterodimer of Epstein-Barr-virus-induced-gene-3 (EBI3) and IL-12p35/α, is a suppressive 
cytokine of the IL-12 family that is primarily produced by Tregs (4). It is not constitutively expressed (72-
74) but its production is potentiated during Treg mediated active suppression of effector T-cells and is 
required for maximal Treg suppressive activity in mice in vivo and in vitro (4). The IL-35 receptor shares the 
gp130 subunit with IL-27 receptor and the IL-12Rβ2 with the IL-12 receptor (75, 76), ligation of which 
results in auto-phosphorylation of Jak1/2 with subsequent phosphorylation of STAT1 and 4 (75). IL-35 
potently inhibits effector T- and B-cells, particularly Th1 and Th17 lineages, by the expansion of Tregs and 
production of IL-10 (77). Furthermore, IL-35 has the ability to convert naïve CD4+ T-cells into suppressive 
IL-35 producing T-cells termed iTreg35, that lack expression of Foxp3, TGF-β and IL-10, by the process of 
infectious tolerance (73). 
 
To the best of our knowledge this is the first study to assess IL-35 in TB, HIV or co-infection. We showed a 
3.442 fold decrease in IL-35 concentration in TB+HIV+ pleurisy thus implying a Treg functional deficit. 
EBI3 is a downstream target of Foxp3 explaining the preferential IL-35 production by Tregs (4) and 
therefore reduced Foxp3 protein would likely result in reduced EBI3 transcription and subsequently IL-35 
concentrations. 
 
A loss of Treg stability is of benefit to both pathogens. Tregs have been shown to down regulate antigen 
specific MTB responses preventing tissue injury by resolving granulomatous inflammation; however, 
hyperactive inflammation results in caseous necrosis, cavitation and transmission of bacilli, hallmarks of 
active infection and the ultimate goal of the bacterial life cycle. In terms of HIV, loss of Treg immune 
suppression inhibits HIV-specific T-cell responses contributing to immune deficiency, heightened chronic 
immune activation and viral replication (78, 79).  
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Notably, despite a significant decrease in Foxp3 protein expression, a 2.345 fold increase in Foxp3 mRNA 
was observed in TB/HIV pleurisy. These disparate transcript and protein results indicate a potent pro-Treg 
signal at the molecular level which is circumvented by post transcriptional and/or translational modifications 
(80). Research into the post translational negative regulation of Foxp3 protein expression has identified 
inflammatory signals (IL-6, TNF-α, CCL3) that mediate Foxp3 polyubiquitination and subsequent 
proteasome-mediated degradation (61, 81-84). Our previous work showed a significantly increased 
concentration of TNF-α in TB+HIV+ pleural fluid compared to a TB-HIV- cohort prompting further 
investigation (manuscript in preparation). In this way the extracellular environment may regulate cellular 
intrinsic transcriptional programs and modulate Treg stability and functionality through modulation of Foxp3 
polyubiquitination (80). Furthermore, in pathological settings Foxp3 mRNA is negatively regulated by miR-
31 (8), miR-15a (85), miR-16 (85), miR-24 (86) and miR-210 (86, 87). The role of poly ubiquitination and 
miRNA regulation in Foxp3 expression needs to be further investigated in TB/HIV co-infection. 
 
2.5 Concluding Remarks 
TB+HIV+ pleurisy induces reduced Foxp3 protein expression and loss of Treg stability in vitro and ex vivo 
due to altered miR-155/SOCS1 dynamics. This was associated with diminished IL-35 levels implying a Treg 
functional deficit. A decreased functional Treg pool may contribute to the pathogenesis of TB and HIV by an 
excessive and dysregulated immune response. 
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T-helper (Th) 17 cells are a pro-inflammatory subset of CD4+ effector T-cells critical in mucosal immunity. 
Imbalances in Th17 cell proportion have been implicated in the pathogenesis of several diseases; however, 
this has not been adequately explored in tuberculosis (TB) and human immunodeficiency virus (HIV) co-
infection. Since Th17 cells are predominantly mucosally associated, we assessed Th17 proportion and 
associated microenvironment in pleural effusions from patients co-infected with TB/HIV. Our results show 
that TB+HIV+ pleurisy results in significantly reduced frequency of CD4+IL-17+RORC+STAT3+ Th17 cells 
compared to TB-HIV- ex vivo (p=0.0054) and was confirmed in conditioned media studies in vitro 
(p=0.0001). This was not associated with alterations in Th17 polarising cytokines interleukin (IL)-6, IL-21 
and IL-23 or changes in Th17 signature cytokines IL-17A and F. However, the mRNA expression of Th17 
signaling molecules, IL-6 (p=0.0022), IL-6R (p=0.0247), IL-1β (p=0.0022) and signal transducer and 
activator (STAT) 3 (p=0.0022) were significantly upregulated. Notably, TB+HIV+ pleural fluid contained 
significantly higher concentrations of IL-1β (p=0.0008), IL-22 (p=0.0115), IL-31 (p=0.0210), TNF-α 
(p=0.0251) and IFN-γ (p=0.0026) than TB-HIV- pleural fluid ex vivo. Taken together, this suggests a reduced 
portion of Th17 lymphocytes in TB/HIV pleurisy is independent of locally mediated cytokine polarisation. 
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Th17 cells are a pro-inflammatory subset of CD4+effector T-cells [1] characterised by the production of IL-
17A/F, surface expression of C-C chemokine receptor (CCR)6 and lineage specific transcription factor RAR-
related orphan rector (ROR)C [2]. Th17 cells predominantly reside at mucosal surfaces where they play a 
pivotal role in inflammatory reactions and protective immunity against intra-[3, 4] and extracellular [5, 6] 
bacterial and fungal infections. An imbalance in Th17 proportion has been implicated in the pathogenesis of 
TB. 
 
Approximately one third of the global population suffers from TB; a granulomatous disease spread by the 
airborne pathogen Mycobacterium tuberculosis (MTB). MTB cell wall component, trehalose-6-6’-
dimycolate (TDM/cord factor) has been shown to induce the production of Th17 differentiating cytokines 
from antigen presenting cells through the C-type lectin Mincle pathway [7]. Conflicting studies have noted 
an expansion of the Th17/IL-17 axis in the peripheral blood [8-10] and pleural fluid [9, 10], and a reduced 
frequency of Th17 cells in peripheral blood [11-15] and broncho-alveolar lavage (BAL) fluid [11] during 
active MTB infection, with correlation to disease severity [9].  
 
HIV is the most powerful risk factor predisposing for active TB infection which remains the number one 
communicable HIV-related cause of death [16]. In South Africa, approximately 62% of TB patients are HIV 
positive [17]. HIV infection is characterised by chronic immune activation and systemic depletion of CD4+ 
T-cells. The preferential loss of Th17 cells from the mucosa and peripheral blood with reduced levels of IL-
17 during HIV infection is well documented. This loss is not completely restored by antiretroviral therapy 
[18-23] suggesting that HIV infection interferes in the generation of Th17 cells [24]. 
 
Th17 lymphocytes are significant in the pathogenesis of TB and a potential predictor of disease severity; 
however, data on the proportion and role of Th17 cells in TB are conflicting. Furthermore, the confounding 
effect of HIV co-infection on Th17 frequency has not been investigated. Notably, 40-80% of HIV-related TB 
is extrapulmonary [25, 26] the most common form being TB pleurisy [27] and the immunological 
mechanisms of which are not accurately reflected systemically [28]. Taken together with the mucosal 
predominance of Th17 cells, this study characterised the proportion of Th17 lymphocytes and the cytokine 









3.2.1 Study population 
This study protocol was approved by the institutional Biomedical Research Ethics Committee (BF170/11). 
Participants were recruited at the Department of Pulmonary and Critical Care, Inkosi Albert Luthuli Central 
Hospital and the Department of Internal Medicine, Prince Mshiyeni Memorial Hospital (Durban, South 
Africa). Newly diagnosed TB patients presenting with a TB pleural effusion and concurrent HIV-infection 
(n=13) were enrolled. Active TB infection was confirmed by clinical diagnosis with bacterial or radiographic 
evidence; AFB culture positive sputum or pleural fluid microscopy (Gram, Zhiel-Neelsen, Auramine), MTB 
DNA (Gene Xpert), pleural histology and pleural fluid cytology. The matched control group was composed 
of patients presenting with a non-infectious pleural effusion (malignancy, cardiac failure, end stage renal 
disease) and confirmed HIV seronegative (n=8). Exclusion criteria included anti-tuberculosis or anti-
retroviral therapy, immunomodulatory treatment and conditions. Blood and pleural fluid were sampled by 
routine venesection and diagnostic pleural tap respectively, after informed consent was obtained from each 
participant. A summary of the demographics and clinical parameters of the study population are represented 






















Age, years, median (range) 58 (46-78) 36 (18-64) 
Gender   
Male 6 (75) 6 (46) 
Female 2 (25) 7 (54) 
Race   
African 5 (63) 13 (100) 
Indian 3 (37) 0 
TB diagnostic criteria   
Histopathology  1 (8) 
Culture positive  8 (62) 
Smear positive  3 (23) 
PCR-MTBDR  8 (62) 
Clinical with radiography  3 (23) 
Resistance to any one first line TB drug  1 (8) 
MDR-TB  1 (8) 
XDR-TB  0 
CD4 count, mm3, mean (range)  169 (9-463) 
Past history of TB infection 0 1 (8) 
Current smoker 3 (37) 2 (15) 
Ex-smoker 1 (13) 0 
Alcohol use 2 (25) 3 (23) 
Definitive cause of PE   
Tuberculosis 0 13 (100) 
Malignancy 5 (63) 0 
End stage renal disease 2 (25) 0 
Heart failure 1 (13) 0 
Co-Morbidities   
Diabetes mellitus 3 (37) 0 
Hypertension 5 (63) 1 (8) 
Hepatitis B 0 2 (15) 





3.2.2 Pleural effusion fluid and mononuclear cell isolation 
Cell free pleural effusion fluid (PEF), pleural effusion mononuclear cells (PEMCs) and peripheral blood 
mononuclear cells (PBMCs) were extracted from heparinised pleural effusion fluid and blood by differential 
gradient centrifugation within 2 hours (h) of pleural tap/venipuncture. Briefly, 5 ml of sample was layered 
onto equivolume Histopaque-1077 (catalogue number 10771-500, Sigma, USA) and centrifuged (1,491rpm, 
30 minutes (min), room temperature (RT)). PEF, represented as the uppermost layer, was aspirated and 
centrifuged (10,000rpm, 10min, 4°C) to remove any cellular constituents. Harvested PEF was pooled from 5 
patients in each group equally and stored at -80°C until further use. Buffy coats containing mononuclear 
cells were aspirated and rinsed in 0.1M phosphate buffered saline (PBS; 1,491rpm, 20min, RT).  
 
3.2.3 CD4+ T-cell isolation 
For the in vitro component of the study, CD4+ conventional T-lymphocytes (Tconvs) were purified by 
negative magnetic selection from PBMCs of a healthy BCG vaccinated volunteer (10ml, EDTA, one blood 
draw), using the Human CD4 T-Lymphocyte Enrichment Set-DM (catalogue number 557939, BD 
Biosciences, USA), according to the manufacturer’s instructions. PBMCs were labelled with biotinylated 
monoclonal antibodies (5μl/10×106 cells, 15min, RT) against antigens on erythrocytes, platelets and non-
CD4+ peripheral leukocytes. The cells were washed (iMag Buffer, 1,491rpm, 20min) and incubated with 
streptavidin conjugated magnetic nanoparticles (5μl/10×106 cells, 30min, RT). The cell suspension was 
placed in a magnetic field (8min, iMagnet; BD Biosciences, USA) and the enriched CD4+ T-cell supernatant 
aspirated. Negative selection of the positive fraction was performed three times to increase the yield of the 
enriched fraction. The purity of the enriched fraction was increased by further negative selection and 
assessed by flow cytometry. 
 
3.2.4 Cell culture and treatment 
Healthy CD4+ T-cells were seeded in triplicate (8×104cells/well, U-bottomed microplate) in PEF conditioned 
complete culture medium (CCM; RPMI 1640, 10% foetal calf serum (FCS), 1% Penstrep-Fungizone, 1% L-
glutamine, final concentrations) in a 1:1 ratio (24h, 37°C, 5% CO2). Treatments included TB
-HIV- PEF and 
TB+HIV+ PEF. Concurrently, cells were activated with Dynabeads Human T-activator CD3/CD28 bead 
solution (catalogue number 11131D, Gibco, Norway) (2μl/well). Following incubation, cells were harvested, 
washed once (0.1M PBS, 1,491rpm, 20min, RT) and the activation beads removed by magnetic selection 
(1min, iMagnet). The supernatants were stored at -80°C for downstream cytokine profiling and the cells 





3.2.5 Flow cytometric analysis 
For surface staining, 2.5x105 cells were re-suspended in staining buffer (25μl, 0.1M PBS containing 1% heat 
inactivated FCS, 0.09% w/v sodium azide) and labelled with fluorescein isothiocyanate (FitC) anti-CD4 (1:5, 
catalogue number 555346) (20mins, 4°c, in the dark). For intracellular staining, cells were fixed in 4% 
paraformaldehyde (500μl, 30min, RT), washed (staining buffer; 1,491rpm, 20min, RT), permeabilized in 
75% cold methanol (500μl, 10min, -20°C) and washed again. Cells were stained with the appropriate 
intracellular antibodies; peridin-chlorophyll-cyanin 5.5 (PerCP-Cy5.5) anti-IL17A (1:20, catalogue number 
560799), phycoerythrin (PE) anti-RORC2 (1:40 catalogue number IC6006P) and Alex Fluor® 647 anti-
pSTAT3 (1:5 catalogue number 557815) (60min, RT, in the dark). Analysis was performed using the Accuri 
C6 flow cytometer (BD Biosciences, USA) and data analysed using FlowJo vX (10.0.7r2). Samples were run 
in triplicate and 30,000 events acquired. Antibodies were purchased from BD Biosciences, USA, with the 
exception of anti-RORC2 which was purchased from R&D Systems. 
 
3.2.6 Molecular profiling 
Total RNA was extracted from PEMCs using Qiazol Lysis Reagent (Qiagen, USA) following an in-house 
protocol. Briefly, cells were added to Qiazol Lysis Reagent (1:1) and incubated at RT (5min) and 
subsequently frozen (-80°C, overnight). Chloroform (200μl) was added, incubated at RT (3min) and 
centrifuged (8,200rpm, 15min, 4°C). Isopropanol (500μl) was added to the aqueous phase and frozen (-80°C, 
overnight). The samples were centrifuged (8,200rpm, 20min, 4°C) and the RNA pellet washed in cold 
ethanol (75%, 1ml). The samples were then centrifuged (6,400rpm, 15min, 4°C), the ethanol aspirated and 
the RNA pellet re-suspended in 15μl of nuclease free water. Total RNA was quantified on a Nanodrop™ 
2000 UV-Vis Spectrophotometer (Thermoscientific, USA) and purity assessed using the A260/A280 ratio. 
 
Copy DNA (cDNA) was synthesised using the RT2 First Strand Kit (catalogue number 330401, Qiagen, 
USA) according to the manufacturer’s instructions. Briefly, 1μg of RNA pooled equally from 5 patients per 
group was added to a genomic DNA elimination mix (5 × gDNA elimination buffer, H20) to a total volume 
of 10μl and incubated at 42°C (5min) followed by 4°C (1min). Subsequently, reverse transcription mix 
(10μl, 5 × RT buffer 3, primer and external control mix, RT enzyme mix, H20) was added and incubated at 
42°C (15min) followed by 95°C (5min), on the GeneAmp® PCR System 9700 (Applied Biosystems, USA), 
to produce cDNA.  
 
Real-time PCR was used to quantify STAT3, IL-6, IL-6 receptor (R) and IL-1β mRNA levels. A 25μl 
reaction consisted of 12.5μl RT2 SYBRGreen Masterrmix (catalogue number 330500, Qiagen, United 
States), 8.5μl nuclease free water, 2μl cDNA and 1μl sense and anti-sense primers.  Primer sequences: 
STAT3 sense 5’- TCTCAACTTCAGACCCGTCAACA-3’ anti-sense 5’-
ACAGCTCCACGATTCTCTCCTCC-3’ (450nM), IL-6 sense 5′-AAATTCGGTACATCCTCGACGG-3′ 
antisense 5′- GGAAGGTTCAGGTTGTTTTCTGC-3’ (500nM), IL-6R sense 5′-
107 
TGAGCTCAGATATCGGGCTGAAC-3′ antisense 5′-CGTCGTGGATGACACAGTGATG-3’ (450nM), 
IL-1β sense 5′-CAGCTACGAATCTCCGACCAC-3′ antisense 5′-GGCAGGGAACCAGCATCTTC-3’ 
(600nM). The mRNA expression was compared and normalised to a housekeeping gene, 18S sense 5’-
ACACGGACAGGATTGACAGA-3’ antisense 5’-CAAATCGCTCCACCAACTAA-3’. Cycling conditions 
were as follows: initial denaturation (95°C, 10min) followed by 40 cycles of denaturation (95°C, 30 seconds 
(s)), annealing (STAT3: 64°C, IL-6: 60°C, IL-6R: 60°C, IL-1β: 60°C for 30s) and extension (72°C, 1min) on 
a CFX Real-Time PCR Detector (Bio-Rad, USA).The quantification and melt curves  were analysed using 
CFX Manager™ Software v3.0 (Bio-Rad, USA). The mRNA levels were calculated using the method 
described by Livak and Schmittgen (2001) [29] and represented as fold changes and relative expression to 
the control. Samples were run in triplicate and the experiments were repeated twice. 
 
3.2.7 Cytokine profiling 
Cytokine profiling was performed using the Bio-Plex Pro Human Th17 Cytokine Panel (IL-1β, IL-4, IL-6, 
IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, sCD40L, TNF-α) (catalogue 
number 171AA001M, Bio-Rad, USA) according to the manufacturer’s instructions. Briefly, standards and 
samples (PEF; 1:6 and supernatant; 1:3), were diluted in standard and sample diluent HB respectively. The 
beads (50μl) were added to the assay plate and washed twice (100μl wash buffer, Bio-Plex Pro™ Wash 
Station). Standards, samples and controls were added and incubated (50μl, 1h in the dark, RT, 350rpm). The 
plate was washed three times and incubated with detection antibody (25μl, 30min in the dark, RT, 350rpm). 
The plate was washed three times and incubated with streptavidin-PE (50μl, 10min in the dark, RT, 350rpm). 
The plate was washed three times and the beads re-suspended in assay buffer (125μl, 30s, in the dark, RT, 
350rpm). Data acquisition was performed on a Bio-Plex 200 and analysis was performed using Bio-Plex 
Manager™ software v6.0. Standards and samples were run in duplicate. Results were analysed using a 5-
paramter logistic regression constructed from recombinant protein standards. The results were normalised to 
the treatment and then compared between groups.  
 
3.2.8 Statistical analysis 
Statistical analysis was performed using GraphPad Prism software (v5.0). The unpaired t-test with Welch 
correction was used in in vitro analyses and the non-parametric Mann-Whitney test in ex vivo analyses to 
avoid the influence of potential outlier values in the small study size. Outlier values were calculated and 
excluded using the interquartile range. Data is expressed as mean ± standard error of the mean (SEM), p 







3.3.1 Reduced proportion of Th17 lymphocytes in TB+HIV+ pleurisy  
To investigate the propensity of TB/HIV co-infected pleural effusion microenvironment to promote Th17 
generation we treated healthy CD4+ Tconvs with PEF conditioned CCM. Interestingly, we observed that the 
proportion of CD4+IL-17+RORC+STAT3+cells was significantly 1.168 fold lower in CD4+ Tconvs treated 
with TB+HIV+ PEF compared to TB-HIV- PEF in vitro (64.400 ± 1.256% vs. 55.156 ± 1.299%, p=0.0001). 
This trend was corroborated when Th17 proportion was directly investigated in patients. PEMC samples 
from TB+HIV+ patients showed a significant 1.769 fold lower number of CD4+IL-17+RORC+STAT3+cells 
compared to TB-HIV- controls (64.100 ± 5.045% vs. 36.233 ± 6.968% p=0.0054), this was associated with a 
significant 1.575 fold decrease in IL-17A protein expression (1454.000 ± 117.167 vs. 923.445 ± 64.418 






























Figure 3.1: T-helper 17 lymphocyte frequency and interleukin-17A protein expression. (A1) Relative fold 
change in the proportion of CD4+IL-17+RORC+STAT3+ T-helper (Th) 17 lymphocytes in pleural effusion 
fluid (PEF) treated CD4+ conventional T-cells in vitro (n=9 replicates in each group, p=0.0001, unpaired t-
test with Welch correction). (A2) Reduced percentage of CD4+IL-17+RORC+STAT3+ Th17 lymphocytes in 
pleural effusion mononuclear cells (PEMCs) ex vivo (TB-HIV-n=5, TB+HIV+ n=5, p=0.0054, Mann Whitney 
test). (B) Interleukin (IL)-17A protein expression was reduced in TB+HIV+ PEMCs represented by peridin-
chlorophyll-cyanin5.5 (PerCP-Cy5.5) mean fluorescence intensity (MFI) (TB-HIV- n=5, TB+HIV+ n=5, 
p=0.0040, Mann Whitney test). (C) Histogram showing the shift in IL-7A-PerCP-Cy5.5 fluorescence in 




3.3.2 TB+HIV+ mediated in mRNA levels 
We then assessed the molecular response of PEMCs with respect to Th17 polarisation. PEMCs from 
TB+HIV+ patients showed a significant upregulation in the transcript expression of molecules which promote 
Th17 differentiation; a notable 30.647 fold increase in STAT3 (17.037 ± 0.089 vs 12.140 ± 0.103 relative 
expression (∆Ct), p=0.0022), 11.662 fold increase in IL-1β (14.638 ± 0.043 vs. 11.102 ± 0.035 relative 
expression (∆Ct), p=0.0022), 3.076 fold increase in IL-6 (19.727 ± 0.143 vs. 18.380 ± 0.284 relative 
expression (∆Ct), p=0.0022) and a 1.657 fold increase in IL-6R (18.752 ± 0.099 vs. 18.092 ± 0.230 relative 




Figure 3.2: Relative messenger RNA expression represented as relative cycle threshold (∆Ct) in pooled 
pleural effusion mononuclear cells (PEMCs) (n=6 replicates in each group, Mann-Whiney test). Signal 
transducer and activator of transcription 3 (STAT3) (p=0.0022), interleukin (IL)-1β (p=0.0022), IL-6 
(p=0.0022) and IL-6 receptor (IL-6R) (p=0.0247). Data represents the mean. 
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3.3.3 The TB+HIV+ cytokine microenvironment 
Since we found increased expression of mRNA transcripts related to Th17 polarisation in TB+HIV+ PEMCs, 
we questioned whether in fact these were translated into secreted cytokine using a Bioplex multi-analyte 
cytokine screen.   
 
Despite the reduced frequency of Th17 cells in TB+HIV+ PEF treatments and pleurisy, there was no 
significant change in the Th17 effector cytokines IL-17A and IL-17F concentrations in both the in vitro and 
ex vivo assays (Figure 3.3 and 3.4). Interestingly, in the TB+HIV+ and TB-HIV- patient cohorts, IL-17F was 
elevated by 6.460 fold (18.281 ± 2.383pg/ml vs. 118.090 ± 8.077pg/ml, p<0.0001) and 7.844 fold (11.938 ± 
2.449pg/ml vs. 93.637 ± 15.357pg/ml, p=0.0009) compared to IL-17A respectively (Figure 3.4). 
 
With respect to Th17 generating cytokines, there were no significant alteration between the TB+HIV+ and 
TB-HIV- PEF treatments in vitro indicating that the reduced proportion of Th17 lymphocytes observed in 
CD4+ Tconvs treated with TB+HIV+ PEF was not a result of the cytokine milieu  (Figure 3.3). In the patient 
samples, we observed a 3.708 fold increase in IL-1β (4.918 ± 1.421pg/ml vs. 18.238 ± 3.064pg/ml, 
p=0.0008) but without a significant change in the levels of IL-6, IL-21 or IL-23. This substantiates the in 
vitro result and infers that a reduced proportion of Th17 lymphocytes found in TB+HIV+ pleurisy is 
independent of the cytokine microenvironment ex vivo (Figure 3.4).  
 
Th1 cytokines have established roles in TB and HIV pathogenesis, accordingly a 3.626 fold increase in TNF-
α (18.233 ± 2.615pg/ml vs. 66.112 ± 13.264pg/ml, p=0.0251) and a 13.559 fold increase in IFN-γ (87.792 ± 
27.282pg/ml vs. 1190.386 ± 361.906pg/ml, p=0.0026) concentration was found in TB+HIV+ PEF (Figure 
3.4). 
 
Notably, a 2.643 fold increase in IL-22 (26.379 ± 8.903pg/ml vs. 69.729 ± 10.318pg/ml, p=0.0115) and a 
3.055 fold increase in IL-31 (158.430 ± 35.615pg/ml vs. 483.957 ± 115.651pg/ml, p=0.0210) was observed 











Figure 3.3: Cytokine profiling of supernatants from CD4+ T-cells treated with pleural effusion fluid conditioned media. Results were normalised to the treating 
pleural effusion fluid (PEF) (n=2 replicates in each group, Unpaired t-test with Welch correction). IL; interleukin, IFN; interferon, sCD40L; soluble CD40 ligand, 
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Figure 3.4: Cytokine profiling of pleural effusion fluid. TB+HIV+ pleural effusion fluid (PEF) showed increased concentrations of interleukin (IL)-1β (p=0.0008), 
IL-22 (p=0.0115), IL-31 (p=0.0210), interferon (IFN)-γ (p=0.0026) and tumor necrosis factor (TNF)-α (p=0.0251). (IL-1β, IL-4, IL-6, IL-10, IFN-γ, TNF-α; TB-
HIV- n=8, TB+HIV+ n=12. IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, sCD40L; TB-HIV- n=5, TB+HIV+ n=5, Mann-Whitney test). Data represents 






































The Th17/IL17 axis is suggested to provide protective immunity against MTB by contributing to 
development and organisation of the granuloma [30-33]. Early expression of pulmonary IL-17 is pivotal in 
granulomatous cellular recruitment by inducing chemokine secretion from non-haematopoietic cells. This 
predominantly results in neutrophil and CCR5+ lymphocyte recruitment, through the induction of IL-8 and 
chemokine C-X-C motif ligand (CXCL) 13 respectively, to form lung lymphoid follicles for optimal 
macrophage activation and bacterial clearance [34-37]. However, during the chronic stages of infection, 
Th17 hyperactivity can lead to immunopathology via IL-17-CXCL mediated influx of immune cells [30, 38-
40], breakdown of the granuloma, cavitation and transmission [31, 41]. Th17 immunity has also been shown 
to contribute to mucosal TB vaccine immunity by IL-17A induction of CXCL13 [34]. However, there is no 
consensus on the proportion of Th17 cells in TB infection and the significance of this contribution to disease 
pathogenesis.  
 
This is further confounded by HIV co-infection. Th17 cells show greater HIV susceptibility than other T-cell 
subsets [42-44]. Th17 lymphocyte  targeting has been correlated with a higher expression of HIV envelope 
receptors CD4, CXCR4, CCR5 and α4β7 and low levels of autocrine production of CCR5 ligands CCL3 and 
CCL4, resulting in higher gp120 binding [43]. This is associated with a significant impairment in the 
generation of Th17 cells from peripheral naïve CD4+ T-cells [22]. In addition, the over expression of 
negative regulators in Th17 differentiation (phosphatase SHP2, suppressor of cytokine signalling (SOCS) 3 
and protein inhibitor of activated STAT (PIAS) 3) have been to linked to Th17 deficiency in a simian 
immunodeficiency virus model [45]. Notably, HIV-1 infected long-term non-progressors [19] and elite 
controllers [46] preserve the Th17 subset in peripheral blood and mucosa. 
 
In our study, a significantly lower proportion of CD4+IL-17+RORC+STAT3+ lymphocytes was found in 
TB+HIV+ pleurisy compared to TB-HIV- pleurisy both in vitro and ex vivo. Classically, Th17 cells 
differentiate under TGF-β/IL-21 [47] or TGF-β/IL-6 and IL-21/IL-23 [48] conditions. This leads to Th17 
lineage commitment via the activation of STAT3 and downstream transcription factor RORC, as well as 
interferon regulating factor 4 (IRF4), which in turn bind to the promoter region of IL17A/F [49-52]. Further 
to this IL-1β and IL-6 are significant in the expansion of differentiated and memory Th17 cells and IL-23 for 
the stabilisation and maintenance of the Th17 phenotype and effector functions [53]. Despite the reduction in 
Th17 frequency, there was no significant difference in the concentrations of IL-6, IL-21, and IL-23 between 
the two groups both in vitro and ex vivo indicating that the reduced proportion of Th17 cells is not a result of 
decreased polarising cytokines. In support of this, previous studies have shown that HIV infection is 
characterised by high levels of TGF-β [54], IL-6 [55] and IL-1 suggesting that failure to generate Th17 cells 
is not due to a lack of promoting cytokines [24]  
 
Notably, TB+HIV+ pleurisy was associated with a significant 3.708 fold increase in IL-1β pleural fluid 
concentration and a 11.662 fold increase in IL-1β mRNA levels in PEMCs. Th17 cells express higher IL-1 
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receptor levels than other CD4 subsets [56, 57], in turn IL-1β upregulates the expression of transcription 
factors IRF4 and RORC and acts synergistically with IL-6, IL-23 and TGF-β to stimulate Th17 
differentiation and maintain IL-17A, IL-17F, IL-21 and IL-22 cytokine production in effector cells [51, 56-
60]. Very recently, a clinical isolate of the hypervirulent W-Beijing strain of MTB has been shown to induce 
a potent IL-17 protective response in a murine model through the induction of dendritic cell IL-1β and the 
subsequent formation of lung lymphoid follicles [34]. Furthermore, it was shown that blocking of IL-1/IL-
1R signalling led to almost complete inhibition of IL-17A production during MTB stimulation in PBMCs 
[61]. Our results indicate that Th17 lymphocytes in TB/HIV pleurisy may be defective in their ability to 
respond to IL-1β 
 
In the current study we found a 1.657 and 3.076 fold increase in IL-6R and IL-6 mRNA levels in co-
infection, respectively but no increase in IL-6 cytokine levels in pleural fluid. This was interesting as 
recently the upregulation of IL-6 has been identified as a potential biomarker of mycobacterial infection in 
vitro [62]. During active TB infection IL-6 levels are increased in plasma [63, 64] and broncho-alveolar 
lavage (BAL) fluid [64, 65] with positive correlation to disease severity [63]. Furthermore, IL-6 is noted to 
be elevated in all phases of HIV chronic infection [66] and a clinical trial has shown that increased IL-6 
levels are associated with increased all-cause mortality in HIV [67]. Our findings suggest that post 
transcriptional regulation of key Th17 polarising cytokines may influence the cytokine microenvironment. 
 
Despite a significant decrease in the frequency of Th17 cells in TB+HIV+ pleurisy, there was no significant 
difference in the concentration of effector cytokines IL-17A and IL-17F between the two groups in vitro and 
ex vivo. In line with our findings, it has been observed that IL-17 mRNA levels in BAL cells of active TB 
patients and healthy controls do not differ significantly [68]. This may be a result of IL-17A production by 
CD8+ T-cells [69], γöT-cells [70], natural killer cells [71], neutrophils [72] innate lymphoid cells [73] and 
mast cells [74]. The contribution of these different cell types to IL-17 associated diseases is still unknown 
[37]. γöT-cells, enriched at mucosal surfaces, such as the lung, have been indicated as a major source of 
early IL-17A production in response to MTB [75, 76] and found to be at significantly higher frequency in 
the peripheral blood of active TB patients compared to healthy donors [76]. γöT-cells can respond to IL-23 
and IL-1β amplifying Th17 responses [75, 77] and therefore it is possible that the IL-17 observed in 
TB+HIV+ pleurisy may be a result of a IL-1β - γöT-cell pathway. 
 
Notably, IL-17F was present at a significantly higher concentration than IL-17A in both TB+HIV+ and TB-
HIV- groups, 6.460 and 7.844 fold respectively. IL-17F alone is generally less inflammatory than IL-17A; 
however, its effects are augmented when combined with TNF-α [78], also significantly increased in 
TB+HIV+ PEF. In support of our results, a previous study noted a decreased frequency of IL-17A producing 
CD4+ T-cells but increased frequency of IL-17F producing CD4+ T-cells in the peripheral blood of HIV 
infected patients [79], implying a HIV mediated selective defect in IL-17A production. 
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TNF-α and IFN-γ have established roles in the pathogenesis of TB [80, 81] and HIV [82-84], their 
significantly increased expression observed in TB+HIV+ pleurisy is not unexpected. IFN-γ is the preeminent 
cytokine in MTB immune defence, its primary function is the activation of macrophages instituting 
mycobacterial killing mechanisms [85-87] which is enhanced by TNF-α [88-90]. HIV-1 Tat protein induces 
production of TNF-α and IFN-γ in human monocytes/macrophages [83], in turn these cytokines 
synergistically stimulate HIV replication in vitro [91]. This suggests that in co-infection TNF-α and IFN-γ 
provide protective immunity against MTB but promote replication of HIV [92], indicating that defence 
against one pathogen allows injury by another. Furthermore, IFN-γ has been shown to limit the size of the 
Th17 population during MTB infection [93]. In our TB+HIV+ cohort we observed significantly a higher 
concentration of IFN-γ over IL-17A (65.116 fold increase, p=0.0006) or IL-17F (10.080 fold increase, 
p=0.0092) possibly contributing to the reduction in Th17 lymphocytes in co-infection.  
 
Our investigations showed a 2.643 fold increase in IL-22 levels in TB+HIV+ pleurisy. IL-22 has been 
implicated in pathogenesis of TB [11, 94, 95] and HIV [96-98]. However, it remains to be determined if IL-
22 is involved in protective or pathogenic immunity in co-infection or the reparative process following the 
immuno-pathological consequences of these diseases. IL-22 significantly exceeded the concentration of IL-
17A (3.814 fold, p<0.0001) but not IL-17F in TB+HIV+ pleurisy. This is in line with previous work where 
IL-22 was found to surpass IL-17A in TB+ pleural fluid [95]. The raised level of IL-22 in the face of 
decreased frequency in Th17 cells could represent contribution by other cell types. In this regard, during 
experimental MTB infection, IL-22 was found to be predominantly produced by Th1 and Th22 cells rather 
than Th17 cells [99]. IFN-γ suppresses PBMC IL-17A production and Th17 activity [1, 11, 99-102] but not 
IL-22 production [11, 99] allowing for effective IL-22 production in the absence of Th17 cells, in line with 
our results. 
 
The 3.055 fold increase in IL-31 concentration in TB+HIV+ pleurisy is novel. IL-31 is generally associated 
with Th2 mediated skin inflammation or allergic responses in the airways and GIT and has not been 
characterised in TB/HIV co-infection or mono-infection. IL-31 mRNA is upregulated in the lungs after 
antigen challenge [103], the targets of which are primarily bronchial epithelial cells, pulmonary fibroblasts 
and macrophages [104] where it upregulates pro-inflammatory cytokine and chemokine gene expression 
involved in cellular recruitment [103, 105-107], in the context of TB this may contribute to granuloma 
organisation. IL-31 can also directly inhibit IL-17A/F mRNA synthesis in Th17 cells through the regulation 
of PIAS molecules [108] possibly augmenting the observed decrease in Th17 frequency.  
 
In HIV infection, the depletion of Th17 cells at the mucosal surface is associated with increased 
translocation of microbial into the systemic circulation rendering a patient more prone to opportunistic 
infections and suggested to be a predominant cause of chronic immune activation and HIV progression [24, 
109-112]. At the respiratory mucosa, a loss of Th17 cells decreases mucosal defence to inhaled MTB and 
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together with reduced IL-17-mediated cellular recruitment and granuloma organisation may result in the 
progression of active TB infection. 
 
3.5 Concluding remarks 
A reduced proportion of Th17 cells were observed in TB+HIV+ pleurisy independent of alteration in the 
levels of Th17 polarising cytokines and IL-17A/F effector cytokines in the localised microenvironment. 
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Monocytes produce cytokines that direct T-cell polarisation. Tuberculosis (TB) and human 
immunodeficiency virus (HIV) infection alter monocyte function and the pathogenesis of both of these 
diseases is largely orchestrated by sub-optimal T-cell responses.  
 
Objectives: We constructed an in vitro supernatant transfer model to investigate the effect of TB/HIV pleural 
exudate on monocyte (THP-1) cytokine production and subsequent cytokine expression and polarisation of 
CD4+ conventional T-cells (Tconvs) into T-helper (Th) 17 and T-regulatory (Treg) lymphocyte subsets, 
compared to a non-infectious pleural effusion. 
 
Design: HIV-related TB most commonly presents as TB pleurisy and monocyte dysfunction is induced by 
secreted factors from MTB, HIV or infected cells. The effect of TB/HIV co-infection on monocyte behavior 
is largely uncharacterised therefore a unicellular model needs to firstly be investigated to elucidate more 
complex findings in multicellular systems. 
 
Methods: Th17 and Treg frequency was assessed by flow cytometry, monocyte and CD4+ T-cell cytokine 
production was measured with ELISA and Bio-Plex platforms respectively.  
 
Results: TB+HIV+ pleurisy altered monocyte cytokine production resulting in increased production of 
interleukin (IL)-1β (p=0.0217), a Th17 generating cytokine. Following supernatant transfer, the TB+HIV+ 
treated monocyte milieu caused significant polarisation of CD4+ Tconvs into Th17 cells and Tregs 
(p<0.0001). However, a significantly greater proportion of Th17 lymphocytes (p=0.0001) was observed, 
associated with elevated intracellular IL-17A protein expression (p<0.0001) and 2.278 and 8.191 fold 
increases in the production of Th17 characteristic cytokines, IL-17A and IL-21 respectively.  
 
Conclusion: The TB/HIV microenvironment modifies monocyte mediated T-cell polarisation towards a pro-
inflammatory Th17 phenotype, possibly due to increased IL-1β production.  
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Monocytes are innate effectors mediating the inflammatory response to pathogens as a source of macrophage 
and dendritic cell precursors, as well as antigen presentation, phagocytosis, and the production of 
antimicrobial substances [1, 2]. In addition, monocytes produce cytokines mediating T-cell polarisation at 
the site of inflammation [2-4].  
 
Tuberculosis, is the second leading killer from a single infectious agent, Mycobacterium tuberculosis (MTB), 
globally, the first being the HIV [5]. Following inhalation of MTB, infected macrophages produce 
chemokines recruiting monocytes to the infection site [6]. These monocytes show increased peripheral and 
localised activation and frequency [7-9], killing MTB by Toll-like receptor (TLR) [10] and inducible nitric 
oxide synthase (iNOS) [11] mediated mechanisms. However, during MTB infection studies have observed 
differentiation of phenotypically and functionally immature monocyte derived macrophages [8], attenuated 
IFN-γ mediated antimycobacterial mechanisms [12], aberrant cytokine production [7, 8, 12] and increased 
monocyte apoptosis and necrosis [13, 14] which has been associated with tissue destruction and cavitation 
[9]. This indicates that MTB causes significant monocyte dysfunction contributing to disease pathogenesis. 
This is further complicated by HIV co-infection. 
 
In South Africa 62% of TB patients are HIV co-infected. HIV increases the risk of active TB by 26-31 times 
with TB being the leading cause of HIV-related mortality [5]. Monocytes are less permissive to HIV-
infection than other cell types. However, monocytes from HIV infected patients show impaired maturation 
and response to TLR ligands [15], alterations in gene expression related to TLR signalling and cytokine 
responses, cytokine-cytokine receptor interaction, activation, apoptosis and proteasome function [16-18], 
associated with disease pathogenesis [16].  
 
The pathogenesis of TB and HIV is primarily mediated by dysregulated CD4+ T-cell responses. During 
pathogen defence, monocytes mediate T-cell polarisation. Both TB and HIV cause monocyte dysfunction, 
but the effect of co-infection on monocyte mediated CD4+ T-cell polarisation has not been explored.  
 
The majority of HIV-related TB is extrapulmonary [19, 20], most commonly TB pleurisy [21]. Classically, 
direct MTB/HIV infection is thought to cause monocyte dysfunction; however, more recently secreted 
factors from MTB, HIV or infected cells are considered to have a greater effect [12, 16]. The consequences 
of TB/HIV co-infection on monocyte behavior is largely uncharacterised therefore a unicellular model needs 
to be initially probed to lay the foundation for observations in a multicellular system. We investigated an in 
vitro supernatant transfer model to question whether a TB/HIV pleural exudate altered monocyte (THP-1) 
cytokine production sufficiently to affect subsequent cytokine expression and polarisation of CD4+ Tconvs 








4.2.1 Study population 
This study protocol was approved by the institutional Biomedical Research Ethics Committee (BF170/11). 
Participants were recruited at Inkosi Albert Luthuli Central Hospital and Prince Mshiyeni Memorial Hospital 
(Durban, South Africa). Newly diagnosed TB patients presenting with a TB pleural effusion and concurrent 
HIV-infection (n=5) were enrolled. Active TB was confirmed by clinical diagnosis with bacterial or 
radiographic evidence; AFB culture positive sputum or pleural fluid, microscopy (Gram, Zhiel-Neelsen, 
Auramine), MTB DNA (Gene Xpert), pleural histology and pleural fluid cytology. The matched control 
group presented with a non-infectious pleural effusion (malignancy, cardiac failure, renal disease) and 
confirmed HIV seronegative (n=5) (Table 4.1). Exclusion criteria included anti-tuberculosis or anti-retroviral 
therapy, immunomodulatory treatment and conditions. Blood and pleural fluid were sampled by routine 


























Age, years, median (range) 55 (46-61) 36 (18-64) 
Gender   
Male 5 (100) 2 (40) 
Female 0 3 (60) 
Race   
African 3 (60) 5 (100) 
Indian 2 (40) 0 
TB diagnostic criteria   
Culture positive  4 (80) 
Smear positive  1 (20) 
PCR-MTBDR  5 (100) 
Resistance to any one first line TB drug  1 (20) 
MDR-TB  1 (20) 
XDR-TB  0 
CD4 count, mm3, mean (range)  51 (12-123) 
Past history of TB infection 0 1 (20) 
Current smoker 2 (40) 1 (20) 
Ex-smoker 1 (20) 0 
Alcohol use 1 (20) 2 (40) 
Definitive cause of PE   
Tuberculosis 0 5 (100) 
Malignancy 2 (40) 0 
End stage renal disease 2 (40) 0 
Heart failure 1 (20) 0 
Co-Morbidities   
Diabetes mellitus 2 (40) 0 
Hypertension 3 (60) 1 (20) 
Hepatitis B 0 1 (20) 







4.2.2 Pleural effusion fluid isolation  
Cell free pleural effusion fluid (PEF) was extracted from heparinised pleural effusion samples by differential 
gradient centrifugation within 2 hours (h) of pleural tap. Briefly, 5 ml of sample was layered onto 
equivolume Histopaque-1077 (catalogue number (CN) 10771-500, Sigma, USA) and centrifuged (1,491rpm, 
30 minutes (min), room temperature (RT)). PEF was aspirated and centrifuged (10,000rpm, 10min, 4°C) to 
remove any cellular constituents. Harvested PEF was pooled from 5 patients in each group equally and 
stored at -80°C. 
 
4.2.3 THP-1 cell culture and treatment 
Human acute monocytic leukaemic (THP-1) cells were obtained from ATCC. Cells were maintained in 
complete culture medium (CCM; RMPI 1640, 10% foetal calf serum (FCS), 1% L-glutamine, 1% Penstrep-
Fungizone, 0.05mM 2-mercaptoethanol, 1mM sodium pyruvate) at 37°C, 5% CO2. Prior to treatment, 7×10
6 
cells were stimulated with 10μg/ml lipopolysaccharide in CCM (4h, 37°C, 5% CO2). Stimulated THP-1 cells 
were harvested, washed (0.1M phosphate buffered saline (PBS), 1,000rpm, 10min, RT) and seeded in 
triplicate (3×105 cells/ml) in PEF conditioned CCM in a 1:1 ratio for 24h (37°C, 5% CO2). Treatments 
included TB-HIV- and TB+HIV+ PEF. Supernatants were harvested by centrifugation (1,000rpm, 10min, RT) 
and stored at -80°C for cytokine profiling and downstream supernatant transfer.   
 
4.2.4 ELISA 
Quantitation of IL-1β, IL-6, IL-10, IL-12p70, TNF-α and IFN-γ in TB+HIV+ PEF, TB-HIV-PEF and PEF 
treated THP-1 supernatants was measured by enzyme-linked immunosorbent assay (ELISA) using OptEIA™ 
Sets (CN IL-1β 557953, IL-6 555220, IL-10 555157, IL-12p70 555183, TNF-α 555212, IFN-γ 555142, BD 
Biosciences, Canada). Microwells were coated with capture antibody (100μl/well, 4°C, overnight). The 
plates were washed three times (wash buffer; 300μl/well) and blocked with assay diluent (10% FCS in 0.1M 
PBS, 200μl/well, 1h, RT, 350rpm). The plates were washed 3 times; standards and samples (100μl) added 
and incubated (2h, RT, 350rpm). The plates were washed five times. IL-1β: detection antibody was added 
(100μl/well, 1h, RT, 350rpm), the plate washed five times and streptavidin-horseradish peroxidase (HRP) 
added (100μl/well, 30min, RT, 350rpm). IL-6, IL-10, IL-12p70, TNF-α, IFN-γ: working detector was added 
(detection antibody and Streptavidin-HRP reagent; 100μl/well, 1h, RT, 350rpm). All plates were washed 7 
times and substrate solution added (100μl/well, 30min, RT). Stop solution (50μl/well) was added and the 
absorbance immediately read at 450nm with a reference of 570nm using a µQuant (Bio-Tek, USA) 
spectrophotometer. Standards and samples were run in triplicate. The results were normalised to the PEF and 






4.2.5 Peripheral blood mononuclear cell isolation 
For use in CD4+ T-cell isolation peripheral blood mononuclear cells (PBMCs) were extracted from whole 
blood (10ml, EDTA, one blood draw) of a healthy BCG vaccinated volunteer by differential gradient 
centrifugation within 2h of venipuncture. Briefly, 5 ml of sample was layered onto equivolume Histopaque-
1077 and centrifuged (1,491rpm, 30min, RT). Buffy coats were aspirated and rinsed (0.1M PBS; 1,491rpm, 
20min, RT). 
 
4.2.6 CD4+ T-cell isolation 
CD4+ T-lymphocytes were purified by negative magnetic selection using the Human CD4 T-Lymphocyte 
Enrichment Set-DM (CN 557939, BD Biosciences, USA). PBMCs were labelled with biotinylated 
monoclonal antibodies (5μl/10×106 cells, 15min, RT) against antigens on erythrocytes, platelets and non-
CD4+ leukocytes. The cells were washed (iMag Buffer, 1,491rpm, 20min) and incubated with streptavidin 
conjugated magnetic nanoparticles (5μl/10×106 cells, 30min, RT). The cell suspension was placed in a 
magnetic field (8min, iMagnet; BD Biosciences, USA) and the enriched CD4+ T-cell supernatant aspirated. 
Negative selection of the positive fraction was performed three times to increase the yield.  
 
4.2.7 CD4+ T-cell culture and treatment 
CD4+ T-cells were seeded in triplicate (8×104cells/well, U-bottomed microplate) in THP-1 supernatant 
conditioned CCM (RPMI 1640, 10% FCS, 1% Penstrep-Fungizone, 1% L-glutamine, final concentrations) in 
a 1:1 ratio (24h, 37°C, 5% CO2).  Treatments included THP-1 supernatant: TB
-HIV- PEF and THP-1 
supernatant: TB+HIV+ PEF. Concurrently, cells were activated with Dynabeads Human T-activator 
CD3/CD28 bead solution (CN 11131D, Gibco, Norway) (2μl/well). Cells were harvested, washed (0.1M 
PBS, 1,491rpm, 20min, RT) and the activation beads removed by magnetic selection (1min, iMagnet). The 
supernatants were stored at -80°C for cytokine profiling and the cells immediately prepared for flow 
cytometric staining. This experiment was repeated three times. 
 
4.2.8 Flow cytometric analysis 
For surface staining, 2.5x105 cells were re-suspended in staining buffer (25μl, 0.1M PBS, 1% FCS, 0.09% 
sodium azide) and labelled with surface antibodies (20min, 4°C); fluorescein isothiocyanate (FitC) anti-CD4 
(1:5, CN 555346), peridin-chlorophyll-cyanin 5.5 (PerCP-Cy5.5) anti-CD25 (1:20, CN 560503). For 
intracellular staining, cells were fixed in 4% paraformaldehyde (500μl, 30min, RT), washed (staining buffer; 
1,491rpm, 20min, RT), permeabilized (75% methanol, 500μl, 10min, -20°C) and washed again. Cells were 
stained with intracellular antibodies (60min, RT); phycoerythrin (PE) anti-Foxp3 (1:5, CN 560046), PerCP-




Accuri C6 flow cytometer (BD Biosciences, USA) and data analysed using FlowJo vX (10.0.7r2). Samples 
were run in triplicate and 30,000 events acquired. Antibodies were purchased from BD Biosciences, USA, 
with the exception of anti-RORC2 which was purchased from R&D Systems, USA. 
 
4.2.9 Cytokine profiling 
Cytokines were measured using the Bio-Plex Pro Human Th17 Cytokine Panel (IL-1β, IL-4, IL-6, IL-10, IL-
17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, sCD40L, TNF-α) (CN 171AA001M, Bio-Rad, 
USA). Standards and samples (THP-1 supernatants and CD4 T-cell supernatants, 1:3) were diluted in 
standard and sample diluent HB respectively. The beads (50μl) were added to the assay plate and washed 
twice (100μl wash buffer, Bio-Plex Pro™ Wash Station). Standards, samples and controls were added (50μl, 
1h, RT, 350rpm). The plate was washed three times and incubated with detection antibody (25μl, 30min, RT, 
350rpm). The plate was washed three times and incubated with streptavidin-PE (50μl, 10min, RT, 350rpm). 
The plate was washed three times and the beads re-suspended in assay buffer (125μl, 30 seconds, RT, 
350rpm). Data acquisition was performed on a Bio-Plex 200 (Bio-Rad, USA) and analysed using Bio-Plex 
Manager™ software v6.0. Samples, standards and controls were run in triplicate. Results were analysed 
using a 5-paramter logistic regression constructed from recombinant protein standards. The results were 
normalised to the treatment and then compared between groups. 
 
4.2.10 Statistical analysis 
The unpaired t-test with Welch correction was performed using GraphPad Prism software (v5.0). Outlier 
values were calculated using the interquartile range. Data is expressed as mean ± standard error of the mean 















4.3.1 TB/HIV pleurisy increases monocyte production of IL-1β  
We first investigated whether TB-HIV- and TB+HIV+ pleural exudates differentially affected monocyte 
cytokine production by measuring IL-1β, IL-6, IL-10, IL-12p70, TNF-α and IFN-γ levels in supernatants of 
THP-1 cells cultured in PEF conditioned media. A significantly 219.737 fold increase in THP-1 production 
of IL-1β, a Th17 generating cytokine was observed (0.076 ± 0.201pg/ml vs. 16.700 ± 2.335pg/ml, p=0.0217) 
following TB+HIV+ PEF treatment (Figure 4.1). 
 
Interestingly, both monocyte activating cytokines IL-6 (-0.769 ± 1.731pg/ml vs. -20.577 ± 1.855pg/ml, 
p=0.0160) and TNF-α (2.500 ± 0.120pg/ml vs -2.847 ± 0.139pg/ml, p=0.0002), were reduced to a 
significantly greater extent in the supernatants of THP-1 cells cultured in TB+HIV+ media compared to TB-





















Figure 4.1: Normalised cytokine concentrations (pg/ml) of supernatants of THP-1 monocytes cultured in TB-HIV- and TB+HIV+ PEF conditioned media. The 
TB+HIV+ pleural exudate resulted in significantly increased monocyte production of interleukin (IL)-1β (p=0.0217) but significantly decreased IL-6 (p=0.0160) and 



































4.3.2 TB/HIV co-infection increases monocyte mediated Th17 polarisation 
We then assessed whether differentially conditioned monocytes and their resulting cytokine milieu were 
sufficient to effect downstream polarisation of CD4+ Tconvs into Treg and Th17 subsets. Supernatants of 
THP-1 cells cultured in TB+HIV+ PEF caused a 1.671 fold increase in the frequency of CD4+CD25+Foxp3+ 
Tregs (33.329 ± 2.470% vs. 55.700 ± 2.249%, p<0.0001), this was associated with a 1.429 fold increase in 
the lineage specific transcription factor, forkhead box P3 (Foxp3) protein expression (1759.000 ± 135.100 
vs. 2514.333 ± 67.804 PE mean fluorescence intensity (MFI), p=0.0004) (Figure 4.2).  
 
More notably, TB+HIV+ THP-1 supernatants resulted in a 2.174 fold increase in the proportion of CD4+IL-
17A+RORC+ Th17 lymphocytes (32.211 ± 1.036% vs. 70.022 ± 1.235%, p<0.0001) with a corresponding 
1.287 fold increase in Th17 characteristic cytokine, IL-17A intracellular protein expression (1387.444 ± 
19.194 vs 1785.111 ± 23.668 PerCP-Cy5.5 MFI, p<0.0001) (Figure 4.3).  
 
Furthermore, while TB-HIV- THP-1 supernatant conditions resulted in similar proportions of Tregs and Th17 
cells (33.329 ± 2.470% vs. 32.211 ± 1.036%, p=0.6875), the TB+HIV+ monocyte milieu resulted in a 
significant 14.322% (1.257 fold) greater proportion of Th17 lymphocytes than Tregs (55.700 ± 2.249% vs. 
70.022 ± 1.235%, p=0.0001). This strongly indicates that TB+HIV+ PEF treatment resulted in a monocyte 
cytokine milieu that predominantly promotes Th17 differentiation, and further suggests that co-infection is 

















Figure 4.2: Change in T-regulatory lymphocyte frequency and forkhead box P3 protein expression. Supernatants of THP-1 cells treated with TB+HIV+ conditioned 
media resulted in a significantly elevated (A) proportion of CD4+CD25+Foxp3+ T-regulatory lymphocytes (p<0.0001) and (B) Forkhead box P3 (Foxp3)-
phycoerythrin (PE) mean florescence intensity (MFI) (p=0.0004) (TB-HIV-n=9, TB+HIV+ n=9, Unpaired t-test with Welch correction). Data represents the mean. 









Figure 4.3: Change in T-helper 17 lymphocyte frequency and interleukin-17A protein expression. Supernatants of THP-1 cells treated with TB+HIV+ conditioned 
media resulted in a significantly elevated (A) proportion of CD4+IL-17A+RORC+ T-helper (Th) 17 lymphocytes (p<0.0001) and (B) interleukin (IL)-17A-peridin-
chlorophyll-cyanin 5.5 (PerCP-Cy5.5) mean fluorescence intensity (MFI) (p<0.0001) (TB-HIV- n=9, TB+HIV+ n=9, Unpaired t-test with Welch correction). Data 







Figure 4.4: Comparison of T-regulatory and T-helper 17 lymphocyte proportion in CD4+ conventional T-
cells treated with supernatants of THP-1 monocytes cultured in PEF conditioned media. TB+HIV+ pleurisy 
resulted in a significantly increased proportion of T-helper (Th) 17 cells in comparison to T-regulatory 
(Treg) lymphocytes (p=0.0001) (TB-HIV- n=9, TB+HIV+ n=9, Unpaired t-test with Welch correction). 
 
4.3.3 Increased CD4+ T-cell production of IL-17A and IL-21 
Next we questioned if there was a differential cytokine microenvironment associated with CD4+ T-cell 
polarisation by performing a Bio-Plex cytokine screen of the extracellular milieu of CD4+ Tconvs treated 
with supernatants of THP-1 monocytes cultured in PEF conditioned media.  
 
TB+HIV+ supernatant transfer resulted in increased CD4+ Tconv production of Th17 characteristic cytokines 
IL-17A (2.278 fold; 6.340 ± 0.855pg/ml vs. 14.440 ± 1.738pg/ml, p=0.0527) and IL-21 (8.191 fold; 3.850 ± 
0.012pg/ml vs. 31.535 ± 12.710pg/ml, p=0.0527) compared to TB-HIV- conditions. Although not significant 
these were the only two cytokines produced by CD4+ Tconvs (Figure 4.5). 
 
Notably, CD4+ Tconvs treated with supernatants of monocytes cultured in TB+HIV+ conditioned media were 
associated with a significantly greater 148.360 fold decrease in the concentration of IL-1β compared to TB-
HIV- pleural exudate (-0.805 ± 0.078pg/ml vs. -119.430 ± 5.646pg/ml, p=0.0023). Furthermore, IFN-γ, a 
cytokine produced by and acting on effector CD4+ T-cells in TB and HIV infection, showed a significantly 
larger 6.133 fold decrease in levels following TB+HIV+ treatment compared to TB-HIV- conditions (-82.290 
± 19.312  vs. -504.700 ± 21.171, p=0.0007) (Figure 4.5).     
  
The extracellular milieu of CD4+ Tconvs following TB+HIV+ supernatant transfer also showed significantly 




IL-22 (-6.515 ± 0.707pg/ml vs. -35.405 ± 1.671pg/ml, p=0.0039), IL-25 (-1.120 ± 0.554pg/ml vs. -4.105 ± 
0.488pg/ml, p=0.0272) and IL-31 (-32.555 ± 5.395pg/ml vs. -109.120 ± 1.882pg/ml, p=0.0055) compared to 





















Figure 4.5: Normalised cytokine concentrations (pg/ml) of CD4+ conventional T-cell supernatants treated with supernatants of monocytes cultured in PEF 
conditioned media. The TB+HIV+ conditions resulted in significantly reduced concentrations of interleukin (IL)-1β (p=0.0023), IL-4, (p=0.0332), IL-22 (p=0.0039), 
IL-25 (p=0.0272), IL-31 (p=0.0055) and interferon (IFN)-γ (p=0.0007) (TB-HIV-n=3, TB+HIV+ n=3, Unpaired t-test with Welch correction). sCD40L; soluble CD40 












































Through differential cytokine production, monocytes play an essential role in directing T-cell responses by 
influencing their polarisation and expansion [22]. Previous studies have shown conflicting alterations in 
monocyte cytokine production during MTB (TNF-α, IL-1β, IL-6, IL-10, IL-12p40 and IL-12p70 [8, 12, 13]), 
and HIV (IL-1β, IL-6, IL8, IL-10 and TNF-α [18, 23]) infection suggesting a modification in the nature of 
the CD4+ T-cell response induced and maintained by monocytes. This has not been assessed in co-infection.  
 
In this study a TB+HIV+ microenvironment resulted in a 219.737 fold greater increase in monocyte IL-1β 
production compared to a non-infectious pleural exudate, this is in line with previous research in both MTB 
[12, 24] and HIV infection [25]. In contrast, a significantly lower level of monocyte stimulating cytokines 
IL-6 and TNF-α was observed in the extracellular milieu, possibly representing cytokine levels following 
THP-1 receptor ligation.  
 
IL-1β/IL-1 receptor (R) signalling has been highlighted as critically required for the early differentiation of 
Th17 cells at the site of inflammation and production of IL-17A during MTB infection [26-30]. Th17 cells 
are a pro-inflammatory subset of CD4+ effector T-cells [31] that contribute to pathogen clearance by the 
production of pro-inflammatory IL-17A/F, IL-21 and IL-22 [32]. During homeostasis, Th17 cells play a 
pivotal role in mucosal immunity against intra-[33, 34] and extracellular [35, 36] bacterial and fungal 
infections and have been implicated in the pathogenesis of TB and HIV. 
 
Th17 cells express higher IL-1R levels than other CD4 subsets [37, 38]. IL-1β ligation upregulates the 
expression of transcription factor interferon regulatory factor 4 (IRF4) and in turn, RAR-related orphan 
receptor C (RORC) which bind to the promoter region of IL17A/F stimulating Th17 differentiation and 
maintaining IL-17A, IL-17F, IL-21 and IL-22 cytokine production [37-42]. IL-21, in combination with TGF-
β promotes Th17 lineage commitment via the activation of STAT3 and RORC [43]. The autocrine 
production of IL-21 by Th17 cells creates a feed forward cycle of Th17 polarisation [44].  
 
CD4+ Tconvs treated with supernatants of monocytes cultured in TB+HIV+ conditioned media were 
associated with a 2.174 and 1.287 fold increase in Th17 lymphocyte proportions and intracellular IL-17A 
protein expression respectively. Furthermore, following TB+HIV+ supernatant transfer, CD4+ Tconvs 
produced 2.278 and 8.191 fold greater amounts of IL-17A and IL-21 respectively with significantly less IL-
1β in the extracellular milieu, likely representing the use of IL-1β in monocyte IL-1R binding. 
 
This suggest that under TB+HIV+ conditions increased monocyte production of IL-1β drives Th17 
polarisation resulting in the predominant Th17 phenotype. In support of this, CD14+ monocytes have been 
observed to spontaneously and specifically promote Th17 responses in blood derived CD4+ T-cells in an IL-
1β dependent manner [3]. Moreover, a clinical isolate of the hypervirulent W-Beijing strain of MTB has 




Tregs, specified by the transcription factor Foxp3, are a suppressive subset of CD4+CD25+ T-cells which 
regulate effector lymphocyte function through contact dependent and independent mechanisms [46]. The 
cytokine milieu of TB+HIV+ PEF treated monocytes also resulted in a 1.671 fold increase in Tregs with a 
corresponding 1.429 fold increase in Foxp3 protein expression compared to TB-HIV- conditions. This; 
however, was not associated with an increased production of Treg cytokine IL-10 implying that Tregs do not 
contribute significantly to the inflammatory microenvironment in TB/HIV pleurisy. Moreover, CD4+ Tconvs 
treated with supernatants of monocytes cultured in TB+HIV+ conditioned media showed a significant 
14.322% greater proportion of Th17 cells compared to Tregs indicting a skewing towards a Th17 
polarisation and a predominant pro-inflammatory environment during TB/HIV pleurisy. 
 
There is a reciprocal relationship between Th17 and Treg developmental pathways exhibiting antagonism as 
well as plasticity [47-49]. Th17 cells and Tregs arise from common precursors and carry out opposing 
functions driven by the cytokine milieu and its effect on specific transcription factors. Foxp3 inhibits Th17 
differentiation by antagonising the effects of RORC, inhibiting IL-17A promoter activation. IL-1β inhibits 
TGF-β induced Foxp3 expression enhancing Th17 differentiation under Th17 polarising conditions [55]. 
Taken together, IL-1β actively promotes Th17 differentiation and survival by upregulating lineage specific 
transcription factors while suppressing Foxp3 expression and Treg polarisation. We suggest that IL-1β 
mediated Foxp3 down regulation may be a potential mechanism facilitating a predominant Th17 lymphocyte 
generation in a TB+HIV+ microenvironment. 
 
The balance of Th17 and Tregs at the infection site influences the outcome of the immune response. The 
Th17/IL-17 axis is suggested to provide protective immunity against MTB by contributing to granuloma 
formation and maintenance [50-53]. Early expression of pulmonary IL-17 is pivotal in cellular recruitment 
by inducing chemokine secretion from non-haematopoietic cells. This results in neutrophil and CCR5+ 
lymphocyte recruitment, through the induction of IL-8 and chemokine C-X-C motif ligand (CXCL) 13 
respectively, to form lung lymphoid follicles for optimal macrophage activation and bacterial clearance [45, 
54-56]. However, during the chronic stages of infection, IL-17-CXCL mediated influx of immune cells 
results in extensive tissue destruction and cavitation [50, 51, 57-60]. Th17 responses also contribute to 
mucosal TB vaccine immunity by IL-17A induction of CXCL13 [45]. In co-infection, the TB+HIV+ 
monocyte mediated promotion of a Th17 pro-inflammatory phenotype may aid in granuloma organisation 
providing a niche of MTB survival and at later stages facilitating transmission, as well as accentuating 
hyper-immune activation contributing to viral replication. 
 
We observed a significantly reduced concentration of IFN-γ, IL-22 and Th2 related cytokines; IL-4, IL-25 
and IL-31 in the extracellular milieu of CD4+ Tconvs treated with supernatants of monocytes cultured in 
TB+HIV+ PEF conditioned media. IFN-γ is the preeminent cytokine in MTB immune defence and acts on 
CD4+ T-cells stimulating apoptosis to limit the T-cell immune response [61, 62]. This suggests that a decline 




22 receptor complex and IL-22 has no effect on resting or activated immune cells in vitro or in vivo [63]. 
Together with a short in vivo half-life of IL-22 in animal models (1.3-2 hours) [64] this indicates that a 
reduced concentration of IL-22 is likely due to cytokine breakdown in the extracellular environment. 
Likewise, MTB has been shown to drive Th2 polarisation by altering the balance of polarising cytokines in 
an IL-1β dependent manner [65]; however, the fact that CD4+ Tconvs did not produce Th2 cytokines under 
TB+HIV+ conditions leads us to conclude that the decreased amounts of IL-4, IL-25 and IL-31 in the 
microenvironment is likely the result of cytokine degradation.  
 
4.5 Concluding Remarks 
The microenvironment in TB/HIV pleurisy alters monocyte cytokine production sufficiently to skew CD4+ 
Tconv polarisation towards a pro-inflammatory Th17 phenotype, potentially due to increased monocyte IL-
1β production. In this way TB/HIV co-infection modifies the adaptive immune response from the initial 
interactions with the innate immune system. 
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TB/HIV co-infection is a global pandemic, of which SA is one of the worst affected countries. The 
pathogenesis of the individual diseases is largely driven by pathogenic dysregulation of CD4+ T-cell 
responses, the subset specific alterations of which have not been assessed in co-infection. TB pleurisy is the 
most common form of extrapulmonary HIV-related TB and provides an optimal localised immune model to 
study host responses to co-infection, which is often neglected. 
 
This study characterised the nature of the Th17 and Treg lymphocyte responses in TB/HIV pleurisy. The 
comparison of biological parameters in a TB+HIV+ and non-infectious pleural effusion indicates that the 
reduced Treg stability (p=0.0084), Th17 proportion (p=0.0054) and monocyte mediated skewing towards 
Th17 polarisation (p<0.0001) is specific to co-infection and precludes the interpretation of a generalised 
pleuritic response. This pilot study is based on a small sample size and this may have limited the extent of 
our findings, these results should be validated in a larger cohort.  
 
The TB/HIV microenvironment was not conducive to Treg stability (52.769 ± 5.413% vs. 31.720 ± 3.821%, 
p=0.0084) or Th17 polarisation (64.100 ± 5.045% vs. 36.233 ± 6.968% p=0.0054) ex vivo and confirmed in 
vitro (p=0.0467 and p=0.0001 respectively), as evidenced by a significantly reduced frequency of these 
subsets. Furthermore an impairment of both pro- and anti-inflammatory CD4+ T-cell immune responses 
indicates a suppression of localised immunity as a whole. In contrast, the TB+HIV+ microenvironment 
altered monocyte cytokine production to promote both Treg (33.329 ± 2.470% vs. 55.700 ± 2.249%, 
p<0.0001) and Th17 (32.211 ± 1.036% vs. 70.022 ± 1.235%, p<0.0001) polarisation in vitro. This suggests 
that the loss of Th17 and Treg localised responses at the infection site is not initiated by a monocytic innate 
immune response or may reflect the differences in a multicellular compared to unicellular model.  
 
A loss of Treg stability ex vivo was associated with an IL-35 functional deficit (p=0.0258) and is likely due 
to altered miR-155/SOCS1 dynamics and loss of IL-2 competitive fitness. We were unable to identify a 
potential mechanism of diminished Th17 proportion but determined that it was not a result of alterations in 
the measured polarising signals at the molecular or cytokine level. This prompts further investigation into 
other inhibitory cytokines and epigenetic modifications involved in Th17 lymphocyte generation. 
Interestingly, there was no impairment in the levels of Th17 effector cytokines (IL-17A/F) observed. 
 
Notably, despite Th17/Treg suppression, a higher proportion of Th17 cells than Tregs was found in PEMCs 
ex vivo (31.720 ± 3.821% vs. 36.233 ± 6.968%, p=0.5490) and in vitro (27.900 ± 2.024% vs. 55.156 ± 
154 
 
1.299%, p=0.0004) indicating a predominantly pro-inflammatory microenvironment. This trend was 
mirrored in the THP-1 monocyte model where the supernatants of monocytes cultured in TB+HIV+ 
conditioned media resulted in CD4+ Tconv polarisation towards a chiefly pro-inflammatory Th17/IL-17A 
phenotype (55.700 ± 2.249% vs. 70.022 ± 1.235%, p=0.0001). This was potentially the result of MTB/HIV 
mediated increase in monocyte IL-1β production (219.737 fold, p=0.0217). IL-1 β was also significantly 
upregulated at the transcript and protein level (p=0.0022 and p=0.0008 respectively) in TB+HIV+ pleurisy, 
likely providing a mechanism of Th17 preponderance. Simplistically, despite a suppressed immunity as a 
whole, a prevailing pro-inflammatory environment advances both TB and HIV pathogenesis potentially by 
promoting granulomatous pathology and bacterial transmission, as well as immune hyperactivation and 








Appendix 2: Corresponding peripheral blood results for Chapter 2 as well as healthy control and 
human immunodeficiency virus mono-infected cohorts 
 
2.1 Foxp3 gene expression 
Foxp3 is indispensable for Treg lineage specification and immunosuppressive activities. We performed 
qPCR to evaluate the expression of Foxp3 transcript. Compared to the healthy control (HC) cohort, the TB-
HIV- PBMCs showed as significant 1.552 ± 0.240 fold increase (p=0.0077) and the TB+HIV+ PBMCs 
showed a significant -4.118  ± 0.240 fold decrease (p=0.0077) in Foxp3 mRNA expression suggesting 
increased and deceased immunosuppressive capacity respectively, at the molecular level (Table A2.1). 
 
Relative to TB-HIV- PBMCs, TB+HIV+ PBMCs showed a remarkable -6.085 ± 0.707 (p=0.0048) fold 
decrease in Foxp3 mRNA expression, this is a reversal of the trend observed in PEMCs indicating a 
disparate localised and systemic Treg immune response between cohorts (Table A2.1).  
 
Furthermore, in both the TB-HIV- and TB+HIV+ cohorts, Foxp3 mRNA was expressed at significantly higher 
levels at the localised pleural effusion site than the peripheral blood (2.457 ± 0.167, p=0.0028 and 33.935 ± 
4.298, p=0.0050 fold increases respectively) implying a greater immunosuppressive capacity at the site of 














Table A2.1: Forkhead box P3 mRNA expression in pooled peripheral blood and pleural effusion 
mononuclear cells 
Population Relative Fold Change p-value 
HC PBMC* : TB-HIV- PBMC 1.552 ± 0.240 0.0077 
HC PBMC* : TB+HIV+ PBMC -4.118  ± 0.886 0.0077 
   
TB-HIV- PBMC* : TB+HIV+ PBMC -6.085 ± 0.707 0.0048 
   
TB-HIV- PBMC* : TB-HIV- PEMC 2.457 ± 0.167 0.0028 
   
TB+HIV+ PBMC* : TB+HIV+ PEMC 33.935 ± 4.298 0.0050 
Results expressed as mean ± SEM, n=6 replicates in each group, Mann-Whitney test. * Indicates control 





















2.2 Foxp3 protein expression 
The change in relative Foxp3 protein expression, represented as mean fluorescence intensity (MFI), was 
measured by flow cytometry. PBMC Foxp3 protein expression did not significantly differ between HC 
PBMCs and TB-HIV- or TB+HIV+ PBMCs. However, HIV mono-infection showed a significant -1.726 fold 
decrease in PBMC Foxp3 protein (1107.333 ± 143.329 vs. 641.533 ± 7.613 phycoerythrin (PE)-MFI, 
p=0.0002) indicating a loss of immunoregulatory capability (Table A2.2). 
 
In comparison to the HIV mono-infected population, the co-infected PBMCs showed a significant 1.269 fold 
increase in Foxp3 protein (641.533 ± 7.613 vs. 814.333 ± 36.032 PE-MFI, p=0008) suggesting increased 
immunosuppressive activity in co-infection (Table A2.2). 
 
In line with the PEMC results, there was significant -1.193 fold decrease in TB+HIV+ PBMC Foxp3 protein 
expression compared to the TB-HIV- population (971. 222 ± 45.938 vs. 814.333 ± 36.032 PE-MFI, 
p=0.0360), highlighting a similar trend in Foxp3 protein levels across the localised and systemic 
compartments (Table A2.2).  
 
Furthermore there was no significant difference in Foxp3 protein expression between TB+HIV+ PBMCs and 
PEMCs implying an even distribution of immunosuppressive function. However, there was a notable 1.641 
fold increase in the level of Foxp3 protein in the TB-HIV- PEMCs compared to PBMCs (971. 222 ± 45.938 
vs. 1594.222 ± 86.189 PE-MFI, p<0.0001) implying an expansion of immunosuppressive activity at the 














Table A2.2: Forkhead box P3 relative protein expression in peripheral blood and pleural effusion 
mononuclear cells 
Population Foxp3-PE (MFI) p-value 
HC PBMC 1107.333 ± 143.329   
TB-HIV- PBMC 971. 222 ± 45.938  
TB+HIV+ PBMC 814.333 ± 36.032  
HIV+ PBMC 641.533 ± 7.613  
TB-HIV- PEMC 1594.222 ± 86.189  
TB+HIV+ PEMC 959.556 ± 127.654  
   
HC PBMC : TB-HIV- PBMC  0.6958 
HC PBMC : TB+HIV+ PBMC  0.3485 
HC PBMC : HIV+ PBMC  0.0002 
   
HIV+ PBMC : TB+HIV+ PBMC  0.0008 
   
TB-HIV- PBMC : TB+HIV+ PBMC  0.0360 
   
TB-HIV- PBMC : TB-HIV- PEMC  <0.0001 
TB+HIV+ PBMC : TB+HIV+ PEMC  0.2238 
Results expressed as mean ± SEM, HC PBMC n=4, TB-HIV- PBMC n=3, TB+HIV+ PBMC n=3, HIV+ 
PBMC n=5, TB-HIV- PEMC n=5, TB+HIV+ PEMC n=5, Mann-Whitney test. Healthy control (HC), HIV 





2.3 MicroRNA-155 expression  
We measured miR-155 expression, a direct target of Foxp3, by qPCR. Relative to healthy controls, both TB-
HIV- and TB+HIV+ PBMCs showed a significant reduction in the expression of miR-155 (-2.336 ± 0.212, 
p=0.0004 and -5.747 ± 0.635, p=0.0004 fold change respectively). In contrast, PBMCs from HIV mono-
infected patients showed a 2.371 ± 0.258 (p=0.0004) fold increase. Taken together, this implies miR-155 
dysregulation in all patient groups (Table A2.3). 
 
In comparison to the HIV mono-infected population, the co-infected PBMCs showed a remarkable -12.607 ± 
0.955 fold decline in the expression of miR-155 (p=0.0004) (Table A2.3).  
 
In line with the PEMC results, TB+HIV+ PBMCs showed a -2.458 ± 0.160 fold reduced expression 
(p=0.0004) of miR-155 compared to TB-HIV- PBMCs indicating a similar immunological trend across 
compartments (Table A2.3).  
 
In both the TB-HIV- and TB+HIV+ cohorts, miR-155 expression was significantly raised in PEMCs as 

















Table A2.3: MicroRNA-155 expression in pooled peripheral blood and pleural effusion mononuclear cells 
Population Relative Fold Change p-value 
HC PBMC* : TB-HIV- PBMC -2.336 ± 0.212  0.0004 
HC PBMC* : TB+HIV+ PBMC -5.747 ± 0.635 0.0004 
HC PBMC* : HIV+ PBMC 2.371 ± 0.258 0.0004 
   
HIV+ PBMC* : TB+HIV+ PBMC -12.607 ± 0.955 0.0004 
   
TB-HIV- PBMC* : TB+HIV+ PBMC -2.458 ± 0.160 0.0004 
   
TB-HIV- PBMC* : TB-HIV- PEMC 1.468 ± 0.090 0.0004 
TB+HIV+ PBMC* : TB+HIV+ PEMC 2.102 ± 0.207 0.0004 
Results expressed as mean ± SEM, n=6 replicates in each group, Mann-Whitney test. * Indicates control 



















2.4 T-regulatory lymphocyte frequency  
MicroRNA-155 positively regulates Treg stability by suppressing SOCS1 translation and conferring IL-2 
competitive fitness. We measured Treg frequency using flow cytometry. The proportion of 
CD4+CD25+Foxp3+STAT5+ Tregs did not significantly differ between the HC PBMCs and TB-HIV- or 
TB+HIV+ PBMCs. However, HIV mono-infection showed a significant -3.269 fold decrease in PBMC Tregs 
compared to HC (39.592 ± 4.757% vs. 12.111 ± 1.115%, p<0.0001) highlighting a loss of Treg stability 
(Table A2.4). 
 
In comparison to the HIV mono-infected population, the co-infected PBMCs showed a significant 3.004 fold 
increase in Treg number (12.111 ± 1.115% vs. 36.384 ± 6.820%, p=0.0280) indicating a more stable Treg 
population (Table A2.4). 
 
In contrast to the PEMC trend, there was no significant difference in the number of Tregs between TB-HIV- 
and TB+HIV+ PBMC populations, highlighting a differential Treg response across the localised and systemic 
compartments (Table A2.4).  
 
Furthermore there was no significant difference in Treg frequency between TB+HIV+ PBMCs and PEMCs 
suggesting both compartments are equally conducive to Treg stability and submitting that Tregs do not 
accumulate at the infection site. However, there was a notable 1.975 fold increase in the number of Tregs in 
the TB-HIV- PEMCs compared to PBMCs (26.723 ± 2.799% vs. 52.769 ± 5.413%, p=0.0010) suggesting a 
microenvironment more favourable towards Treg stability and expansion at the infection site in non-


















HC PBMC 39.592 ± 4.757   
TB-HIV- PBMC 26.723 ± 2.799  
TB+HIV+ PBMC 36.384 ± 6.820  
HIV+ PBMC 12.111 ± 1.115  
TB-HIV- PEMC 52.769 ± 5.413  
TB+HIV+ PEMC 31.720 ± 3.821  
   
HC PBMC : TB-HIV- PBMC  0.0644 
HC PBMC : TB+HIV+ PBMC  0.9326 
HC PBMC : HIV+ PBMC  <0.0001 
   
HIV+ PBMC : TB+HIV+ PBMC  0.0280 
   
TB-HIV- PBMC : TB+HIV+ PBMC  0.1425 
   
TB-HIV- PBMC : TB-HIV- PEMC  0.0010 
TB+HIV+ PBMC : TB+HIV+ PEMC  0.5579 
Results expressed as mean ± SEM, HC PBMC n=6, TB-HIV- PBMC n=7, TB+HIV+ PBMC n=6, HIV+ 
PBMC n=5, TB-HIV- PEMC n=7, TB+HIV+ PEMC n=5, Mann-Whitney test. Healthy control (HC), HIV 






2.5 IL-35 concentration 
We quantified IL-35, a suppressive Treg characteristic cytokine, by ELISA. There was no significant 
difference between IL-35 in HC plasma and that of the TB-HIV- cohort. However, compared to HC plasma 
there was a notable -5.122 fold decrease in co-infected plasma (25.106 ± 7.101 vs. 4.902 ± 0.656, p=0.0015) 
and -12.178 fold decrease HIV mono-infected plasma (25.106 ± 7.101 vs. 2.062 ± 0.142, p<0.0001) 
implying a Treg functional deficit (Table A2.5). 
 
In comparison to the HIV mono-infected plasma, the co-infected plasma showed a significant 2.377 fold 
increase in IL-35 levels (2.062 ± 0.142 vs. 4.902 ± 0.656, p=0.0154) indicating greater Treg 
immunosuppressive activity (Table A2.5). 
 
In line with the PEF results, there was a remarkable -6.599 fold decrease in IL-35 concentration in TB+HIV+ 
plasma relative to TB-HIV- (32.348 ± 9.431 vs. 4.902 ± 0.656, p= 0.0579), suggesting a Treg functional 
insufficiency in the TB+HIV+ cohort and a similar IL-35 trend across the localised and systemic 
compartments between cohorts (Table A2.5).  
 
Furthermore there was no significant difference in IL-35 levels between TB-HIV- or TB+HIV+ plasma and 
















Table A2.5: Interleukin-35 concentration in plasma and pleural effusion fluid 
Population IL-35 (ng/ml) p-value 
HC Plasma  25.106 ± 7.101   
TB-HIV- Plasma 32.348 ± 9.431  
TB+HIV+ Plasma 4.902 ± 0.656  
HIV+ Plasma 2.062 ± 0.142  
TB-HIV- PEF 18.784 ± 4.911  
TB+HIV+ PEF 5.457 ± 0.905  
   
HC Plasma : TB-HIV- Plasma  0.5431 
HC Plasma : TB+HIV+ Plasma  0.0015 
HC Plasma : HIV+ Plasma  <0.0001 
   
HIV+ Plasma : TB+HIV+ Plasma  0.0154 
   
TB-HIV- Plasma : TB+HIV+ Plasma  0.0579 
   
TB-HIV- Plasma : TB-HIV- PEF  0.9075 
TB+HIV+ Plasma : TB+HIV+ PEF  0.6427 
Results expressed as mean ± SEM, HC plasma n=9, TB-HIV- plasma n=9, TB+HIV+ plasma n=11, HIV+ 
plasma n=8, TB-HIV- PEF n=8, TB+HIV+ PEF n=8, Mann-Whitney test. Healthy control (HC), HIV mono-






Appendix 3: MicroRNA-21 expression 
 
MicroRNA-21 has been shown to positively regulate peripheral Treg development by indirectly regulating 
the expression of Foxp3. Relative to HC, both TB-HIV- and TB+HIV+ PBMCs showed a significant reduction 
in the expression of miR-21 (-1.522 ± 0.054, p=0.0004 and -1.565 ± 0.047, p=0.0004 fold change 
respectively). In contrast, PBMCs from HIV mono-infected patients showed a 2.258 ± 0.298 (p<0.0001) fold 
increase. Taken together, this implies miR-21 dysregulation in all patient groups (Table A3.1). 
 
In comparison to the HIV mono-infected population, the co-infected PBMCs showed a significant -3.254 ± 
0.029 fold decline in the expression of miR-21 (p=0.0004) (Table A3.1).  
 
Both TB+HIV+ PBMCs (-1.008 ± 0.061, p=0.7304) and PEMCs (-1.120 ± 0.041, p=0.0062) showed a 
decrease in miR-21 expression compared to TB-HIV- counterparts indicating a similar immunological trend 
across compartments, although this was only significant in the pleural fluid compartment (Table A3.1). 
These results were not included in Chapter 2 as despite the significance the fold change was not considered 
strong enough. 
 
In both the TB-HIV- and TB+HIV+ cohorts, miR-21 expression was significantly raised in PEMCs as 















Table A3.1: MicroRNA-21 expression in pooled peripheral blood and pleural effusion mononuclear cells 
Population Relative Fold Change p-value 
HC PBMC* : TB-HIV- PBMC -1.522 ± 0.054 0.0004 
HC PBMC* : TB+HIV+ PBMC -1.565 ± 0.047 0.0004 
HC PBMC* : HIV+ PBMC 2.258 ± 0.298 <0.0001 
   
HIV+ PBMC* : TB+HIV+ PBMC -3.254 ± 0.029 0.0004 
   
TB-HIV- PBMC* : TB+HIV+ PBMC -1.008 ± 0.061 0.7304 
TB-HIV- PEMC* : TB+HIV+ PEMC -1.120 ± 0.041 0.0062 
   
TB-HIV- PBMC* : TB-HIV- PEMC 1.387 ± 0.091 0.0014 
TB+HIV+ PBMC* : TB+HIV+ PEMC 1.271 ± 0.101 0.0062 
Results expressed as mean ± SEM, n=6 replicates in each group, Mann-Whitney test. * Indicates control 













Appendix 4: The 2-ΔΔCt method for the analysis of quantitative PCR 
 
The 2-ΔΔCt method refers to the method of analysis used to obtain a relative fold change of a treated sample 
compared to an appropriate control group as described by Livak and Schmittgen (2001) [1]. The table below 
extracted directly from the original article highlights an example of relative quantification. 
 




1. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative 










Appendix 5: Corresponding peripheral blood results for Chapter 3 as well as healthy control and 
human immunodeficiency virus mono-infected cohorts  
 
5.1 Th17 lymphocyte frequency 
The frequency of Th17 lymphocytes was measured by flow cytometry. Compared to the HC cohort (52.925 
± 5.113%), TB-HIV- (-1.983 fold, 26.692 ± 2.135%, p=0.0006), TB+HIV+ (-1.969 fold, 26.877 ± 7.907%, 
p=0.0179) and HIV mono-infected (-4.137 fold, 12.792 ± 1.543%, p<0.0001) groups all showed a 
significantly lower proportion of peripheral CD4+IL-17+RORC+STAT3+ Th17 cells indicating a suppression 
of the Th17 pro-inflammatory immune response (Table A5.1). 
 
There was no significant difference in Th17 frequency between HIV mono-infected and TB/HIV co-infected 
groups (Table A5.1).  
 
In contrast to PEMC results, there was no significant difference in Th17 proportion between TB-HIV- and 
TB+HIV+ PBMCs indicating a similar peripheral Th17 pro-inflammatory response between cohorts (Table 
A5.1). 
 
There was also no significant difference in Th17 frequency between TB+HIV+ PBMCs and PEMCs 
suggesting an even distribution of this subset between localised and systemic compartments, with the 
microenvironment in both compartments being equally conducive to Th17 generation. In contrast, TB-HIV- 
PEMCs showed a 2.327 fold increase (26.692 ± 2.135% vs 62.100 ± 5.045%, p=0.0001) in the proportion of 
Th17 lymphocytes compared to PBMCs implying a potent localised Th17 response in non-infectious pleural 



















HC PBMC 52.925 ± 5.113  
TB-HIV- PBMC 26.692 ± 2.135  
TB+HIV+ PBMC 26.877 ± 7.907  
HIV+ PBMC 12.792 ± 1.543  
TB-HIV- PEMC 62.100 ± 5.045  
TB+HIV+ PEMC 36.233 ± 6.968  
   
HC PBMC : TB-HIV- PBMC  0.0006 
HC PBMC : TB+HIV+ PBMC  0.0179 
HC PBMC : HIV+ PBMC  <0.0001 
   
HIV+ PBMC : TB+HIV+ PBMC  0.2904 
   
TB-HIV- PBMC : TB+HIV+ PBMC  0.9663 
   
TB-HIV- PBMC : TB-HIV- PEMC  0.0001 
TB+HIV+ PBMC : TB+HIV+ PEMC  0.5362 
Results expressed as mean ± SEM, HC PBMC n=6, TB-HIV- PBMC n=7, TB+HIV+ PBMC n=6, HIV+ 







5.2 IL-17A protein expression 
Relative protein expression of the Th17 characteristic cytokine, IL-17A, was measured by intracellular flow 
cytometry and represented as peridin-chlorophyll-cyanin 5.5 (PerCP-Cy5.5) MFI. Compared to the HC 
cohort (1097. 667 ± 70.949 PerCP-Cy5.5 MFI), TB+HIV+ PBMCs did not show a significant change in IL-
17A protein expression, however both TB-HIV- (-1.253 fold, 876.333 ± 35.230 PerCP-Cy5.5 MFI, 
p=0.0491), and HIV mono-infected (-1.347 fold, 815.067 ± 25.429 PerCP-Cy5.5 MFI, p=0.0012) groups 
showed a significantly lower expression of IL-17A indicating a reduced pro-inflammatory immune response 
in these groups (Table A5.2). 
 
There was no significant difference in PBMC IL-17A protein expression between HIV mono-infected and 
TB/HIV co-infected groups (Table A5.2).  
 
In contrast to PEMC results, there was no significant difference in IL-17A protein expression between TB-
HIV- and TB+HIV+ PBMCs indicating a similar peripheral Th17 pro-inflammatory response between cohorts 
(Table A5.2). 
 
There was also no significant difference in IL-17A protein expression between TB+HIV+ PBMCs and 
PEMCs implying a similar IL-17A mediated pro-inflammatory response between localised and systemic 
compartments. In contrast, TB-HIV- PEMCs showed a 1.659 fold increase in IL-17A protein expression 
compared to PBMCs (876.333 ± 35.230 vs. 1454.000 ± 117.167 PerCP-Cy5.5 MFI, p=0.0026) implying a 




















HC PBMC 1097. 667 ± 70.949  
TB-HIV- PBMC 876.333 ± 35.230  
TB+HIV+ PBMC 895.500 ± 16.280  
HIV+ PBMC 815.067 ± 25.429  
TB-HIV- PEMC 1454.000 ± 117.167  
TB+HIV+ PEMC 923.445 ± 64.418  
   
HC PBMC : TB-HIV- PBMC  0.0491 
HC PBMC : TB+HIV+ PBMC  0.1012 
HC PBMC : HIV+ PBMC  0.0012 
   
HIV+ PBMC : TB+HIV+ PBMC  0.1498 
   
TB-HIV- PBMC : TB+HIV+ PBMC  0.8099 
   
TB-HIV- PBMC : TB-HIV- PEMC  0.0026 
TB+HIV+ PBMC : TB+HIV+ PEMC  0.5287 
Results expressed as mean ± SEM, HC PBMC n=4, TB-HIV- PBMC n=3, TB+HIV+ PBMC n=3, HIV+ 
PBMC n=5, TB-HIV- PEMC n=5, TB+HIV+ PEMC n=5, Mann-Whitney test. Healthy control (HC), HIV 






5.3 Cytokine profiling 
 
Compared to HC plasma: 
TB-HIV- plasma showed significantly increased concentrations of IL-1β (105.133 fold, 0.015 ± 0.001pg/ml 
vs. 1.577 ± 0.663pg/ml, p=0.0050), IL-6 (32.263 fold, 1.786 ± 1.087pg/ml vs. 57.622 ± 11.328pg/ml, 
p=0.0050), IL-10 (27.521 fold, 0.530 ± 0.001pg/ml vs. 14.586 ± 4.123pg/ml, p=0.0134), IL-31 (47.475 fold, 
0.668 ± 0.158pg/ml vs. 31.713 ± 3.296pg/ml, p=0.0080), IL-33 (7.670 fold, 121.568 ± 29.205pg/ml vs. 
932.409 ± 253.009pg/ml, p=0.0283), IFN-γ (12.695 fold, 0.210 ± 0.001pg/ml vs. 2.666 ± 2.278pg/ml, 
p=0.0106), sCD40L (10.374 fold, 24.493 ± 9.868pg/ml vs. 254.083 ± 53.920pg/ml, p=0.0040) and TNF-α 
(8.578 fold, 0.683 ± 0.514pg/ml vs. 5.859 ± 0.751pg/ml, p=0.0050). There was no significant change in the 
levels of IL-4, IL-17A, IL-17F, IL-21, IL-22, IL-23 and IL-25 (Figure A5.1).  
 
TB+HIV+ plasma showed significantly elevated levels of IL-1β (284.00 fold, 0.015 ± 0.001pg/ml vs. 4.272 ± 
0.401pg/ml, p=0.0039), IL-4 (4.757 fold, 5.749 ± 3.179pg/ml vs. 27.335 ±7.571pg/ml, p=0.0356), IL-6 
(647.542 fold, 1.786 ± 1.087pg/ml vs. 2108.583 ± 1156.510pg/ml, p=0.0032), IL-10 (30.219 fold, 0.530 ± 
0.001pg/ml vs. 16.016 ± 3.870pg/ml, p=0.0035), IL-25 (23.825 fold, 0.080 ± 0.001pg/ml vs. 1.906 ± 
0.465pg/ml, p=0.0084), IL-31 (121.708 fold, 0.668 ± 0.158pg/ml vs. 81.301 ± 13.738pg/ml, p=0.0080), IFN-
γ (357.610 fold, 0.210 ± 0.001pg/ml vs. 75.098 ± 21.629pg/ml, p=0.0032), sCD40L (10.229 fold, 24.493 ± 
9.868pg/ml vs. 240.541 ± 78.887pg/ml, p=0.0081), TNF-α (26.432 fold, 0.683 ± 0.514pg/ml vs. 18.053 ± 
4.089pg/ml, p=0.0044) and no significant alterations in IL-17A, IL-17F, IL-21, IL-22, IL-23 and IL-33 
(Figure A5.1) 
 
Plasma from HIV mono-infected individuals showed significantly raised levels of IL-1β (29.867 fold, 0.015 
± 0.001pg/ml vs. 0.448 ± 0.030pg/ml, p=0.0286), IL-31 (60.012 fold, 0.668 ± 0.158pg/ml vs. 40.088 ± 
18.623pg/ml, p=0.0265), sCD40L (11.745 fold, 24.493 ± 9.868pg/ml vs. 287.665 ± 68.737pg/ml, p=0.0286) 
and TNF-α (12.750 fold, 0.683 ± 0.514pg/ml vs. 8.708 ± 1.315pg/ml, p=0.0286). Concentrations of IL-4, IL-
6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-33 and IFN-γ were not significantly changed 
(Figure A5.1). 
 
HIV mono-infected compared to TB+HIV+ co-infected plasma: 
Relative to plasma from HIV mono-infected patients, there was a significant 9.536 fold increase in IL-1β 
(0.448 ± 0.300pg/ml vs. 4.272 ± 0.401pg/ml, p=0.0036) in TB/HIV co-infected patients. No significant 
difference in the levels of IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-






TB-HIV- compared to TB+HIV+ plasma: 
Compared to TB-HIV-, the plasma of patients with TB+HIV+ co-infection showed significantly elevated 
concentrations of IL-1β (2.709 fold, 1.577 ± 0.663pg/ml vs. 4.272 ± 0.401pg/ml, p=0.0058), IL-17F (84.750 
fold, 0.120 ± 0.001pg/ml vs. 10.170 ± 3.529pg/ml, p=0.0376), IL-31 (2.564 fold, 31.713 ± 3.296pg/ml vs 
81.301 ± 13.738pg/ml, p=0.0180), IFN-γ (11.266 fold, 6.666 ± 2.278pg/ml vs. 75.098 ± 21.629pg/ml, 
p=0.0169) and a significant reduction in IL-33 (-3.154 fold, 932.409 ± 253.009pg/ml vs. 295.644 ± 
105.002pg/ml, p=0.0379). There was no significant alteration in IL-4, IL-6, IL-10, IL-17A, IL-21, IL-22, IL-
23, IL-25, sCD40L and TNF-α levels (Figure A5.3). 
 
When comparing results between TB-HIV-/TB+HIV+ PEF and plasma we observed a similar trend for IL-1β, 
IL-31 and IFN-γ, all significantly raised in plasma and PEF of TB+HIV+ patients. In contrast, IL-22 showed 
an inverse trend; significantly increased in TB+HIV+ PEF compared to TB-HIV- PEF but decreased in 
TB+HIV+ plasma, however this was not significant in plasma. TNF-α was increased in TB+HIV+ plasma and 
PEF but it was only a significant result in PEF. IL-17F was increased in TB+HIV+ plasma and PEF but it was 
only a significant result in plasma. IL-33 was decreased in TB+HIV+ plasma and PEF but it was only 
significant in plasma (Figure A5.3 and Figure 2B). 
 
TB-HIV- PEF compared to plasma: 
TB-HIV- PEF relative to TB-HIV- plasma showed significantly elevated concentrations of IL-4 (2.278 fold, 
18.895 ± 7.147pg/ml vs. 43.042 ± 9.590pg/ml, p=0.0200), IL-6 (1745.528 fold, 57.622 ± 11.328pg/ml vs. 
100580.806 ± 30145.472pg/ml, p<0.0001), IL-10 (5.404 fold, 14.586 ± 4.123pg/ml vs. 78.820 ± 
14.729pg/ml, p=0.0033), IL-17F (780.308 fold, 0.120 ± 0.001pg/ml vs. 93.637 ± 15.357pg/ml, p=0.0006), 
IL-21 (4.656 fold, 13.737 ± 8.650pg/ml vs. 63.959 ± 12.567pg/ml, p=0.0047), IL-25 (7.502 fold, 1.170 ± 
0.650pg/ml vs. 8.777 ± 1.872pg/ml, p=0.0021), IL-31 (4.996 fold, 31.713 ± 3.296pg/ml vs. 158.430 ± 
35.615pg/ml, p=0.0367), IFN-γ (13.170 fold, 6.666 ± 2.278pg/ml vs. 87.793 ± 27.282pg/ml, p=0.0064) and 
TNF-α (3.112 fold, 5.859 ± 0.753pg/ml vs. 18.233 ± 2.615pg/ml, p=0.0004). No change in IL-1β, IL-17A, 
IL-22, IL-23, IL-33, sCD40L levels were observed (Figure A5.4) indicating a differential systemic and 
localised cytokine response. 
 
TB+HIV+ PEF compared to plasma: 
In comparison to TB+HIV+ plasma, TB+HIV+ PEF showed significantly raised levels of IL-1β (4.272 ± 
0.401pg/ml vs. 18.239 ± 3.064pg/ml, p=0.0004), IL-6 (2108.583 ± 1156.513pg/ml vs. 78778.906 ± 
21300.368pg/ml, p<0.0001), IL-10 (16.016 ± 3.870pg/ml vs. 85.835 ± 15.680pg/ml, p=0.0005), IL-17A 
(0.035 ± 0.001pg/ml vs 18.281 ± 2.383pg/ml, p=0.0003), IL-17F (10.170 ± 3.529pg/ml vs. 118.090 ± 
8.077pg/ml, p=0.0004), IL-21 (1.866 ± 0.673pg/ml vs. 61.792 ± 2.995pg/ml, p=0.0004), IL-22 (1.230 ± 
176 
 
0.001pg/ml vs. 69.729 ± 10.318pg/ml, p=0.0003), IL-25 (1.906 ± 0.465pg/ml vs. 12.945 ± 1.240pg/ml, 
p=0.0004), IL-31 (81.301 ± 13.738pg/ml vs 483.957 ± 115.651pg/ml, p=0.0002), IL-33 (295.644 ± 
105.002pg/ml vs. 600.367 ± 63.523pg/ml, p=0.0205), IFN-γ (75.098 ± 21.629pg/ml vs. 1190.386 ± 
361.906pg/ml, p=0.0003), TNF-α (18.053 ± 4.089pg/ml vs. 66.112 ± 13.264pg/ml, p=0.0058). There was no 
significant difference in IL-4, IL-23 or sCD40L concentrations (Figure A5.5) indicating a differential 


























Figure A5.1: Cytokine profiling of plasma. Significance determined relative to the healthy control (HC) cohort. Interleukin (IL)-1β, IL-4, IL-6, IL-10, interferon 
(IFN)-γ, tumour necrosis factor (TNF)-α; HC n=4, TB-HIV- n=8, TB+HIV+ n=12, HIV+ n=4. IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, 



























































Figure A5.2: Cytokine profiling HIV mono-infected and TB+HIV+ co-infected plasma. Interleukin (IL)-1β, IL-4, IL-6, IL-10, interferon (IFN)-γ, tumour 
necrosis factor (TNF)-α; TB+HIV+ n=12, HIV+ n=4. IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, soluble CD40 ligand (sCD40L); 











































Figure A5.3: Cytokine profiling of TB-HIV- and TB+HIV+ plasma. Interleukin (IL)-1β, IL-4, IL-6, IL-10, interferon (IFN)-γ, tumor necrosis factor (TNF)-α; 
TB-HIV- n=8, TB+HIV+ n=12. IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, soluble CD40 ligand (sCD40L); TB-HIV- n=5, TB+HIV+ 












































Figure A5.4: Cytokine profiling of TB-HIV- plasma and pleural effusion fluid (PEF). Interleukin (IL)-1β, IL-4, IL-6, IL-10, interferon (IFN)-γ, tumour 
necrosis factor (TNF)-α; TB-HIV- plasma and PEF n=8. IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, soluble CD40 ligand (sCD40L); 

















































Figure A5.5: Cytokine profiling of TB+HIV+ plasma and pleural effusion fluid (PEF). Interleukin (IL)-1β, IL-4, IL-6, IL-10, interferon (IFN)-γ, tumour 
necrosis factor (TNF)-α; TB+HIV+ plasma and PEF n=12. IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, soluble CD40 ligand (sCD40L); 


















































5.4 mRNA expression of Th17 signalling molecules 
Messenger RNA expression of Th17 signalling molecules, STAT3, IL-1β, IL-6 and IL-6R, was measured by 
qPCR. Relative to the HC PBMCs, TB-HIV- PBMCs showed significantly increased fold expression of 
STAT3 (2.347 ± 0.247, p=0.0048) and decreased fold expression of IL-6R (-1.178 ± 0.082, p=0.0048) 
without significant changes in IL-1β (1.068 ± 0.047) and IL-6 (1.017 ± 0.099) (Table A5.3).  
 
TB+HIV+ PBMCs showed significantly elevated expression of STAT3 (6.303 ± 0.670, p=0.0048), IL-6 
(3.603 ± 0.583, p=0.0048) and IL-6R (1.695 ± 0.119, p=0.0048) and significant reduction on IL-1β (-2.657 ± 
0.140, p=0.0048) fold expression compared to HC PBMCs (Table A5.3). 
 
Taken together, this suggests that infectious and non-infectious microenvironments have a differential and 
selective effect on peripheral mechanisms of the pro-inflammatory response.   
 
HIV mono-infected PBMCs showed a remarkable fold rise in STAT3 (161.827 ± 15.714, p=0.0048), IL-1β 
(20.233 ± 1.040, p=0.0048), IL-6 (231.298 ± 61.258, p=0.0131) and IL-6R (19.496 ± 1.476, p=0.0075) 
indicating up-regulation at all stages of Th17 signalling measured (Table A5.3). 
 
Compared to HIV mono-infected PBMCs, TB/HIV co-infected PBMCs showed a notable decline in the 
expression of STAT3 (-26.127 ± 2.098, p=0.0048), IL-1β (-53.462 ± 3.249, p=0.0048), IL-6 (-51.420 ± 
5.166, p=0.0048) and IL-6R (-11.193 ± 0.130, p=0.0048) implying a suppression of Th17 signalling 
networks peripherally (Table A5.3).  
 
In line with the trends seen in the PEMCs, TB+HIV+ PBMCs showed significant fold elevations in the 
mRNA expression of STAT3 (2.693 ± 0.154, p=0.0048), IL-6 (3.473 ± 0.338, p=0.0048) and IL-6R (1.953 ± 
0.056, p=0.0048) relative to TB-HIV- PBMCs indicating a more active peripheral Th17 signalling during co-
infection. However, in contrast to the PEMCs, TB+HIV+ PBMCs showed marked fold decrease in IL-1β (-
2.807 ± 0.075, p=0.0048) mRNA highlighting a differential peripheral IL-1β response between groups 
(Table A5.3). 
 
In non-infectious pleural effusions, there was a significant down regulation of STAT3 (-1.262 ± 0.071, 
p=0.0048), IL-1β (-5.742 ± 0.282, p=0.0048) and IL-6R (-1.117 ± 0.076, p=0.0048) mRNA expression 
together with a significant up-regulation of IL-6R (2.257 ± 0.227, p=0.0048) mRNA between systemic and 
localised compartments (PBMC vs. PEMC) (Table A5.3). 
 
In co-infected individuals, STAT3 (9.018 ± 0.701, p=0.0048), IL-1β (5.705 ± 0.095, p=0.0048) and IL-6 
(1.906 ± 0.592, p=0.0075) mRNA was significantly elevated and IL-6R (-1.447 ± 0.209, p=0.0048) 
significantly down regulated in the localised PEMCs compared to the systemic samples (Table A5.3).  
183 
 
Taken together this suggests that in both infectious and non-infectious pleural effusions there is a differential 




Table A5.3: Signal transducer and activator of transcription 3, interleukin -1β, -6, and 6 receptor messenger RNA expression 
Population 
Relative Fold Change (p-value) 
STAT3 IL-1β IL-6 IL-6R 
HC PBMC* : TB-HIV- PBMC 2.347 ± 0.247 
(0.0048) 
1.068 ± 0.047 
(0.0637) 
1.017 ± 0.099 
(0.9357) 
-1.178 ± 0.082 
(0.048) 
HC PBMC* : TB+HIV+ PBMC 6.303 ± 0.670 
(0.0048) 
-2.657 ± 0.140 
(0.0048) 
3.603 ± 0.583 
(0.0048) 
1.695 ± 0.119 
(0.0048) 
HC PBMC* : HIV+ PBMC 161.827 ± 15.714 
(0.0048) 
20.233 ± 1.040 
(0.0048) 
231.298 ± 61.258 
(0.0131) 
19.496 ± 1.476 
(0.0075) 
     
HIV+ PBMC* : TB+HIV+ PBMC -26.127 ± 2.098 
(0.0048) 
-53.462 ± 3.249 
(0.0048) 
-51.420 ± 5.166 
(0.0048) 
-11.193 ± 0.130 
(0.0048) 
     
TB-HIV- PBMC* : TB+HIV+ PBMC 2.693 ± 0.154 
(0.0048) 
-2.807 ± 0.075 
(0.0048) 
3.473 ± 0.338 
(0.0048) 
1.953 ± 0.056 
(0.0048) 
     
TB-HIV- PBMC* : TB-HIV- PEMC -1.262 ± 0.071 
(0.0048) 
-5.742 ± 0.282 
(0.0048) 
2.257 ± 0.227 
(0.0048) 
-1.117 ± 0.076 
(0.0048) 
     
TB+HIV+ PBMC* : TB+HIV+ PEMC 9.018 ± 0.701 
(0.0048) 
5.705 ± 0.095 
(0.0048) 
1.906 ± 0.592 
(0.0075) 
-1.447 ± 0.209 
(0.0048) 
Results expressed as mean ± SEM, n=6 replicates in each group, Mann-Whitney test. * Indicates control group used in analyses. Healthy control (HC), HIV mono-
infected (HIV+), signal transducer and activator of transcription 3 (STAT3), interleukin (IL); receptor (R). 
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